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Studying biological processes on the level of live cells with the help of biocompatible reactions 
has tremendously advanced our understanding of basic biology. However, the great complexity of 
many human pathologies such as cancer, diabetes and neurodegenerative diseases requires new tools 
that would allow investigation of biological processes throughout the organism. 
The 2-cyanobenzothiazole (CBT)-based ligation reaction has received a recent interest in the 
chemical biology community. It has been reported in the literature for various applications, ranging 
from fluorescent labelling of proteins to nanostructures formation, and, most importantly, the reaction 
was shown to proceed in cells. This selective reaction between D-cysteine and hydroxy-CBT (HO-CBT) 
or amino-CBT (H2N-CBT), also named as split luciferin reaction, generates as product a D-luciferin ana-
logue, one of the most commonly used substrates for bioluminescence imaging (BLI). Therefore, the 
split luciferin reaction has high potential for BLI applications. 
In this work, we have shown that production of a luciferin substrate via the split luciferin reac-
tion can be visualized in live mice using BLI. Furthermore, the split luciferin approach allows interroga-
tion of target tissues using a masking approach, where D-luciferin is formed only under certain condi-
tions. This reaction was successfully applied to real-time non-invasive imaging of apoptosis, associated 
with caspase 3/7 activity. Caspase-dependent release of free D-cysteine from a caspase 3/7 specific 
peptide substrate allowed selective reaction with H2N-CBT in vivo to form 6-amino-D-luciferin with 
subsequent light emission in the presence of the firefly luciferase enzyme. Importantly, this strategy 
was found to be superior to the use of the commercially available DEVD-aminoluciferin substrate for 
imaging caspase 3/7 activity. The same methodology was extended to imaging activity of other caspa-
ses as well as thrombin enzyme in an in vitro set-up. Furthermore, the split luciferin approach enables 
dual imaging, where each reaction partner would be individually caged to report on separate biological 
events. This approach was used for simultaneous imaging of caspase 3 and ?-galactosidase in vitro, 
validating the use of the split luciferin reaction for imaging multiple processes. Moreover, the split 
luciferin reaction was also successfully applied to both quantification of Neutrophil Elastase activity in 
Abstract 
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vitro and real-time non-invasive imaging of Neutrophil Elastase in an in vivo inflammation model. Al-
together, the present study suggests that the split luciferin approach is an efficient and versatile tool 
for in vivo applications.   
?????????
Biocompatible reaction; Bioorthogonal reaction; Bioluminescence imaging; Luciferase; D-luci-
ferin; Split luciferin reaction; in vivo imaging; Protease imaging; Enzymatic assay; Caspase; Neutrophil 
Elastase; Bioluminogenic probes.
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L'étude des processus biologiques dans les cellules vivantes grâce aux réactions biocompa-
tibles a énormément amélioré notre compréhension de la biologie fondamentale. Cependant, la 
grande complexité de nombreuses pathologies humaines telles que le cancer, le diabète et les mala-
dies neurodégénératives requiert de nouveaux outils indispensables à l’étude des processus biolo-
giques à l’échelle d’un organisme. 
La réaction de ligature basée sur le 2-cyanobenzothiazole (CBT) a perçu un récent intérêt de la 
part de la communauté de biologie chimique. L’utilisation de cette réaction a été rapportée dans la 
littérature pour des applications variées, allant de la modification de protéines avec des marqueurs 
fluorescents à la formation de nanostructures. Mais aussi et surtout, il a été démontré que cette réac-
tion peut avoir lieu dans un milieu cellulaire. Cette réaction sélective entre la D-cystéine et le hydroxy-
CBT (HO-CBT) ou amino-CBT (H2N-CBT), également appelée réaction de split luciférine, génère comme 
produit un analogue de la D-luciférine, qui est l’un des substrats les plus couramment employés pour 
l'imagerie par bioluminescence. Par conséquent, la réaction de split luciférine présente un fort poten-
tiel pour des applications d'imagerie par bioluminescence.  
Dans le cadre de ce travail, nous avons montré que la production de luciférine, via la réaction 
de split luciférine, peut être visualisée dans des souris vivantes, au moyen de l’imagerie par biolumi-
nescence. En outre, l’utilisation de la réaction de split luciférine permet l'interrogation de tissus cibles 
par le biais d’une approche qui consiste à masquer la D-cystéine. Celle-ci ne peut donc réagir avec le 
CBT qu’après avoir été libérée par un processus biologique spécifique, se traduisant par une formation 
de D-luciférine, dans certaines conditions particulières. Cette approche a été appliquée avec succès à 
l'image non-invasive en temps réel de l’apoptose, associée à l'activité des caspases 3/7. La libération 
de D-cystéine d’un peptide substrat des caspases 3/7 permet la réaction sélective avec H2N-CBT in vivo 
afin de former la 6-amino-D-luciférine, qui, en présence de luciférase, produit une émission de lumière 
qui est donc dépendante de l’activité des caspases. Il est notable que cette stratégie se révèle être 
supérieure à l’utilisation de la sonde bioluminogène DEVD-aminoluciférine, laquelle est commerciali-
sée pour l’imagerie de l'activité des caspases 3/7. La même méthodologie a ensuite été étendue à 
l'imagerie d'autres caspases ainsi que de la thrombine dans des conditions in vitro. 
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En outre, la réaction de split luciférine permet une double imagerie, où chaque partenaire de 
réaction serait individuellement masqué, permettant de détecter simultanément des événements bio-
logiques séparés. Cette approche a été adoptée pour l'imagerie simultanée de la caspase 3 et de la ?-
galactosidase in vitro, validant ainsi l'utilisation de la réaction de split luciférine pour l’imagerie de 
processus multiples. Enfin, la réaction de split luciférine a été appliquée avec succès, d’une part, à la 
quantification de l'activité de la neutrophile élastase in vitro en temps réel et d’autre part, à l'imagerie 
non-invasive de la neutrophile élastase dans un modèle in vivo d'inflammation. En conclusion, la pré-
sente étude suggère que la réaction de split luciférine est un outil efficace et polyvalent pour diverses 
applications in vivo. 
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Réaction biocompatible; Réaction bioorthogonale; Imagerie par bioluminescence; Luciférase; 
D-luciférine; Réaction de Split luciférine; Imagerie de protéase; Analyse enzymatique; Caspase; Neu-
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Bioluminescence is the naturally occurring form of chemiluminescence where the light is re-
leased upon a chemical reaction. It occurs in various organisms such as marine vertebrates or inverte-
brates and terrestrial insects. Majority of bioluminescent organisms lives in the seas and include fishes, 
crustaceans as well as microorganisms. Fireflies (Figure 1.1), click beetles, glow worms and some types 
of mushrooms can be sited as examples of terrestrial bioluminescent organisms. These organisms use 
bioluminescence for a number of purposes including camouflage, attracting mates, communication 
and repulsion.[1,2] 
 
Figure 1.1: Bioluminescent firefly in nature (Photos courtesy of Jack Moreh and copyright Free Range Stock, www.freerang-
estock.com). 
Basic research was carried to understand the biology of light-emitting organisms. Fundamental 
knowledge acquired on the molecular mechanisms of bioluminescence resulted in the translation from 
nature to laboratories applications. Understanding living systems requires tools to explore molecular 
processes in cells and animals. Chemical or genetic approach coupled to different imaging modalities 
are now widely used for molecular imaging applications. Among these imaging techniques, Biolumi-
nescence imaging (BLI) is nowadays popular for sensing molecular and cellular functions in cells and in 
vivo. The principle of Bioluminescence (BL) relays on the reaction of a class of enzymes, luciferases, 
with their respective substrate, luciferins. Luciferases are oxidative enzymes that catalyze the oxidation 
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of their substrates, luciferins, to an oxidation product in an excited-state that decays with light emis-
sion. Some luciferases require cofactors such as ATP or magnesium cations.[3,4] BLI is a powerful meth-
odology for molecular imaging and is now routinely used both in vitro and in vivo for a wide range 
applications including imaging gene expression, tumor growth monitoring and biological processes.[3,5] 
Although many different luciferase/luciferin pairs were identified in nature, only a few of them (e.g. 
Firefly luciferase (FLuc), Click beetle luciferase, Renilla and Gaussia luciferases) have been employed 
for molecular imaging (Table 1.1).  
Firefly, Green click beetle and Red click beetle luciferases utilize D-luciferin ((S)-2-(6-Hydroxy-
2-benzothiazolyl)-2-thiazoline-4-carboxylic acid, also called firefly luciferin) as substrate and require 
dioxygen and ATP as cofactors (Table 1.1, entry 1). D-luciferin is oxidized to oxyluciferin in an electron-
ically excited state, whose decay to the ground state generates a photon emission. Insect luciferases 
all use the D-luciferin as substrate, while having different light emission spectrum (Table 1.1, entry 1-
3). The exact emission wavelength is determined by both the substrate molecule and the enzyme in-
ternal microenvironment of the active site.[6]  
Luciferases native of marine organisms such as Renilla or Gaussia luciferases use coelentera-
zine as substrate (Table 1.1, entry 4-6). In the presence of a molecular oxygen, bioluminescent light is 
emitted upon luciferase-catalyzed oxidation of coelenterazine to coelenteramide.[7] Recently, NanoLuc 
was added to this class of enzyme. A native luciferase enzyme from the deep sea shrimp Oplophorus 
was engineered for stability and optimal luminogenic substrate resulting in NanoLuc enzyme which 
uses a coelenterazine derivative, Furimazine, as substrate (Table 1.1, entry 7).[8] This class of luciferases 
are ATP independent and do not require exogenous cofactors to produce light. Their light emission 
peaks in the blue-green region of the light spectrum. 
Finally, the last family of luciferases that has been used for molecular imaging is bacterial lu-
ciferases. Luminous bacteria mainly come from marine environment and are often isolated as organ 
symbionts of fishes. Interestingly, these bacterial luciferases produce light in a two-step mechanism, 
where a reduced flavin mononucleotide (FMNH2) bound to the luciferase enzyme reacts with dioxygen 
to produce a peroxy-intermediate that will then react with an aliphatic aldehyde to generate a second 
intermediate. This exited-state product then reaches ground state while generating a photon of light 
(Table 1.1, entry 8).[9] The bacterial luciferase genes luxA and luxB (luxAB) encode for proteins involved 
in the light emission process, and the so called lux operon (luxCDABE) encode for both the luciferases 
and all the proteins that produce the necessary substrates. Therefore, lux operon provides all the nec-
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essary components for light emission, resulting in a luminescent system that does not require an ex-
ternal luciferin substrate.[10] While this Lux operon had initially been limited to bacterial applications, 
it was recently adapted for use in mammalian cells.[11]  
Table 1.1: Commonly used luciferases for BLI with their respective substrates, and the resulting BL emission wavelength (table 
adapted from [6] and [12]). 
 
Luciferase Substrate (lu-
ciferin) 
Enzymatic reaction ?* 
[nm] 
Ref. 
1 
Firefly  
(Photinus Pyralis) 
D-luciferin 
 
612 13 
2 
Click beetle red  
(Pyrophorus Plagi-
ophthalamus) 
611 13,14 
3 
Click beetle green  
(Pyrophorus Plagi-
ophthalamus) 
544 13,14 
4 
Renilla reniformis  
(native, RLuc8) 
Coelenterazine 
 
480 15 
5 
Renilla reniformis  
(RLuc8.6-535) 
535 16 
6 
Gaussia princeps  
(GLuc) 
480 17,18 
7 NanoLuc Furimazine 
 
460 8 
8 Lux AB 
FMNH2 + 
Aliphatic alde-
hyde 
 
490 19 
* At 37 °C, represent the peak of emission. 
Mammalian tissues are not transparent and thus attenuate optical signal by both absorbing 
and scattering light. The changes in refractive index between tissue boundaries, cell membranes or 
organelles are responsible for scattering of light in living systems but the influence of wavelength is 
minor within the visible light spectrum. Absorption of photons depends on the type of tissue and en-
dogenous chromophores such as hemoglobin that absorbs principally in the blue-green region (460-
570 nm) of the visible spectrum,[20,21] which hinders the signal detection from deep tissues. In the red 
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and near-infrared spectrum (? > 600 nm), absorption by hemoglobin is lower, allowing red light pene-
tration through tissue with a depth of a few centimeters.[13] Since Renilla, Gaussia and bacterial lucif-
erases emit light in the blue/green region (460-570 nm) that yields lower tissue penetration, they are 
less suitable for in vivo studies compared to the FLuc/D-luciferin pair which produces a more red-
shifted light. Nevertheless, the ATP independence of Renilla or Gaussia luciferases is still attractive for 
in vitro applications as they could sense both intra- and extra-cellular environments. Moreover, multi-
ple luciferase/luciferin pairs having different emission wavelengths can be combined and used simul-
taneously for multicolor imaging.[3] This would allow monitoring several processes at the same time by 
recording different wavelengths of light emission. 
???? ????????????????????????????????????
The FLuc/D-luciferin pair is one of the main luciferase/luciferin system used in biolumines-
cence imaging in vitro and in vivo. Due to its light emission wavelength, FLuc/D-luciferin pair is partic-
ularly suited for applications in living animals. The reaction between D-luciferin and FLuc in the pres-
ence of ATP, Mg2+ and a molecular oxygen produces a photon of light.[22] The intensity of the light 
output is closely correlated with the amount of D-luciferin available for the enzyme, and therefore it 
is possible to quantify the amount of D-luciferin by measuring the light emission.  
The catalytic reaction, shown in Scheme 1.1, starts with the adenylylation of D-luciferin (D-LH2) 
by FLuc to yield D-luciferin-adenylate (D-LH2-AMP), followed by oxygenation. The AMP substituent on 
D-LH2-AMP increases the acidity of the C4 proton, resulting in the formation of a carbanion interme-
diate, further performing a nucleophilic attack on molecular oxygen. In the following step, a luciferin 
dioxetanone anion (Dx-), which consists of a four membered strained ring formed upon AMP release. 
Thereafter, light emitter intermediate, the excited singlet state of oxyluciferin OL- [1(OL-)*], is gener-
ated. Finally, the luminescent light is produced with a peak intensity around 560 nm (at pH 7.6) upon 
1(OL-)* relaxation to the ground state.[23,24] The emission wavelength is dependent on a number of 
factors including the pH and temperature.[13,24,25]  
 
Scheme 1.1: Mechanism of D-luciferin oxidation by firefly luciferase. 
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Beside its oxidase activity in bioluminescent reaction, FLuc enzyme displays several lateral re-
actions. An alternative to the bioluminescent reaction is the reaction of D-LH2-AMP with dioxygen 
yielding an oxidized product, dehydroluciferyl-AMP (L-AMP), a process in which hydrogen peroxide is 
produced (Scheme 1.2). This is a dark process where no light is generated during the reaction.[26,27] 
 
Scheme 1.2: Dehydroluciferyl adenylate and hydrogen peroxide production by FLuc. 
 FLuc enzyme could also act as acyl-CoA ligase.[23,28,29] Biosynthesis of the D-luciferin is not yet 
fully understood. As in nature only L-amino acids occur in proteins, it was proposed that D-luciferin 
could be produced from L-luciferin via an enzyme-mediated inversion of configuration. L-luciferin 
would be produced by the reaction of HO-CBT with L-cysteine, then L-luciferin would be adenylated to 
form L-luciferin-AMP (L-LH2-AMP). This compound would be further converted to L-luciferin-CoA 
which can racemize to the D-enantiomer via enolization (Scheme 1.3). Hydrolysis of the D-luciferin-
CoA by esterases would yield the D-luciferin molecule. This pathway could also explain the capability 
of FLuc to produce light with L-luciferin as substrate.[30] Moreover, the production of luciferin-CoA is 
stereospecific and only occurs with the L-luciferin. This indicates that FLuc distinguishes the L- and D-
isomer of luciferin and thus acts as Acyl-CoA synthetase only for L-luciferin, saving the use of the D-
isomer for the bioluminescent reaction.[31,32] 
 
Scheme 1.3: Proposed biosynthesis pathway of D-luciferin from L-luciferin. The split luciferin reaction between HO-CBT and 
L-cysteine yield L-luciferin, that further undergo a FLuc-mediated adenylylation reaction resulting in the formation of L-lucif-
erin-AMP (L-LH2-AMP). CoA reacts then with L-LH2-AMP, yielding the L-luciferin-CoA (L-LH2-CoA) which is racemized by enoli-
sation to the D-enantiomer. Hydrolysis of D-luciferin-CoA by esterases yield to the product D-luciferin (Scheme Adapted from 
[32]). 
The CoA addition reaction also occurs with L-AMP to yield dehydrolucyferl-CoA (L-CoA). As L-
AMP is a strong-binding inhibitor of FLuc (Ki = 3.8 ± 0.7 nM), while L-CoA is a less powerful inhibitor (Ki 
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= 0.88 ± 0.03 μM), the formation of the acyl-adenylate in which the thiol of CoA displace the AMP 
moiety favors the bioluminescent pathway.[23,32-35] Besides L-AMP, the product of the bioluminescent 
reaction, oxyluciferin, also have an inhibitory effects on FLuc (Ki = 0.50 ± 0.03 μM). Both of these com-
pounds are mainly responsible for the light emission pattern of FLuc with D-Luciferin as substrate in 
vitro. It consists of an initially highly intense signal (flash of light) which quickly decays to a sustained 
lower intensity luminescence (Figure 1.2). However, addition of coenzyme A (CoA) yields a more-sta-
ble, high-intensity luminescence that decays over a longer duration period.[23] 
 
Figure 1.2: In vitro light emission in function of the time by FLuc with D-luciferin substrate. D-luciferin (10 μM) was added to 
FLuc (40 μg/mL) solution containing MgSO4 (3.3 mM) and ATP (3.3 mM) in Tris-HCl buffer at pH8. After rapidly reaching the 
maximum, a fast decay is observed. Error bars are ± SD for three independent measurements. 
???? ??????????? ???????????
Replacement of the aromatic hydroxyl group in D-Luciferin (Figure 1.3, compound 1) with an 
amino group, yielded 6’-amino-D-luciferin (D-aminoluciferin) (Figure 1.3, compound 2), with an emis-
sion wavelength (605 nm) independent of the pH upon reaction with FLuc.[25] Additionally, the D-ami-
noluciferin has higher affinity to FLuc than the natural D-luciferin.[36] Successive groups have attempted 
to synthesize analogues of D-luciferin to produce higher affinity molecules, but the high substrate spec-
ificity of FLuc does not tolerate large modifications on the scaffold without reduction or loss of affinity. 
Structure-activity studies showed that an electron-donating substituent at the 6'-position is essential 
for light emission. Alkylation or acylation of D-luciferin at the 6’-phenol position or acylation of D-ami-
noluciferin at the 6’-amino position has been shown to affect the luciferase/substrate reaction and 
such analogues have no BL capacity.[25] In another study, a series of N-mono and N-di-alkylated ami-
noluciferins have been proven to be substrates for FLuc. A number of analogs including molecules 3-5 
(Figure 1.3), showed stronger light emission than the D-aminoluciferin.[37] More recent studies evalu-
ated the bioluminescent properties of conformation-restricted cyclic alkylaminoluciferin substrates 6-
9 (Figure 1.3) which produced red-shifted photon flux. However, most of these novel luciferins require 
mutant luciferases to have acceptable light emitting properties and thus cannot be conveniently used 
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for in vivo studies, with the exception of compound 6.[38-41] Another approach that consists of replacing 
the sulfur atom in the thiazolin ring with selenium (Figure 1.3, compound 10), resulted in a red-shifted 
bioluminescent signal but much lower quantum yield compared to the D-aminoluciferin.[42] Examples 
for modifications on the benzothiazole core with various heterocyclics (11-13),[43,44] replacement with 
naphthol derivatives (14-15)[45] or extended ?–conjugation systems (16-19)[43,46] are shown in Figure 
1.3.  
 
Figure 1.3: Examples of synthetic D-luciferin analogues as substrates for firefly luciferase.  
 Although strategies to synthesize novel D-luciferin derivatives that emit light at different 
wavelengths with a high quantum yield are still of high interest, D-luciferin and D-aminoluciferin are 
still the most frequently used substrates in BLI applications in vivo.[47] Both D-luciferin and its amino 
analogue are commercially available and have already been validated for in vivo application.[48] 
???? ????????????????????????????? ?????????????????in vivo?
As mentioned earlier, modifications on the 6’-hydroxyl group of D-luciferin or 6’-amino group 
of aminoluciferin often restrict the recognition by the FLuc enzyme and thus prohibit the production 
of light. On the other hand, this restriction permits the development of caged-luciferin derivatives 
which are modified (i.e. caged) with groups that are sensitive to a biological process and luminescence 
is emitted only in the presence of the biological process of interest.[47,49] These caged-luciferin probes 
have been used to monitor various biological processes such as enzymatic activity, real-time imaging 
of small molecule uptake, cell surface modifications, metabolite production, as well as to study the 
efficiency of delivery, linker release, and biodistribution of cell-penetrating peptide conjugates.[50] The 
strategy of caging involves the 6'-hydroxy, 6'-amino or carboxyl group of D-luciferin (or aminoluciferin) 
to be modified with a cleavable functional group (Scheme 1.4). The presence of a bulky side group 
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causes steric hindrance and prevents the access to the luciferase active site. Upon removal of the cag-
ing group, D-luciferin molecule is released and can be oxidized by luciferase. Therefore, the amount of 
emitted signal is proportional to the quantity of free luciferin released. In other words, the light emis-
sion is correlated to the efficiency of uncaging and thus to the activity of the enzyme or the biomole-
cule of interest. 
 
Scheme 1.4: Caged-luciferin strategy. The luciferins can be modified with a caging group on the phenolic hydroxyl, amino or 
carboxyl group that would prohibit the interaction with FLuc until the caging group is removed. 
BLI has been widely used for longitudinal imaging of enzymatic activity.[51] While there are a 
number of luciferin derivatives validated for in vitro assays, only a few of them have been validated for 
real-time imaging in vivo, examples of which are described below. 
?????? ?????????????????????????????????????????????
Apoptosis, or programmed cell death, is a highly regulated process, essential for the removal 
of damaged cells in multicellular organisms. Cytosolic caspases play central roles in mediating the ini-
tiation and propagation of the apoptotic cascade. Activation of both caspase 3 and caspase 7 is critical 
in the apoptotic pathway,[52,53] and is also linked to pathologies such as cancer and neurodegenerative 
disease.[54-56] A bioluminescent probe, DEVD-aminoluciferin, was developed to image caspase 3 activa-
tion in vitro and in vivo (Scheme 1.5), where the aminoluciferin derivative carries an Asp-Glu-Val-Asp 
(DEVD) peptide that is known to be a selective sequence for caspase 3 and to a lesser extent for caspase 
7. The cleavage occurs at the C-terminal of the second aspartic acid (Asp) residue that yields the ami-
noluciferin release, which is used to quantify the caspase 3/7 activity. The use of this probe was shown 
to be beneficial for monitoring caspase 3/7 activity in vitro, screening caspase inhibitors and monitor-
ing apoptotic effect of chemotherapeutics in cells.[57,58] The probe also provides a unique tool to eval-
uate the efficacy of therapeutic agents as well as to study the role of apoptosis in several disease mod-
els in vivo non-invasively.[59] 
 
Scheme 1.5: DEVD-aminoluciferin probe for imaging Caspase 3/7 activity. DEVD peptide is selectively cleaved-off by caspase 
3/7, releasing bioluminogenic D-aminoluciferin molecule. 
Using DEVD-aminoluciferin, Shah et al. demonstrated real-time imaging of caspase 3 mediated 
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apoptosis in living mice that were subcutaneously implanted with FLuc transfected glioma cells.[59]  An-
other example of in vivo caspase 3/7 imaging using DEVD-aminoluciferin probe is monitoring apoptosis 
in living mice upon chemotherapeutic treatment, where apoptotic effect of docetaxel was evaluated 
on subcutaneous ovarian and mammary xenograft models.[60] Similar experiments were reported for 
monitoring induction of apoptosis and inhibition of tumor growth upon camptothecin and te-
mozolomide treatment in different mouse xenografts models.[61] Moreover, DEVD-aminoluciferin was 
also used for measuring caspase 3/7 activity in a mouse liver failure model.[62]  
Probes similar to DEVD-aminoluciferin have been developed and used for monitoring activity 
of other caspases such as caspases 8 and 9.[63] However, to date, these probes have only been evalu-
ated in cells and zebrafish embryos but not validated in living mice. 
Another example of protease imaging with caged-luciferin probes is imaging furin protease 
activity. Furin enzyme, ubiquitously expressed in mammalian cells, is a member of pro-protein con-
vertase family which activates a number of precursor proteins upon cleavage.[64] Recent research has 
shown that furin is overexpressed in head and neck cancer, breast tumor, lung cancer and following 
viral-induced inflammatory conditions, such as HIV, influenza and dengue fever.[64-66] Inhibition of the 
furin enzyme has been shown to reduce the invasiveness and tumorigenicity of several human cancer 
cells lines in vitro and in vivo.[67,68] Furin cleaves at the C-terminus of a four-residue motif (Arg-X-
Lys/Arg-Arg) where X is any amino acid[69] and this sequence is critical for binding the active furin.[70] In 
an aim to monitor furin activity in vivo, three tetrapeptides were conjugated to aminoluciferin (Figure 
1.4); Ac-RYKR-aminoluciferin, Ac-RVRR-aminoluciferin, both of which are recognized by furin, and a 
control probe Ac-RRKY-aminoluciferin that is a not recognizable by furin.[71] The first two probes 
demonstrated high specificity for furin cleavage in cell-free enzymatic assays, as well as in cells with 
high levels of furin expression. The control probe, Ac-RRKY-aminoluciferin, could not be hydrolyzed by 
furin, and therefore this probe was not bioluminescent. The Ac-RVRR-aminoluciferin probe, which gen-
erated higher bioluminescence signal in vitro compared to Ac-RYKR-aminoluciferin, was further vali-
dated in a mouse xenograft model.  
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Figure 1.4: Structures of caged-luciferin probes for imaging furin activity. (a) Ac-RYKR-aminoluciferin, (b) Ac-RVRR-aminolu-
ciferin and (c) the control probe Ac-RRKY-aminoluciferin.[71] 
Carboxypeptidases (CPs) are a protease family of enzymes that hydrolyze polypeptides and 
proteins at the C-terminal end, performing diverse roles in normal biological processes and diseases.[72] 
Two probes for bioluminescence imaging of Carboxypeptidase A (CPA) and Carboxypeptidase G (CPG) 
activities were reported in the literature.[73] Quinolyl-D-luciferin (QLuc) and D-luciferin were modified 
on the carboxylic acid of the thiazoline ring with respectively a tyrosine (QLuc-Tyr) and a glutamic acid 
(Luc-Glu) as shown in Figure 1.5. These probes were shown to be cleaved specifically by CPA and CPG 
releasing free QLuc and Luc. To our knowledge, these probes were only tested in cell-free assays in 
vitro.  
 
Figure 1.5: Caged substrates for imaging carboxypeptidases activity. QLuc-Tyr and Luc-Glu probes for carboxypeptidase G and 
carboxypeptidase A imaging respectively.[73] 
Among other proteases, only the caged probes to assay caspase 3/7 and furin activity have 
been validated in vivo. However, this methodology could theoretically be used to image the activity of 
a number of proteases that cleave after specific peptide sequences without requirement of fixed 
amino acids after the cleavage site. The examples of such proteases and their specific amino acid se-
quences include caspase 2 (VDVAD),[74] caspase 6 (VEID),[74] caspase 8 (LETD) and capase 9 (LEHD),[63] 
caspase 12 (ATAD),[75] thrombin (GGR),[76] dipeptidyl peptidase 4 (GP, AP or VP),[77,78] and tryptase 
(PRNK).[77,79] Additionally, this method could also be applied for a wide variety of bacterial, viral and 
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parasite proteases that are essential for infectious diseases.[80] Examples of these proteases and their 
specific amino acid sequences include SARS protease (TSAVLQ),[81,82] caspase-like (nLPnLD)[83] and tryp-
sin-like (LRR) proteases.[77]  
?????? ????????????????????????????????????????????????????????
Apart from proteases, caged-luciferin probes for imaging a wide variety of enzymes and bio-
logical processes were also reported in the literature. Covering all the examples in detail is beyond the 
scope of this introduction, however a brief overview will be provided. Probes developed via function-
alization of the 6’-position on the luciferin scaffold are shown in Table 1.2. These caged-luciferins were 
modified on the phenyl oxygen or 6’-nitrogen atom by conjugation with a specific substrate of the 
enzyme of interest. For example, a probe for imaging ?-galactosidase was developed via conjugating 
the phenolic oxygen of D-luciferin to a galactoside moiety. The resulting probe, a D-luciferin-O-?-ga-
lactoside, also named Lugal, has been validated for sensing galactosidase activity in numerous exam-
ples and is now commercially available (Table 1.2, entry 3). Lugal reacts specifically with the ?-galac-
tosidase enzyme to release D-luciferin in vivo.[46,84] Similarly, caged-luciferin probes for ?-lac-
tamases,[85] glutathione S-transferase,[86] alkaline phosphatase[87] and sulfatase[88] were reported for 
imaging in different experimental setups, ranging from in vitro cell-free assays to in vivo experiments 
(Table 1.2, entries 4-7). 
Our laboratory recently reported a caged luciferin probe for imaging nitroreductase (NTR) en-
zyme in living animals.[89] D-luciferin scaffold was modified on the phenolic oxygen with a nitrofuryl 
moiety (Table 1.2, entry 8). The reduction of the nitro group by NTRs results in an electron-donating 
amino group which promotes the cleavage of the C-O bond leading to subsequent release of D-lucif-
erin. This probe was validated for imaging NTRs in living bacteria, mammalian cells as well as in mouse 
models of cancer and bacterial infection.[89] This new probe should significantly simplify the screening 
of prodrugs in vivo and accelerate the process to develop enzyme-activatable therapeutics. 
As described earlier, BLI is a powerful imaging modality to quantify enzymatic activities in real 
time with specific caged-luciferin derivatives, and not surprisingly, this method has also been used to 
study metabolites in vivo. Metabolites are small molecules that play essential roles in diverse biological 
processes such as energy production, protein synthesis and signaling. The ability to image real time 
metabolite uptake, spatial localization of transport and absorption, or concentration variation during 
a biological process is of high importance. Cohen et al. developed a bioluminescent assay to measure 
level of glycosylation on the cellular membrane using the caged-luciferin approach.[90] In this study, the 
probe had D-luciferin conjugated to a triphenylphosphine that, upon reaction with azido groups on the 
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targeted azido-modified glycans, released free D-luciferin via bioorthogonal Staudinger ligation (Table 
1.2, entry 9). This approach could potentially be applied to any metabolite or molecule of biological 
interest that can be modified with an azido group. 
Table 1.2: List of reported caged-luciferin probe for imaging processes of interest (target). The cage molecular structures on 
the 6’-position of D-luciferin for specific targets are depicted as well as the scope of the reported application. 
?
?
 Cage Structure(s) 
 
Target(s) Validated Applica-
tion Scopes 
Ref. 
1 
 
z-DEVD-aminoluciferin 
Caspase-3/7 In vivo 57-62 
2 
 
Ac-RVRR-aminoluciferin 
Furin In vivo 71 
3 
 
Lugal 
?-galactosidase In vivo 46,84,91 
4 
 
Bluco 
?-Lactamases In vivo 
 
85 
5 
 
glutathione S-transferase In vitro cell-free 
 
86 
6 
 
Alkaline phosphatase In vitro cell-free 
 
87 
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7 
 
Sulfatase In vitro 
cell lysate and 
live cell 
 
88 
8 
 
nitrofuryl caged-luciferin 
Nitroreductase In vivo 89 
 
9 
 
triphenylphosphine caged-luciferin 
Glycosylation  
(azido-modified sugars) 
In vitro cell-based 90 
10 
 
PCL-1 
Hydrogen peroxide In vivo 92 
11 
 
Hydrogen sulfide In vivo 93,94 
12 
 
Photocaged-luciferin 
Light irradiation In vivo 95,96 
13 
 
Cellular uptake  
(probe reduction  
by Glutathione) 
In Vivo 97,98 
14 
 
FFA-SS-Luc probe 
Cellular uptake of fatty acid 
(probe reduction by Gluta-
thione) 
In vivo 99 
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?
? In the same way, a caged-luciferin probe, PCL-1, was developed for imaging H2O2 production 
in living systems (Table 1.2, entry 10).[92] Based on a similar approach, caged-luciferin probes for de-
tection and imaging of H2S were developed,[93,94] as well as photocaged-luciferins (Table 1.2, entry 11) 
where the uncaging process occur via photolysis at specific wavelength.[95,96] 
 Another application of caged-luciferin approach is monitoring cellular uptake of molecules in 
cells. Methods to monitor cellular uptake of a target molecule is highly beneficial to understand the 
mechanism of uptake, quantify the uptake’s efficiency or adapt the dose treatment. The most com-
monly used method to study cellular uptake of drug molecules and biomolecules is to couple the mol-
ecule of interest with a fluorophore (e.g. FITC, TAMRA) and then measure the fluorescence of the 
treated cells with fluorescence spectroscopy or FACS.[100] These methods may however suffer from a 
non-specific signal coming from molecules bound to the cell surface that cannot be discriminated from 
the internalized signal.[101] Moreover, hydrophobic and large fluorescent probes could significantly al-
ter the properties and behavior of the molecule of interest.[102-104] To date, only few examples describ-
ing the application of BLI to monitor cellular uptake of molecules were reported. This methodology is 
based on the fact that, for mammalian cells expression, FLuc enzyme is a cytosolic enzyme, and there-
fore, light is emitted only when the molecule of interest had already crossed the membrane barrier. 
Caged-luciferin molecules designed to monitor cytosolic uptake would facilitate the evaluation of in-
ternalization mechanisms and kinetics in living systems. 
 Examples of caged-luciferin molecules to study cellular uptake includes cell-penetrating pep-
tides coupled to D-luciferin via a disulfide linker, which is selectively cleaved upon cellular entry where 
high concentration of glutathione is present (Table 1.2, entry 13). The intermediate thiol then under-
goes an intramolecular cyclization reaction to release D-luciferin, which would subsequently emit light 
in the presence of FLuc enzyme.[97] These probes were validated in vivo for real-time quantification of 
cell permeable peptides uptake.[98] A similar strategy was adapted to investigate fatty acid uptake in 
vivo. The caged probe consists of a long-chain fatty acid conjugated to D-luciferin via an intracellular 
releasable linker (Table 1.2, entry 14).[99] 
 All the bioluminescent probes covered so far were developed via “caging” the D-luciferin (or 
amino analogue) through acylation or alkylation of the 6’-substituant, the phenyl-oxygen or nitrogen 
atom. Another possibility to cage luciferins is to modify the thiazoline carboxylic acid. Such examples 
were reported in the literature as probes to image fatty acid amide hydrolase activity, in which the 
carboxyl group of D-luciferin (or derivatives) were replaced with an carboxamide moiety (Table 1.3, 
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entry 1), or Lucifeirn-IPA, an isopropyl acetal of D-luciferin, to image Cytochrome P450 3A4 isoform 
activity (Table 1.3, entry 2). Luciferin-IPA probe is initially processed by CYP3A4, yielding a D-luciferin 
ester that further need to be hydrolyzed by esterases for the generation of free D-luciferin.[105-107] Both 
probes were validated in living mice for imaging of their respective targets.  
In addition to caging through either hydroxyl/amino or carboxyl groups, a dual caged luciferin 
probe was developed for imaging monoamine oxidase (MAO) activity. This probe consists of a D-lucif-
erin scaffold, caged on the phenolic oxygen with an aminopropyl group and on the carboxylic acid with 
a methyl group (Table 1.3, entry 3). MAO enzyme converts the amine group to imine that will undergo 
non-enzymatic reactions to yield D-luciferin methyl ester. Then, esterase function is necessary to re-
lease the bioluminogenic D-luciferin molecule.[108] 
Table 1.3: Reported probes caged on the carboxylic acid of luciferin scaffold. The probe structures for specific targets are 
depicted as well as the scope of the reported application. 
 Caged-luciferin Structure(s) Target(s) Application Scope Ref.
1 
 
Fatty acid amide hydrolase In vivo 105 
2 
 
Luciferin-IPA 
Cytochrome P450 In vivo 106,107 
3 
 
Monoamine oxidases (iso-
zymes A and B) 
In vitro cell-free and 
cell lysate 
 
108,109 
 
?
Development of caged-luciferin derivatives extended the use of BLI in vitro and in vivo. These 
modified luciferins allowed imaging of multiple biological events non-invasively in real time. Number 
of caged-luciferin probes were validated for imaging and quantifying enzymatic activities, monitoring 
metabolite production, cellular uptake or cargo delivery as well as detecting cellular proximity. The 
variety of probes based on D-luciferin or derived scaffold demonstrates the versatility of modifications 
that can be realized, broadening the scope of BLI applications. 
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Compared to other in vitro and in vivo optical imaging techniques, BLI has the advantage of 
high sensitivity, convenience and ease of use. Unlike fluorescence, BLI does not demand an excitation 
light source, resulting in no background signal from naturally occurring fluorophores or induced photo-
toxicity.[110] Consequently, BLI is highly sensitive and yields superior signal-to-background ratio, making 
it advantageous over fluorescence imaging especially for in vivo applications.[5] On the other hand, 
fluorescent probes are usually brighter compared to bioluminescent reporters as they can be used 
with powerful excitation sources.[20] Moreover, available emission wavelengths of fluorescent probes 
cover almost all the light spectrum, offering an straightforward possibility of multicolor imaging. These 
properties render fluorescence imaging a preferred solution for in vitro applications such as fluores-
cence microscopy, which provides subcellular information.[6]  
BLI has found considerable use in monitoring biological processes such as tumor growth,[111,112] 
gene expression,[113] pathogen detection and therapy evaluation,[114,115] protein-protein interac-
tions[116] as well as ADMET (absorption, distribution, metabolism, excretion and toxicity) studies.[6] 
Moreover, BLI is a non-invasive imaging technique which, when coupled with the low toxicity of the 
substrate D-luciferin in vivo, allows multiple imaging on the same subject over a prolonged period of 
time, facilitating the tracking of molecular changes longitudinally. BLI probes are ideal for in vivo appli-
cations, providing good sensitivity with low toxicity. Excitation light is not required in BLI, thus over-
coming related drawbacks of traditional fluorescent probes. The main limitation of the D-luciferin/FLuc 
system is the dependence on the luciferase enzyme which limits BLI applications to biological systems 
expressing this enzyme (e.g. engineered cells or genetically-modified animals). Another limitation of 
BLI is the sub-optimal tissue penetration of the produced light. Recent developments on the red-
shifted and brighter D-luciferin derivatives however, address the low tissue penetration of light with 
BL.[41-43,45,117] These novel molecules show great promise to enhance the detection sensitivity and 
therefore offer the possibility to monitor biological events occurring in deep tissues. The progress on 
the development of red-shifted luciferase mutants,[16,118-121] coupled with increased selectivity of new 
luciferin scaffolds will allow BLI with better sensitivity. This is promising for imaging fewer cells in vivo 
and will provide new opportunities for multiplexing imaging, where different luciferin/luciferase pairs 
could be used and measured simultaneously at different wavelength.[40]  
???? ??????????????????????????????
The discovery of green fluorescent protein (GFP) greatly enhanced the field of protein imaging 
in living environment.[122] Fusion proteins with GFP or other fluorescent protein variants have proven 
to be a very efficient tools to study and visualize proteins in their native environment. Other genetically 
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encoded tags were also developed for covalent labelling of proteins with fluorescence imaging 
agents.[123] These methods include self-labelling enzymes (e.g. SNAP or CLIP tags),[124-126] peptide-based 
post-translational labeling[127,128] and enzymatic labelling of proteins (e.g. probe incorporation medi-
ated by enzyme, PRIME).[129,130] However, non-proteinaceous biomolecules such as nucleic acids, gly-
cans, lipids as well as post-translational modifications on proteins cannot be monitored using the ge-
netic-encoded tags. In order to image these biomolecules in their native environment, further chemical 
modifications are necessary. To overcome this question, bioorthogonal ligation reactions were em-
ployed. In a first step, a small tag – the chemical reporter – is introduced in the biomolecules of interest 
using metabolic or enzymatic labelling.[130,131] In a second step, the biomolecule of interest is conju-
gated to a molecular probe bearing a functionality complementary to the chemical reporter.[132,133] In 
order to perform this conjugation reaction, selective and efficient ligation reactions are necessary. 
Bioorthogonal ligation reaction (or biocompatible click reactions), do not interfere with chemical func-
tionalities found in living system (Figure 1.6).[131,133] They fulfill all the requirements to be used in com-
plex and molecularly diverse environments as biological systems. The reaction needs to be very selec-
tive to minimize the background, have a fast reaction rate at physiological temperature and be com-
patible with physiological conditions such as the presence of water and oxygen. Moreover, the ligation 
product needs to be stable and non-toxic. Apart from application in living system, functionalization of 
targeting molecules (e.g. antibodies, proteins) is also simplified with bioorthogonal chemistry, allowing 
easy and selective conjugation with simpler purification steps. 
 
Figure 1.6: Bioorthogonal reactions: The reaction between compounds X and Y occurs efficiently and selectively to form the 
ligation product without interfering with the functionalities naturally found within biological environment (Figure adapted 
from [133]). 
Bioorthogonal reactions have gained in popularity in the previous decades.[133] While a number 
of biocompatible ligation reactions have been used to study biological molecules, only a fraction of 
them possess the requirements necessary for application in living cells. Even though studies with live 
cells have tremendously advanced our understanding in many human pathologies, their great com-
plexity requires tools to study on the level of the whole organism. Since multiple animal models of 
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various human pathologies have been successfully established,[134-139] development of new biocompat-
ible reactions applicable to the whole animal could play crucial role in biology and medical research.   
The complexity of the system increases when moved from cellular to living animal environ-
ment, and therefore the requirements for the chemistry increase to be more efficient and selective. 
The two components now have to react with each other in the presence of a much more complex 
biological environment with many other additional active substances. Moreover, a living animal rep-
resents a dynamic system, where the reagents could be quickly metabolized or simply cleared from 
the circulation before they are able to react. Parameters such as toxicity, bio-distribution and half-life 
of the reagents are crucial for the success of this methodology in vivo. Regarding all these restricting 
requirements, only a few biocompatible reactions have been validated in living organisms and animals. 
These in vivo bioorthogonal reactions encompass the strain-promoted azide-alkyne cycloaddition 
(SPAAC),[140-145] the Staudinger ligation (SL)[146-154] and the inverse electron demand Diels-Alder reaction 
(IED DA) (Table 1.4).[155-161]  
Azides are one of the most widely used bioorthogonal reactive partners in bioligation and la-
belling applications. Due to their small size, azides can be incorporated into biomolecules without sig-
nificantly affecting the molecular characteristics or interaction of the biomolecule within the natural 
environment. Azide functional group is not endogenously available and is inert in biological conditions. 
They can react efficiently and selectively with different various bioorthogonal reagents such as SL rea-
gents or alkynes via SPAAC (Table 1.4). 
Table 1.4: Bioorthogonal ligation reactions for in vivo applications. The chemical reporter (Reagent X) on the biomolecule of 
interest is conjugated with a molecular probe (Reagent Y) bearing the complementary bioorthogonal functionality. The yellow 
star represents the imaging reporter (e.g. fluorophore, radiolabel). 
?
 Reaction Reagent X Reagent Y Ligation product Ref.* 
1 Staudinger Ligation (SL) 
 
  
90,143,149,150,162-
164 
2 
Strain-Promoted Azide-
Alkyne Cycloaddition 
(SPAAC) 
 
 
165-170 
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3 
 
163,169 
4 
Inverse Electron Demand 
Diels-Alder reaction (IED 
DA)  
 
 
156,163,171-175 
* Examples for in vivo applications of the bioorthogonal reaction. 
The SL is a modified type of Staudinger Reaction where an electrophilic intramolecular trap is 
introduced on the triarylphosphine, leading to formation of a covalent bond, enabling the conjugation 
(Table 1.4, entry 1).[147] SL is particularly advantageous as it occurs under physiological conditions with-
out a catalysts.[176] However, SL has disadvantages such as poor shelf life of the SL reagent due to sen-
sitivity of phosphine to oxidation and relatively slow reaction kinetics (k = 2.5×10-3 M-1s-1)[146] compared 
to other bioorthogonal reactions.[177] 
The SL has extensively been used for fluorescent labelling in living cells.[152,153,178-180] Due to 
favorable pharmacokinetic properties and low toxicity, the SL has also been shown to work efficiently 
in living mice, avoiding non-specific binding to other biomolecules. Beside its applications in cells, SL 
was reported for labelling and imaging cell surface glycans in living mice,[90,143,145,149,150] including radi-
onuclide and fluorescent labelling in a mouse subcutaneous xenograft model.[162] 
SPAAC reaction consist of a 1,3-dipolar cycloaddition between a cyclic alkyne and an azide to 
yield a substituted triazole. Functionalized activated cyclooctynes were developed as bioorthogonal 
reagents and many derivatives were reported for biological applications.[177] In order to activate the 
alkynes in cyclooctynes, different strategies were applied, such as the introduction of electron with-
drawing groups on the alpha position of the triple bond (e.g. difluorinated cyclooctyne (DIFO)) (Table 
1.4, entry 2),[181] or increasing the ring strain by introduction of unsaturation on the cyclic octyne (e.g. 
dibenzocyclooctyne (DIBO)) (Table 1.4, entry 3).[144] Different cyclooctyne derivatives combining these 
two activation approaches were reported,[141,142,182] with reaction kinetics ranging from 10×10-3 to 
400×10-3 M-1s-1.[183] Therefore, SPAAC reagents such as DIFO or DIBO that induce fast reactions with no 
toxicity have been shown to be better alternatives for live cell applications compared to SL. On the 
other hand, cyclooctyne-based probes seem to be less attractive than Staudinger reagents for in vivo 
Introduction 
20 
applications in rodents, probably because of unfavorable bioavailability.[90,143,149,169] Using a DIFO-fluor-
ophore conjugate, non-invasive imaging of cell-surface glycans in zebrafish embryos was performed 
upon metabolic labelling with an azido-modified sugar, allowing the spatiotemporal study of cell-sur-
face glycan expression with multicolor fluorescence microscopy.[166,168] Using a similar approach, the 
distribution and dynamics of glycans biosynthesis was studied in Caenorhabditis elegans (C. ele-
gans).[167] In mice, Azido labelled splenocytes were modified in vivo using SPAAC, further revealed with 
a fluorescent probe ex vivo and analyzed by flow cytometry.[165] Another example of SPAAC use in vivo 
is the fluorescent imaging of azido labelled glycans in a subcutaneous mouse model.[163]  
Tetrazines can react selectively with trans-cyclooctenes (TCO) via an IED DA reaction (Table 
1.4, entry 4), followed by a retro-[4 + 2] cycloaddition, yielding the ligation product with N2 re-
lease.[159,184] Different TCO or tertazines derivatives were reported, resulting in different reaction rates 
(k ranging from 103 to 104 M-1s-1).[159,173,185-187] IED DA reactions between tetrazines derivatives and TCO 
conjugates were used as bioorthogonal reactions for fluorescent labelling on cell surface and intracel-
lular targets.[188-191] Using a pre-targeting approach with a TCO labelled antibody, fluorescent labelling 
of cancer epitopes was performed by subsequent reaction with tetrazines-polymer conjugate in a tu-
mor xenograft mouse model. The polymer was functionalized with fluorophores or a positron emission 
tomography (PET) tracer, allowing in vitro and in vivo microscopy as well as PET analysis in living 
mice.[156] Other reports of the IED DA reaction for imaging application include fluorescent labelling,[163] 
PET analysis in murine cancer models[171,172] and single-photon emission computed tomography 
(SPECT) applications[173-175] 
???? ?????????????????????????????? ?????????????????????????????? ???
????????????
Bioorthogonal reactions have been extensively used for multiple biochemical or imaging appli-
cations. Such chemistries revealed to be convenient, reliable and versatile as ligation reactions, both 
in vitro and in biological systems. Nevertheless, there is still a need for new biocompatible ligation 
reactions as supplementary tools that can potentially be more efficient and/or be used in conjugation 
with other bioorthogonal reactions. There has been a recent interest in 2-cyanobenzothiazole (CBT)-
based ligation reaction for bioconjugation applications. This reaction is a condensation reaction be-
tween CBT derivatives (e.g. 6-hydroxy-CBT (HO-CBT) or 6-amino-CBT (H2N-CBT) conjugates) and a 1,2-
aminothiol group. When the aminothiol moiety is a D-cysteine molecule, the reaction is called split 
luciferin reaction (Scheme 1.6), which was first reported in 1963 as the final step in the synthesis of D-
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luciferin.[192] As split luciferin reaction potentially occurs naturally and efficiently in fireflies, it is bio-
compatible and therefore can be used as ligation reaction in biological environments.  
 
Scheme 1.6: Condensation reaction between 6-hydroxy-2-cyanobenzothiazole or 6-amino-2-cyanobenzothiazole with D-cys-
teine yielding D-luciferin or D-aminoluciferin, respectively. 
The CBT condensation reaction with 1,2-aminothiols is particularly appealing for bioconjuga-
tion applications, because it can be conducted at ambient temperature under physiological (i.e. aque-
ous) conditions and shows high selectivity toward aminothiols over any other biological nucleophiles. 
Moreover, the reaction is highly rapid: second-order rate constant for the reaction of cysteine with a 
CBT derivative (N-(2-cyano-benzothiazol-6-yl)-succinamic acid) is 9.19 M-1s-1.[193] This second order re-
action rate is significantly higher than other well established bioorthogonal reactions such as the reac-
tion of azides with cyclic-octynes (SPAAC) or phosphines (SL), respectively two and three order of mag-
nitude higher (i.e. DIFO: k = 7.6×10-2 M-1s-1[165]; substituted triphenylphosphine k = 2.0×10-3 M-1s-1[146]). 
Moreover, split luciferin reaction is highly efficient, resulting in high yields, with chromatographic pu-
rification not systematically necessary.[194-198] 
Condensation of cysteine with electrophilic nitriles occurs in three steps, optimally at slightly 
basic pH (Scheme 1.7): reversible attack of the cysteine (2) thiol to the nitrile (1) to form a thioimidate 
intermediate (3); intramolecular attack of vicinal amine to the thioimidate forming the thiazolidine (4); 
and loss of ammonia to form the thiazoline product (5). 
 
Scheme 1.7: Reaction mechanism between 6-hydroxy-2-cyanobenzothiazole (HO-CBT) and cysteine. 
The bimolecular interaction between cysteine and the nitrile in the first step is the rate-limiting 
step (Scheme 1.7). The second and third reaction steps are rapid intramolecular processes that lead to 
the formation of thiazoline product. Reaction of electrophilic nitriles with thiols that lack the vicinal 
amino group stops at the first step to yield thioimidates (3). Accordingly, simultaneous treatment of 
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electrophilic nitriles with aminothiols and simple thiols results in the formation of thiazoline products 
derived from the aminothiols. This suggests that aminothiols can react with the thioimidates of simple 
thiols or that the reversibility of the thioimidate reaction with simple thiols allows formation of the 
stable thiazoline product to predominate.[193] Aminothiols are thus selective coupling partners even in 
the presence of simple thiols (e.g., N-terminal cysteines in peptides and proteins can form stable prod-
ucts in the presence of internal cysteines). 
The CBT-condensation reaction with 1,2-aminothiols was employed for several bioconjugation 
applications (Scheme 1.8a). The split luciferin reaction can be blocked (caged) via chemical modifica-
tion of the 1,2-aminothiol moiety. When the amine, the thiol or both are functionalized, the conden-
sation reaction with CBT is blocked. Therefore, addition of specific molecular patterns on these posi-
tions opens up the possibility to control the reaction by specific stimuli. This concept has generated 
multiple applications where the CBT-based ligation reaction is only occurring under specific conditions.   
 
Scheme 1.8: 2-cyanobenzothiazole (CBT) condensation reaction with 1,2-aminothiols. a) Ligation reaction between the nitrile 
of CBT and 1,2 aminothiol. X moiety on the CBT molecule or Y moiety on the 1,2 aminothiol can be modified for particular 
applications. b) Site specific fluorescent labelling of proteins containing N-terminal cysteine.[193] c) Polymeric condensation 
reaction controlled by pH, disulfide reduction or enzymatic cleavage depending on the nature of R1 and R2 groups. R3 can be 
used for functionalization with a fluorophore or a tag (e.g. biotin).[194] 
Selective functionalization of proteins at N-terminal cysteine residue with a fluorophore was 
performed using the CBT-based ligation reaction in living cells (Scheme 1.8b).[193] In this study, a fluor-
ophore-CBT conjugate was used for imaging a cell-membrane protein, engineered to have an N-termi-
nal cysteine residue. Importantly, the CBT fluorescent conjugate selectively reacts with the N-terminal 
cysteine but not with thiols from cysteine residues present in the middle of the sequence. Using a 
similar CBT molecule conjugated to a fluorescent probe, site specific labelling of proteins was achieved 
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by the use of a genetically encoded 1,2-aminothiol.[199,200] The reverse strategy was applied with a CBT-
modified nucleotide in combination with a 1,2-aminothiol fluorophore construct and employed for 
site-specific modification of DNA.[201] Moreover, site-specific immobilization of proteins and biomole-
cules containing terminal 1,2-aminothiols were performed using the CBT-based ligation reaction.[202,203] 
A controlled assembly of polymer and nanostructure in living cells was achieved by creative design of 
a monomer, a CBT molecule conjugated to functionalized-1,2-aminothiol (Scheme 1.8c).[194] The trig-
gering process of the condensation reaction is the removal of the molecular masks on the aminothiol 
function, revealing free 1,2-aminothiol that could then react with the nitrile of another monomer. The 
condensation reaction can be directed by pH, disulfide reduction or protease cleavage. Moreover, the 
structure of the monomer can tune the size of the assembled structure properties. Protease imaging 
by controlled macro-cyclization was performed using a comparable approach.[195] 
Liang and coworker have used the potential of split luciferin reaction for multiple applications. 
They used the CBT-based ligation reaction for the preparation of nanostructures. For example, multi-
functional small monomers containing both the 1,2-aminothiols and CBT nitrile functionalities were 
designed to produce a controllable and reversible polymerization process to prepare oligomeric nano-
particles.[196] Similarly, glutathione (GSH) dependent self-assembly of nanorings was used for in vitro 
detection of GSH,[198] as well as a caspase-3 dependent condensation reaction for self-assembling bio-
tinylated nanoparticles that can capture and subsequently turn on the fluorescence signal of FITC-la-
belled streptavidin.[204] 
The CBT-based ligation reaction was also applied to various imaging modalities. Miao et al. 
used a furin-controlled intracellular formation of nano-structure formed by the CBT-based condensa-
tion reaction of radiolabeled-monomers. This could help retaining the radionuclides in cancer cells and 
thus could be promising for potential nuclear medicine applications.[205] Moreover, the condensation 
reaction between CBT and 1,2-aminothiols was reported for the assembly of Gadelinium labelled na-
noparticles that process an enhanced relaxivity in vitro and in living cells compared to the precur-
sors.[206] Using an 18F-modified CBT, Jeon et al. reported radio-labelling of a dimeric cRGD peptide bear-
ing 1,2-aminothiol functionality and its subsequent use for in vivo tumor imaging using PET. Site spe-
cific 18F-labelling of a protein was also shown using the same chemistry,[207] as well as 18F-labelling of 
cyclo-(RGDfK) targeting moiety (Figure 1.7).[208] 
 
Figure 1.7: Functionalization of targeting moieties with imaging reporters via the CBT-based ligation reaction. 
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 Any targeting moieties, such as peptides, proteins, antibodies or small molecules, could poten-
tially benefit from the CBT-based ligation reaction for functionalization with imaging probes. CBT could 
be conjugated to an imaging reporter such as a fluorophore, radionuclide or chelating agent (e-g- 
DOTA, NOTA) and thus could be used for the development of targeted probes for imaging. Moreover, 
as the 1,2-aminothiol can be easily introduced in proteins or peptides as N-terminal cysteine, it simpli-
fies greatly the introduction of a chemical handle for functionalization on proteinaceous molecules.
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Studies on the level of living cells have tremendously advanced our understanding of patholo-
gies. However, the great complexity of diseases requires animal models of human pathologies[134-139] 
and thus tools that allow imaging on the level of whole organism (in vivo) are necessary. Accordingly, 
development of new biocompatible ligation reactions applicable for studies of biological processes in 
vivo can play a crucial role in biology and medical research. When the complexity of the system in-
creases from cells to animals, more requirements come into play for a successful ligation reaction. In 
the past decade many biocompatible ligation reactions have been developed to study various biologi-
cal processes in cells.[133] However, only a fraction of these reactions can be used in living animals. 
These in vivo bioorthogonal reactions comprise the strain-promoted azide-alkyne cycloaddition 
(SPAAC),[140-145] the Staudinger ligation (SL)[146-154] and the inverse electron demand Diels-Alder reaction 
(IED DA) (Table 1.4, chapter 1).[155-161] 
 Considering all this, novel in vivo compatible bioorthogonal reactions are needed in order to 
expend the application scope of imaging and functionalization methodology. One reaction of interest 
is the split luciferin reaction between D-cysteine and 6-hydroxy-2-cyanobenzothiazole (HO-CBT) that 
was first reported half a century ago as the final step in the synthesis of D-luciferin (Scheme 2.1).[192] 
More recently, other groups have reported applications of this reaction for selective labeling of pro-
teins on N-terminal cysteines[193,199] as well as for controlled assembly of polymers in physiological so-
lutions and living cells.[194,195] Notably, the rate of split luciferin reaction has been reported to be three 
orders of magnitude faster than that of Staudinger ligation.[193] 
?
?
?
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Scheme 2.1: Split luciferin reaction. Condensation reaction between HO-CBT or H2N-CBT with D-cysteine resulting in the for-
mation of respectively D-luciferin or D-aminoluciferin. 
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 The reaction between D-cysteine and HO-CBT or 6-amino-2-cyanobenzothiazole (H2N-CBT) can 
yield substrates for firefly luciferase (FLuc), and thus has great potential for use in bioluminescence 
imaging (BLI).[6,114,209] In this chapter, the evaluation and validation of the split luciferin reaction for BLI 
application is reported. The bioluminescence emission resulting from the administration of HO-CBT or 
H2N-CBT and D-cysteine were compared with that from corresponding luciferins, in enzymatic, cells 
and animals assays. Until the current study, the split luciferin reaction has neither been employed in 
vivo, nor for BLI applications. We demonstrated that D-cysteine and HO-CBT or H2N-CBT can efficiently 
generate luciferins in biological environment such as living cells and living mice. This split luciferin liga-
tion reaction is therefore highly valuable for in vivo imaging applications and could be of interest for in 
vivo biocompatible labeling. 
?
???? In vitro?????????????? ??????????????? ?????????????????????????????????
??????????
Since the previously reported reactions between HO-CBT or H2N-CBT and cysteine derivatives 
produce luciferin-like structures,[193-195,199] whether HO-CBT and H2N-CBT could form their respective 
luciferins directly in a physiological environment and could be detected by BLI was initially investigated 
(Figure 2.1).  
 
Figure 2.1: Overall schematic of the split luciferin ligation reaction between D- or L-cysteine and hydroxy- or amino-cyano-
benzothiazole derivatives (HO-CBT and H2N-CBT) in various biological environments. 
H2N-CBT or HO-CBT were incubated with either D- or L-cysteine in buffer containing FLuc en-
zyme (Figure 2.2) the BL emission was acquired. Importantly, the signal produced from the sample that 
had both H2N-CBT and D-cysteine was 1000-folds higher than the signals obtained from the sample 
containing H2N-CBT alone. H2N-CBT plus L-cysteine generated 50-folds higher light emission than CBT 
alone (Figure 2.2a). Similar results were obtained with HO-CBT and D-cysteine, with 1200-folds and 
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20-folds increase compared to respectively HO-CBT/D-cysteine and HO-CBT alone or HO-CBT/L-cyste-
ine and HO-CBT alone (Figure 2.2b). 
 
Figure 2.2: Formation of D-luciferin in vitro. (a) Total bioluminescent signal integrated over 30min observed from incubation 
of H2N-CBT (10 μM) with D-cysteine (10 μM), L-cysteine (10 μM) or vehicle in PBS solution, followed by addition of a FLuc 
solution and imaging. Error bars are ± SD for three independent measurements. (b) Total bioluminescent signal integrated 
over 30min observed from incubation of HO-CBT (10 μM) with D-cysteine (10 μM), L-cysteine (10 μM) or vehicle in PBS solu-
tion, followed by addition of a FLuc solution and imaging. Error bars are ± SD for three independent measurements. Statistical 
analyses were performed with a two-tailed Student’s t test. **P < 0.001, *P < 0.05. 
Next, formation of corresponding D-luciferin and D-aminoluciferin was confirmed using high 
performance liquid chromatography (HPLC) and high resolution mass spectrometry (HRMS). H2N-CBT 
or HO-CBT was incubated with D-cysteine in PBS buffer and the samples were analyzed (Figure S2.1). 
The results demonstrate efficient formation of luciferin analogs in PBS, that could directly produce 
photons of light in the presence of FLuc enzyme, confirming that the BL emission observed in the en-
zymatic assay (Figure 2.2) correlates with D-luciferin or amino analogue formation. 
?????? ????????????????????????????????????????????????????????????????????????
We next studied the rate of the reaction between CBT derivatives and L-cysteine under 
pseudo-first order conditions, using a standard HPLC assay.[195] The rate constants for the reactions of 
HO-CBT and H2N-CBT with L-cysteine were 3.2 and 2.6 M-1s-1 respectively, which is three orders of 
magnitude faster than those reported for the Staudinger ligation.[146,148,151,152] We further compared 
these reaction rates to that of a previously reported N-succinamidyl CBT derivative[193] (compound 3, 
Table 2.1, Figure S2.2, Figure S2.3, Figure S2.4). The rate constant for this compound was found to be 
7.1 M-1s-1 that is in agreement with the previously published value of 9.1 M-1s-1.[193] The lower reaction 
rate of H2N-CBT compared to its less electron-donating succinamide derivative is consistent with me-
someric effects on the reactivity of the nitrile. Thus, the rate of this reaction with CBT derivatives could 
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be further modulated by the introduction of electron-donating or electron-withdrawing ring substitu-
ents, and other electrophilic nitriles could be suitable reaction partners for cysteine.[210]  
Table 2.1: Reaction rate constants between 2-cyanobenzothiazoles derivatives and L-cysteine. 
 
Compound Structure 
Rate constant 
[M-1s-1] 
[M+H]+ of product 
(found) 
[M+H]+ of product 
(calculated) 
1 HO-CBT 
 
3.24 ± 0.117 280.9991 281.0055 
2 H2N-CBT 
 
2.63 ± 0.264 280.0200 280.0209 
3 N-succinamidyl-CBT 
 
7.10 ± 0.106 380.0372 380.0369 
???? ??????????????????????????????????????????????????????????????? ??????
???????????????????????????????????????
Next, whether HO-CBT and H2N-CBT could form their respective luciferins directly in live cells 
was investigated (Figure 2.1). Ovarian and breast cancer cells, stably expressing FLuc (SKOV3-luc-D3 
and MDA-MB-231-luc-D3H2LN), were treated with HO-CBT or H2N-CBT only, followed by imaging with 
a cooled CCD camera. Consistent with the in vitro cell-free results, treatment with either CBT derivative 
or D-cysteine alone produced only a low level of signal. L-luciferin was reported to produce light under 
certain conditions, but is also behave as a competitive inhibitor with respect to D-luciferin.[30,35] L-lucif-
erin formed upon HO-CBT reaction with endogenous L-cysteine could have affected the results either 
by generating background light emission upon administration of CBT only or lowering light emission 
upon CBT derivatives and D-cysteine treatment and could have resulted in high background upon ad-
ministration of CBT only or diminished light emission upon CBT derivatives and D-cysteine treatment 
by FLuc inhibitory effect. The BL signal from cells treated with HO-CBT only is approximately 23 times 
higher than the one without CBT, but remains very low compared to HO-CBT plus D-cysteine light 
emission. Signal measured from cells treated with HO-CBT only is more than 200 times lower than the 
light emitted from cells administered with HO-CBT and D-cysteine (Figure 2.3, Figure 2.4, Figure 2.5). 
Similarly, cells treated with equimolar amounts of both HO-CBT and L-cysteine produced a background 
signal close to the light emission of cells treated with HO-CBT alone. Similar results were observed with 
H2N-CBT instead of the hydroxyl analogue. It can be concluded that endogenous or supplemented L-
cysteine produce only a negligible light production after reaction with both HO-CBT or H2N-CBT com-
pared to similar experiments with D-cysteine.  In contrast, cells treated with either D-luciferin or D-
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aminoluciferin produced robust signal that was significantly higher than background (Figure 2.3, Figure 
2.4, Figure 2.5). 
 
Figure 2.3: Light emission resulting from the split luciferin reaction in living cells. (a) Total luminescence produced in 1 h from 
live SKOV3-Luc-D3 cells incubated with corresponding reagents, calculated by integrating the area under corresponding ki-
netic curves in Figure 2.3b. SKOV3-Luc-D3 cells were incubated for 1 h with either D-cysteine; HO-CBT; HO-CBT and L-cysteine 
(added simultaneously); D-luciferin, or HO-CBT and D-cysteine (added simultaneously) at 75 μM in PBS (wells 1-5). Cell first 
pretreated with D-cysteine for 20 min, followed by washing and 1 h incubation with HO-CBT and cell first pretreated with HO-
CBT for 20 min, followed by washing and 1 h incubation with D-cysteine (all at 75 μM in PBS, wells 6-7). Error bars are ± SD 
for three independent measurements. (b) Observed bioluminescence produced as a function of time from SKOV3-Luc-D3 live 
cells, incubated with following reagents: D-cysteine; HO-CBT; HO-CBT plus L-cysteine; HO-CBT plus D-cysteine; and D-luciferin 
(all at 75 μM in PBS pH=7.4). Error bars are ± SD for three independent measurements. 
 When the cells were incubated with equimolar concentrations of HO-CBT in the presence of 
D-cysteine, the amount of light produced by the cells treated with D-cysteine and HO-CBT exceeded 
the signal from an equivalent amount of D-luciferin by more than a factor of 5 (Figure 2.3, Figure 2.5a). 
Incubation of live ovarian cancer cells with a 1:1 ratio of HO-CBT and D-cysteine produced 5-fold more 
light than incubation with an equimolar amount of D-luciferin (Figure 2.3). Similarly, a 6.5-fold en-
hancement was obtained when the same experiment was repeated in live breast cancer cells (Figure 
2.5a). An increase in light emission was also observe when cells were incubated with equimolar con-
centrations of H2N-CBT in the presence of D-cysteine compared to the resulting light emission after D-
aminoluciferin treatment (Figure 2.4, Figure 2.5b). The signal produced from the two luciferin precur-
sors was concentration dependent in both cell lines. A higher BL signal was observed with increasing 
concentrations of HO-CBT or H2N-CBT and D-cysteine (Figure S2.5, Figure S2.6). The higher signal with 
HO-CBT or H2N-CBT and D-cysteine compared to the corresponding luciferins could be explained by 
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differences in their cell permeability. HO-CBT or H2N-CBT and D-cysteine may have better cell perme-
ability than the D-luciferin itself. It was previously reported that D-luciferins have sub-optimal pene-
tration properties, which can be improved by making their structures more lipophilic.[38,40] 
 
Figure 2.4: Split luciferin ligation reaction in living SKOV3-Luc-D3 cells. (a) Total bioluminescence signal observed over a period 
of 1 h (AUC) with SKOV3-Luc-D3 cells. Cells were first incubated 5 min with D-cysteine (7.5 or 75 μM), L-cysteine (75 μM) or 
PBS, followed by addition of H2N-CBT (7.5 or 75 μM) or D-aminoluciferin (75 μM) just before imaging. Error bars are ± SD for 
three measurements. 
 We speculated that if the hypothesis that the luciferin precursors possess higher cell penetra-
tion abilities is true, a big portion of the reaction should be happening inside the cell. In order to see 
whether this is the case, the cells were pre-incubated with one of the reagents, followed by washing. 
Light emission was observed in both cases, with higher signal being produced when the cells were pre-
incubated with D-cysteine, followed by extensive washing and subsequent addition of CBT (Figure 
2.3a, Figure S2.5a, Figure S2.6a). In fact, only 20 min exposure of the cells to D-cysteine followed by a 
wash and subsequent addition of HO-CBT, resulted in 30% and 60% of the overall signal produced in 
SKOV3-Luc D3 and MDA-MB-231-Luc-D3H2LN cells respectively, compared to incubation with equimo-
lar concentrations of both of the reagents simultaneously for the same period of time (Figure 2.3a, 
Figure S2.5a, Figure S2.6a). In addition, these signals are respectively 20% and 400% higher than the 
signal observed from the SKOV-Luc D3 and MDA-MB-231-Luc-D3H2LN cells, treated with equimolar 
concentration of D-luciferin control (Figure 2.3a, Figure S2.5a, Figure S2.6a).  
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Figure 2.5: Split luciferin ligation reaction in living MDA-MB-231-Luc-D3H2LN cells. (a) Total bioluminescence signal observed 
over a period of 1 h (AUC) with MDA-MB-231-Luc-D3H2LN cells. Cells were first incubated 5 min with D-cysteine (7.5 or 75 
μM), L-cysteine (75 μM) or PBS, followed by addition of HO-CBT (7.5 or 75 μM) or D-luciferin (75 μM) just before imaging. (b) 
Total bioluminescence signal observed over a period of 1 h (AUC) with MDA-MB-231-Luc-D3H2LN cells. Cells were first incu-
bated 5 min with D-cysteine (7.5 or 75 μM), L-cysteine (75 μM) or PBS, followed by addition of H2N-CBT (7.5 or 75 μM) or D-
aminoluciferin (75 μM) just before imaging.  Error bars are ± SD for three measurements. 
 However, when the same experiment was repeated where the sequence of addition of the 
reagents was reversed (pre-incubated with HO-CBT for 20 min, then washed and treated with D-cys-
teine), less than 10% of overall signal was observed in comparison to the signal resulted from simulta-
neous addition of both CBT and D-cysteine reagents in both cell lines (Figure 2.3b, Figure S2.5a, Figure 
S2.6a). The light emission from the experiments where SKOV-3 cells were first incubated with D-cys-
teine, washed and incubated with HO-CBT is 20 times higher (40 times for MDA-MB-231 cells) than the 
same experiments where HO-CBT is incubated first (Figure S2.5a, Figure S2.6a). This suggest that D-
cysteine remains available for reaction with HO-CBT after 20 min incubation and washing. On the other 
hand, it seems not to be the case for HO-CBT and a possible explanation would be a poorer cell per-
meability of CBT compared to D-cysteine. This might also be explained by reaction of HO-CBT with 
intra- or extra-cellular nucleophiles, reducing the CBT molecules available to react with D-cysteine. The 
reversible reaction of CBTs with free thiols was reported before, although the reaction remains selec-
tive for 1,2-aminothiols over free thiol moieties.[193] Cell permeability of luciferin precursors and lucif-
erins could have been investigated in more detail by incubation of non-luciferase expressing cells with 
or without D-cysteine and HO-CBT or H2N-CBT, followed by cell lysis after incubation. Addition of Fluc 
to cell lysate and subsequent BL acquisition would have been gainful to determine and compare cell 
permeability of different luciferin precursors and corresponding luciferin analogues. 
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Lastly, a robust concentration-dependent increase in signal was observed when the cells were 
treated with increasing amounts of D-cysteine, while the concentration of HO-CBT or H2N-CBT was 
kept constant (Figure S2.5, Figure S2.6). Importantly, this increase was not due to changes in FLuc 
activity as no increase in signal production was observed when the control cells were incubated with 
D-luciferin and increasing concentrations of D-cysteine (Figure 2.6). 
 
Figure 2.6: Effect of high D-cysteine concentrations on bioluminescence emission in SKOV3-Luc-D3 (a) and MDA-MB-231-luc-
D3H2LN (b) living cells. Total bioluminescence signal integrated over 1 h. Cells were incubated with D-cysteine (7.5 or 75 μM) 
or PBS together with either D-luciferin (7.5 or 75 μM) or D-aminoluciferin (7.5 or 75 μM). The cells were imaged immediately 
after addition of the last compound. Error bars are ± SD for three measurements.  
 Taken all together, these data suggest that both reagents might have much higher permeability 
than D-luciferin alone or higher stability in biological environment, which is supported by a significant 
increase in signal after equimolar addition of the two precursors in comparison to full luciferin controls 
(Figure 2.3, Figure S2.5, Figure S2.6). Indeed, HO-CBT or H2N-CBT are more hydrophobic than luciferins 
due to lack of carboxylic acid moiety, which could explain their better diffusion through the cell mem-
branes. Moreover, while no specific transporters are known to facilitate penetration of luciferins, D-
cysteine could still be a substrate for cysteine transporters, responsible for the uptake of L-cysteine by 
mammalian cells.[211-214] In addition, better stability and longer life time of the split luciferin ligation 
reagents in comparison to luciferins[25,37,58,97,215,216] may also play a significant role in the increased light 
output from live cells.  
Such excellent signal to background ratio and low contribution of endogenous L-cysteine 
makes split luciferin reaction ideal for bioluminescence imaging applications.[6,114,194] Moreover, the 
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significantly higher light observed from the addition of luciferin precursors in comparison to its corre-
sponding luciferin analogue presents an opportunity for much higher sensitive imaging of biological 
processes in live cells. 
???? ????????????????????????????????????????????????????????????????????????
??????????????????????????????????
Inspired by the exciting data from live cell assays, whether both of the luciferin precursors, HO-
CBT or H2N-CBT and D-cysteine, can react directly in living animals to form their respective luciferins 
was investigated (Figure 2.7). In order to visualize the luciferin formation non-invasively in real-time, 
transgenic animals that ubiquitously express luciferase in every cell under the control of the beta-actin 
promoter (FVB-luc+ mice) were used.[217,218] 
  
Figure 2.7: Imaging split luciferin reaction in living mice. Overall schematic of in situ formation of D-luciferin or D-aminolucif-
erin in living transgenic reporter animals.  
 First, the mice were injected with either HO-CBT or H2N-CBT alone and the resulting lumines-
cence emission was measured. Similarly to the results obtained in living cells, only background signals 
were observed (Figure 2.7, Figure 2.8) with the HO-CBT or H2N-CBT compared to luciferins signals. 
When these experiments were repeated with addition of an equimolar amount of D-cysteine 3 min 
before injection of HO-CBT or H2N-CBT, a robust signal was obtained only a few minutes after injection, 
suggesting the relatively fast rate of conversion of the reagents to full D-luciferin scaffold in vivo (Figure 
2.9).  
Notably, the signal produced from the animals injected with D-cysteine and H2N-CBT was 2.4 
times higher, but not significantly, than the signal from HO-CBT and D-cysteine (P = 0.0883, Figure 
2.8a), which is consistent with previously reported data for relative light output between D-aminolu-
ciferin and D-luciferin, being very close.[36,40] The split luciferin ligation reagents appear to possess de-
sirable pharmacokinetic properties, supported by the fact that robust signal is observed throughout 
the body of the living animal shortly after injection of both reagents (Figure 2.8b).  
Bioluminescence Imaging Using Biocompatible Split Luciferin Reaction 
34 
 
 
Figure 2.8: Split luciferin ligation reaction in living mice. (a) Total luminescence over 50 min from resulting bioluminescent 
signal from luciferase transgenic mice after IP injection of HO-CBT; D-cysteine and HO-CBT in equimolar concentrations (1:1); 
D-cysteine and HO-CBT in 1:10 ratio; and D-luciferin (1 equivalent represent a dose of 0.268 mmol·kg-1 in 100 μL of PBS). Error 
bars are ± SD for five measurements. Statistical analyses were performed with a two-tailed Student’s t test. (b) Representative 
image of mice 15 min post-injection of HO-CBT, HO-CBT + D-cysteine (equimolar concentration), HO-CBT + D-cysteine (10:1 
respective concentration ratio), HO-CBT + D-cysteine (1:10 respective concentration ratio) and D-luciferin(1 equivalent rep-
resent a dose of 0.268 mmol·kg-1 in 100 μL of PBS). 
?????? ???????????????????????????????????????????????????????????????????? ????
The total light output produced in the mice injected with D-cysteine and equimolar amounts 
of HO-CBT or H2N-CBT were approximately 10 and 20 % of the overall signal obtained from D-luciferin 
or D-aminoluciferin injected groups, respectively (Figure 2.8a). The opposite trend was observed in 
cells where the split luciferin reagents produced several fold higher light emission than the correspond-
ing luciferin derivatives (Figure 2.3, Figure 2.4, Figure 2.5). This difference in the ratio of signal produc-
tion between live animals and tissue culture cells could be explained by the fact that, in mice, the 
reaction is taking place in a large and complex environment. Reaction of CBT derivative with free en-
dogenous L-cysteine, binding to serum proteins, or metabolism of CBT in the liver could influence the 
yield of reaction and thus the resulting light emission. 
 Since increased concentration of D-cysteine led to a significant increase in the overall signal 
production in cells (Figure 2.3, Figure S2.5, Figure S2.6), the FVB luc+ mice were injected with 10 equiv-
alents of D-cysteine, followed by one equivalent of HO-CBT or H2N-CBT administration. The resulting 
signal increased by 7- and 6- fold for HO-CBT and H2N-CBT respectively, compared to the light output 
from injection of 1:1 ratio of both reagents (Figure 2.8). Substantially, the total light output from the 
mice injected with a 1:10 ratio of HO-CBT and D-cysteine produced half of the signal obtained from D-
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luciferin control group. Moreover, animals injected with a 1:10 ratio of H2N-CBT and D-cysteine pro-
duced an equivalent amount of light to the mice injected with the D-luciferin or D-aminoluciferin (Fig-
ure 2.8). This significant signal enhancement in vivo with increased concentration of D-cysteine is con-
sistent with the cell culture experiments (Figure 2.3, Figure S2.5, Figure S2.6). When the animals were 
injected with 1 equivalent of D-Cysteine and 10 equivalents of either HO-CBT or H2N-CBT, significant 
light enhancement was observed only in case of HO-CBT when compared to equimolar amounts of 
both the reagents. This observation might be explained by the fact that HO-CBT or H2N-CBT compounds 
might have different pharmacokinetic properties in living animals. But, it is important to keep in mind 
that the background generated by 10 equivalent of CBT derivatives alone would probably contribute 
to the enhanced signal. Further experiments would be necessary, to estimate the background gener-
ated by 10 equivalents of HO-CBT and H2N-CBT. 
?????? In vivo????????????????????? ??????????????????? ???????????????????????????????????? ????
?????????????
D-luciferin, when injected IP, typically produces a sharp peak reaching maximum at around 15 
min post-injection with about 3- to 4-fold increase in intensity of the signal, followed by the sudden 
drop.[36,113] This rapid change in the intensity of the signal with D-luciferin injection in animals has been 
recognized as a critical disadvantage in BLI.[113,219,220] For example, BLI has been widely used to quantify 
the size of the tumor in xenograft models where the animals are injected with luciferase-transfected 
human cancer cells.[221,222] This model, in combination with BLI, has been one of the major tools in drug 
discovery for testing anticancer drugs in animals.[223,224] However, since the BL signal from injected D-
luciferin changes significantly over time,[36,219,220] it could be difficult to assess the tumor size accurately. 
Currently, methods to stabilize the D-luciferin signal is even more urgent as new 3D BLI technologies 
have become routine and require longer imaging times.[225,226] 
Table 2.2: Signal variability of D-luciferin and its derivatives upon I.P. injection in living mice. 
Compounds Signal peak [min] 
% of increase be-
fore signal peak 
% of decrease af-
ter signal peak 
Decrease in intensity com-
pared to unmodified lucif-
erin 
Synthetic modifi-
cation / commer-
cial availability 
Amino-D-luciferin a) 10 300 75 in 50 min No / Yes
D-luciferin a) 5 200 67 in 50 min No / Yes
D-luciferin b) 15 200 60 in 1 h No / Yes
Glycine-D-aminoluciferin a) 20 c) 30 in 1 h 20-30 x  Yes / No
PEG-D-aminoluciferin d) 240 150 60 in 8 h 1.2 x Yes / No
HO-CBT + D-Cysteine b) 15 30 40 in 1 h 10 x No / Yes
a) Reference 36, b)Figure 2.9, c) the bioluminescence emission from Glycine-D-luciferin starts at 0 Total photon/sec and increase to approxi-
mately 2.5 Total photon/sec in 20 min.[36], d) Reference [220]. 
? Several attempts have been reported to address the D-luciferin signal variability in vivo includ-
ing usage of costly implantable osmotic pumps[219] and repeated substrate injections.[36] However, 
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suboptimal results were obtained in both cases leading to development of new chemically modified 
luciferins, which allow stabilization of the signal. Shinde et al.  reported a glycine-D-aminoluciferin an-
alog, which produced  much more stable signal in comparison to D-luciferin alone, although the inten-
sity of the signal was 20-30 times lower than that of D-luciferin or D-aminoluciferin.[36] Similarly, the 
Denmeade group reported PEGylated luciferin derivatives that yield more stable and prolonged light 
production compared to D-Luciferin, albeit with a significant reduction in overall light output (Table 
2.2).[220] 
 
Figure 2.9: Split luciferin ligation reaction in living mice. (a) Observed luminescence as a function of time after i.p. injection of 
HO-CBT; D-cysteine and HO-CBT in equimolar concentrations (1:1); D-cysteine and HO-CBT in 1:10 ratio; and D-luciferin (1 
equivalent represent a dose of 0.268 mmol·kg-1 in 100 μL of PBS). Error bars are ± SD for five measurements. (b) Observed 
luminescence as a function of time after IP injection of H2N-CBT; D-cysteine and H2N-CBT in equimolar concentrations (1:1); 
D-cysteine and H2N-CBT in 1:10 ratio; and D-aminoluciferin (1 equivalent represent a dose of 0.268 mmol·kg-1 in 100 μL of 
PBS). Error bars are ± SD for five measurements. 
 Figure 2.9a shows the kinetics of light production with D-luciferin in FVB-Luc+ mice in compar-
ison to equimolar injections of two luciferin ligation precursors (HO-CBT and D-cysteine). The signal 
from D-luciferin increased 200% in the first 15 minutes, reaching the maximum value, followed by 60% 
decrease from the peak by 60 min post injection, representing a significant change in a short period of 
time (Figure 2.9a, red line). However, the signal from HO-CBT and D-cysteine increased by only 30% in 
the first 15 minutes followed by 40% decrease from the peak by 60 min post injection, producing much 
smaller variability in overall signal. In addition, the light output could be dramatically enhanced by 
injection of increased amounts of D-cysteine or HO-CBT without significant loss in signal stability (Fig-
ure 2.9a, orange and yellow lines). Therefore, the new in vivo ligation reaction between HO-CBT and 
D-cysteine achieved remarkable stabilization of the signal without any synthetic manipulation (Table 
2.2). Since HO-CBT and D-cysteine are commercially available and are several times cheaper than un-
modified D-luciferin, this technology offers a simple and powerful tool to overcome signal variability 
of D-luciferins and have high potential in 3D imaging applications. On the other hand, H2N-CBT and D-
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cysteine did not produce a stable the light emission over time, unlike HO-CBT and D-cysteine. Differ-
ences in biodistribution or pharmacokinetics could be part of the explanation. This observation sug-
gests that HO-CBT and D-cysteine would be the imaging reagents of choice for BLI application where 
having a stable signal over time is important.  
???? ???????????
In this chapter the study of split luciferin reaction in enzymatic assay, living cells and animals, 
was presented. Current study shows that D-cysteine and HO-CBT or its amino analogue can efficiently 
react with each other in physiological environment, and therefore, the split luciferin approach is ap-
propriate for bioluminescence imaging of biological systems.  
In cells, the bioluminescent signal with the split luciferin reaction was higher than with the 
already formed D-luciferin or its amino analogue, suggesting that the luciferin precursors benefit from 
higher cellular permeability. A strong light emission was also observed in luciferase expressing animals 
after sequential administration of HO-CBT or its amino analogue and D-cysteine. In addition, the inten-
sity of the light output resulting from split luciferin ligation reaction increased significantly by injection 
of higher concentration of D-cysteine (Figure 2.8). The light emission was more stable over time than 
the emission generated by luciferins – an interesting property that might be useful for different appli-
cations requiring signal quantification or three dimensional imaging. Several-fold signal variation over 
a short period of time with D-luciferin causes significant errors in quantification of tumor size or tran-
scriptional activation.[211,213,214] Split luciferin reaction in mice resulted in major signal stabilization com-
pared to D-luciferin signal (30% vs 200% in signal variation in the first 15 min post-injection for equimo-
lar concentrations) without use of any specially synthesized or expensive reagent, nor implanted os-
motic pumps (Figure 2.9).[211,213,214] 
L-luciferin, upon reaction with FLuc enzyme, was reported to be capable of light emission un-
der certain condition.[30,31] As HO-CBT or H2N-CBT reacts with L-cysteine to form the corresponding L-
luciferin or its amino analogue, the resulting emission background could have been problematic. With 
the concentrations of reagent used in the present study, the influence of endogenous L-cysteine on 
signal was found to be negligible in both living cells and animals.  
Apart from bioluminescence imaging, the condensation reaction of CBT derivatives with 1,2-
aminothiols could be used for conjugation applications. The condensation reaction between the lucif-
erin precursors is selective and highly efficient with rate of reaction faster than many other efficient 
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biorthogonal reactions.[177,227,228] The reaction rates of the split luciferin reaction is three orders of mag-
nitude higher than that of Staudinger ligation, opening wide range of opportunities for the use of this 
reaction to study fast biological processes where the use of the Staudinger ligation was not feasible 
(Table 2.1). The condensation reaction of CBT derivatives with 1,2-aminothiols could be used for con-
jugation in tandem with the known bioorthogonal reactions. The split luciferin chemistry is compatible 
with the chemistry of other classical bioorthogonal reactions, which involve either azide, alkyne, tri-
phenylphosphine or tetrazine moieties.[133,140-153,155-159,161] This could be particularly useful in vivo, 
where applications of multiple biocompatible reactions have not been reported to study simultaneous 
events at the same time. It is worth mentioning that the SPAAC or SL reactions were employed in 
conjugation with tetrazine/trans-cyclooctene ligation reaction in the same experiments in living mice. 
Despite the fact that these double biorthogonal reactions were used for a two-steps labeling approach 
and not for imaging multiple biological process, it allowed use of lower reagent concentration for the 
second step due to higher reaction rate of the IED DA reaction.[163,229] These features make split lucif-
erin reaction highly valuable to study complex biological processes. 
Altogether, this study demonstrate that the split luciferin ligation reaction possesses several 
unique features which could make it very useful for a wide variety of biological applications, depicting 
high potential for the field of chemical biology and medical research. More applications of this tech-
nology for non-invasive imaging of biological process in vivo are currently being explored in our labor-
atories. 
Notes. Simultaneously to this study, another research group has also investigated the use of 
the split luciferin reaction for bioluminescence applications. Our works were published duringthe same 
period.[230,231] 
???? ?????????????????????
General Material and Methods. N-succinamidyl-CBT derivative (compound 3, Table 2.1) was 
synthesized according to a reported procedure.[195] D-cysteine (Sigma-Aldrich) and H2N-CBT (Sigma-
Aldrich), L-cysteine (Alfa Aesar), HO-CBT (ABCR GmbH), D-luciferin potassium salt (Biosynth AG), D-
aminoluciferin (Assay biotechnology Company Inc.), Luciferase (Sigma-Aldrich prod. number L9506 or 
SRE0045), Adenosine 5'-triphosphate disodium salt (ATP, AppliChem GmbH), Phosphate Buffered Sa-
line (PBS) (Life Technologies Corporation) were obtained from commercial sources and used without 
further purification. HPLC analysis was performed on Agilent Infinity 1260 HPLC system with either an 
Agilent Eclipse-XDB-C18 5 μm 4.6 x 250 mm column or Agilent Poroshell 120 EC-C18 2.7 μm 4.6 x 75 
mm column using degassed HPLC gradient grade solvent (Fisher Chemicals) and Millipore water. The 
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products of the reaction were initially analyzed by Agilent 6120 Quadrupole LC/MS (Agilent). More 
detailed HR ESI-MS measurements were conducted at the EPFL ISIC Mass Spectrometry Service using 
Micro Mass QTOF Ultima (Waters Corp). Millipore water was used for sample preparation of all the in 
vitro, cellular, and animal assays. Luciferase buffer used to quantify the amount of luciferin formed 
during incubation was prepared as following: 60 ?g mL-1 firefly luciferase (Sigma-Aldrich) in in 0.1M 
Tris-HCl pH=7.4, 2 mM ATP, and 5 mM MgSO4. All in vitro and cellular studies were performed in clear 
bottom black 96 well plates (Becton Dickinson and Co.). Spectramax Gemini (Molecular Devices), IVIS 
100 (Xenogen) or IVIS Spectrum (Xenogen) were used to measure the amount of BLI signal production.  
Split luciferin reaction - Cell-free experiments.  In a black 96-well plate, 98 μL of PBS were 
added in the wells followed by the addition of 1 μL of a D-cysteine solution (1 mM in PBS), L-cysteine 
solution (1 mM in PBS) or PBS. Then, 1 μL of a HO-CBT solution (1 mM in DMSO), H2N-CBT solution (1 
mM in DMSO) or DMSO was added to the solutions. Finally, 50 μL of a luciferase solution (120 μg/mL 
luciferase enzyme in Tris-HCl pH 8, 4 mM ATP and 10 mM MgSO4) were added just before the imaging. 
The plate was imaged in an IVIS 100 imaging system for 30 min at 37 °C with one minute intervals 
under automatic settings. BLI signal was quantified using region-of-interest (ROI) analysis available on 
Living Image software 4.4 (Caliper Life Sciences). 
HPLC Assays. 100 μL solution of 0.01M of HO-CBT or H2N-CBT was mixed with 50 μL solution 
of 0.01M L-cysteine, and 5 μL of the resulting solution was injected into LC-MS. The following condi-
tions were used to separate the resulting products (Figure S2.1 a-b): Agilent Poroshell 120 EC-C18 2.7 
μm 4.6x75mm column: 2 mL/min flow, 0-1 min 10% MeCN + 90 % water, containing 0.1% HCOOH, then 
from 1 to 5.5 min concentration of MeCN was linearly increased to 100%. After that the column was 
washed and pre-equilibrated with 10% MeCN + 90% water, containing 0.1% HCOOH for 2.5 min before 
the next injection. 
Split luciferin reaction – Kinetic experiments. All the solvents were freshly degassed and the 
solutions of reagents (HO-CBT, H2N-CBT or N-succinamidyl-CBT and L-cysteine) were freshly prepared 
prior to the experiments. The degree of conversion was determined by the intensity of UV absorbance 
at the corresponding characteristic wavelength of pure CBT derivative on HPLC data. The pseudo-first 
order constants were determined for each concentration of L-cysteine by linearization in ln [C(nitrile)] 
vs time coordinates (Figure S2.2, Figure S2.3, Figure S2.4). Second order constants were determined 
for each concentration of L-cysteine by dividing the pseudo-first order values to the corresponding 
cysteine concentration in the resulting reaction mixture. Procedure for rate constant determination 
for HO-CBT and H2N-CBT and N-succinamidyl-CBT derivative[193] (respectively compound 1, 2 and 3, 
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Table 2.1): 20 μL 0.01 M solution of the CBT derivative in MeCN was added to 950 μL of PBS and mixed. 
To this mixture, a solution of 30 μL 0.1, 0.125, 0.15 or 0.2 M of L-cysteine in PBS was added followed 
by extensive shaking. The resulting aliquots of 100 μL of the reaction mixture was taken at 1-5 min 
time points and quenched with 200 μL of 10% aqueous HCl to stop the reaction. Aliquots of 100 μL of 
the quenched solution was directly injected into analytical LC-MS to determine the degree of conver-
sion. The resulting products were initially analyzed by ESI-MS, followed by product isolation and fur-
ther analysis by HRMS. 
Split luciferin reaction - Cellular Experiments.  IVIS Spectrum (Xenogen) was used for biolumi-
nescent imaging in all cell experiments. SKOV-3-Luc-D3 cells (PerkinElmer) were cultured in McCoy's 
5A modified media (Life Technologies). MDA-MB-231-Luc-D3H2LN cells (PerkinElmer) were cultured in 
Minimum Essential ? Medium (Life Technologies Corporation). Both of the cell culture media con-
tained 10% FBS, 1% GlutaMAX and 1% Penicillin/Streptomycin mixture. Cells were seeded (1 x 104 
cells/well) in a black 96-well plate with clear bottoms (Becton Dickinson and Co.). 48 h later, the growth 
medium was removed and the cells were initially washed with 200 μL of PBS, followed by incubation 
for 5 min with 100 μL (150 μM, 15 μM or 1.5 μM) D-cysteine or L-cysteine solution in PBS or PBS alone. 
Then, 100 μL (150 μM, 15 μM or 1.5 μM) solutions of HO-CBT, H2N-CBT, D-luciferin or D-aminoluciferin 
in PBS were added, the cells were immediately placed in IVIS Spectrum and imaged for 1 h with one 
image acquired every minute. The BLI signal was quantified using region-of-interest (ROI) analysis avail-
able on Living Image software 4.4 (Caliper Life Sciences). 
Animals. FVB-Luc+ transgenic mice (FVB-Tg(CAG-luc,-GFP)L2G85Chco/J)[217,218] were kindly 
provided by the laboratory of Prof. Christopher Contag at Stanford University, re-derived at  UC Davis, 
and bred at UC Berkeley. The breeding colony was housed in groups of 4-5 mice according to their age 
and gender with free access to food and water at 22 °C with regular light-dark cycle. All studies were 
approved and performed according to the guidelines of the Animal Care and Use Committee of the 
University of California, Berkeley. 
Split luciferin reaction - Animal experiments in FVB-Luc+ mice. IVIS Spectrum (Xenogen) was 
used for BLI imaging in all animal experiments and the resulting data were processed using Living Image 
software 4.2 (Caliper Life Sciences). All solutions were prepared in sterile DMSO (Sigma-Aldrich) and 
PBS. Mice were anesthetized via inhalation of isoflurane (Phoenix), that was premixed with medical 
grade oxygen (Praxair) for both injection and imaging procedure. 6-10 weeks old Female FVB-Luc+ mice 
(5 mice per group) were IP injected with either HO-CBT; H2N-CBT; D-Cysteine and HO-CBT in equimolar 
concentrations (1:1); D-Cysteine and H2N-CBT in equimolar concentrations (1:1); D-Cysteine and HO-
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CBT in 1:10 ratio; D-Cysteine and H2N-CBT in 1:10 ratio; D-luciferin; and D-aminoluciferin. All injections 
were done with one equivalent corresponding to a dose of 0.267 mmol·kg-1 in 100 ?L of PBS (D-Cyste-
ine, 32.34 mg·kg-1; D-luciferin, 85.01 mg·kg-1) and/or in 20 ?L DMSO (HO-CBT, 47.04 mg·kg-1; H2N-CBT, 
46.78 mg·kg-1; D-aminoluciferin, 74.58 mg·kg-1). The time period of 3 min between IP injection of D-
cysteine and CBT derivatives was respected, and the animals were imaged right after the second injec-
tion. The animals injected with D-luciferin were imaged right after the injection with the compound.  
???? ??????????????????????
?
Figure S2.1: In vitro formation of luciferins. (a) HPLC chromatogram of aminoluciferin formation. Condensation reaction be-
tween H2N-CBT and L-Cysteine was performed with the addition of 100 μL H2N-CBT 10mM solution to 50 μL of a 10 mM L-
cysteine solution. The resulting mixture was injected into HPLC-MS. (b) HPLC chromatogram of luciferin formation. Conden-
sation reaction between HO-CBT and L-Cysteine was performed with the addition of 100 μL HO-CBT 10mM solution to 50 μL 
of a 10 mM L-cysteine solution. The resulting mixture was injected into HPLC-MS. 
  
  
Figure S2.2: Pseudo-first order rate constant determination for the reaction of HO-CBT with different concentrations of L-
cysteine. 
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Figure S2.3: Pseudo-first order rate constant determination for the reaction of H2N-CBT with different concentrations of L-
cysteine. 
  
  
Figure S2.4: Pseudo-first order rate constant determination for the reaction of N-succinamidyl CBT derivative 1 with different 
concentrations of L-cysteine. 
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Figure S2.5: Split luciferin ligation reaction in SKOV3-Luc-D3 living cells. (a) Total bioluminescence signal observed over a 
period of 1 h when cells were incubated with HO-CBT (7.5 or 75 μM) and D-cysteine (7.5, 15, 37.5, 75 μM) or L-cysteine (75 
μM). Alternatively, cells were first incubated D-cysteine (75 μM) or HO-CBT (75 μM) and after 20 min of incubation time, cells 
were washed with PBS (200 μL) and further incubated with the complementary reagent such as HO-CBT (75 μM) or D-cysteine 
(75 μM) respectively. (b) Total bioluminescence signal observed over a period of 1 h when cells were incubated with H2N-CBT 
(7.5 or 75 μM) and either D-cysteine (7.5, 15, 37.5, 75 μM) or L-cysteine (75 μM). Error bars are ± SD for three measurements. 
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Figure S2.6: Split luciferin ligation reaction in living MDA-MB-231-Luc-D3H2LN cells. (a) Total bioluminescence signal observed 
over 1 h when cells were incubated with HO-CBT (7.5 or 75 μM) and either D-cysteine (7.5, 15, 37.5, 75 μM) or L-cysteine (75 
μM). Alternatively, cells were first incubated D-cysteine (75 μM) or HO-CBT (75 μM) and after 20 min of incubation time, cells 
were washed with PBS (200 μL) and incubated with the complementary reagent such as HO-CBT (75 μM) or D-cysteine (75 
μM) respectively. (b) Total bioluminescence signal observed over 1 h when cells were incubated with H2N-CBT (7.5 or 75 μM) 
and either D-cysteine (7.5, 15, 37.5, 75 μM) or L-cysteine (75 μM).  Error bars are ± SD for three measurements. 
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BLI has recently been used to probe molecular signatures of target tissues through caged lu-
ciferin substrates, which are uncaged only by a specific biological activity or environment. The under-
lying principle in the design of these caged luciferin probes is based on the principle that luciferin sub-
stituted on the 6’-position oxygen or nitrogen are not capable of light emission (Scheme 1.2, chapter 
1).[84,90,92,99] This concept was used for the development of probes to sense enzymatic activity (e.g. 
beta-galactosidase,[84] caspases,[59-62,77] furin,[71] beta-lactamases,[85] and nitroreductase[89]) that have 
been used extensively for imaging in living animals. Previously, the caged luciferin approach was also 
successfully applied to real-time imaging and quantification of fatty acid uptake,[99] cell surface glyco-
sylation,[90] hydrogen peroxide fluxes,[92] as well as to study cell-penetrating peptide conjugates effi-
ciency of delivery, linker release, and biodistribution.[215] In addition, the preparation of new red-
shifted luciferin derivatives and their corresponding luciferase enzymes for multi-color application of 
BLI have recently been reported.[38,40,42,44]  
Although caged luciferin probes are powerful tools for imaging processess in vivo, their 
synthesis can be rather challenging and costly. On the other hand, D-luciferin precursors (i.e. D-cyste-
ine and HO-CBT) and their derivatives are much easier to synthesize and these compounds have higher 
stability in comparison to luciferins,[37,58,97,215] which are known to be sensitive to light, pH and oxy-
gen.[25,216] In this chapter, the potential of using the split luciferin reaction for imaging specific biological 
processes (i.e. protease activity) using the “caging” approach was evaluated. Caged D-cysteine probes 
were designed, allowing D-luciferin or D-aminoluciferin formation in a protease-dependant manner 
(Scheme 3.1). This methodology was then used to measure the activity of proteases (i.e. thrombin and 
caspase enzymes) in vitro and in vivo. Additionally, since both CBT and D-cysteine moieties can be 
modified with different caging groups simultaneously, the split luciferin approach can be utilized for 
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dual detection of events in vivo. For example, the hydroxy or amino group on the CBT moiety can be 
caged as a sensor for various biomolecules, similar to the whole luciferin scaffolds (Scheme 3.2).[59-
62,71,77,84,85,90,92,99] At the same time, the amine group on the D-cysteine moiety can be caged with a 
substrate for proteases including caspases,[59-62,77] thrombin,[77,232] prostate specific antigen,[233,234] and 
many others that are known to be cleaved after defined peptide sequences.[77,235] As a proof of princi-
ple, dual imaging of ?-galactosidase and caspase 3 activity has been demonstrated in vitro, suggesting 
that the split luciferin reaction could be a valuable tool for imaging multiple biological processes. 
???? In vitro?????????????????????????????????????????????????????
Caged D-luciferin scaffolds have been previously reported to quantify and visualize activity of 
various proteases in living cells and animals.[57-62,77,236,237] The use of the reaction between HO-CBT or 
H2N-CBT and D-cysteine can be expanded to in vivo imaging of protease activity and thus improve 
applications of this exciting set of tools. The structure of D-cysteine is ideal for being caged with a 
substrate for proteases, by simply incorporating it on to the end of a protease-specific sequence 
(Scheme 3.1, Movie S1). Importantly, multiple essential mammalian and bacterial proteases are 
known to cleave after specific N-terminal amino acid sequences.[63,80,86,109,193,238] While the synthesis of 
short peptides is cheap and can be readily performed with the help of automated peptide synthesiz-
ers,[239,240] the synthesis of fully caged luciferin scaffolds involves much more complex and low yielding 
synthetic procedures.[38,40,42,44,57,59,71,84,85,89,90,92,99] The production of caged luciferins is further compli-
cated by the fact that only a few reactions have been reported to work on the full luciferin scaffold. 
They include TFA deprotection,[58] hydrogenation,[37] and the formation of a carbonate from the phe-
nolic oxygen.[97,215] Moreover, luciferins are known to be inherently more sensitive to light, base, and 
oxidation.[25,216] This greatly limits the production of a broad variety of caged luciferin scaffolds as bio-
luminescent sensors. Thus, despite many protease-specific sequences known today, very few of them 
have been used for BLI in the context of caged luciferins[3,5,47,50,51,58,77,241] and even fewer are commer-
cially available.[77] Since CBTs and cysteine derivatives are easier to manipulate and possess higher in-
trinsic stabilities to light and pH,[25,37,97,215,216] it was reasoned that the use of these precursors might 
circumvent the significant synthetic challenges posed by caged luciferin scaffolds and therefore signif-
icantly expand their applications.  
 To test the viability of this approach, caspase 3 as well as thrombin protease, which all play 
important roles in several human pathologies, were selected.[52,54,55,242] Activation of both caspase 3 
and 7 are directly connected to apoptosis,[52,53] which plays a key role in many human pathologies such 
as cancer and neurodegenerative disease.[54-56] Caspases are expressed as zymogen, an inactive form 
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of the enzyme requiring activation to exercise proteolytic activities. Caspases have been classified in 
three main groups: initiator (e.g. caspase 8, 9 and 10), executioners (caspase 3, 7 and 6) and inflam-
matory (e.g. caspase 1 and 4). The initiator group is further divided in two categories that are caspases 
involved in the intrinsic (caspase 9) or extrinsic (caspase 8 and 10) apoptotic pathway. These pathways 
consist of a multistep proteolytic cascades where the executioner caspases are activated by the initia-
tors ones via proteolytic cleavage. The intrinsic pathway is a non-receptor mediated process that is 
triggered by stimuli such as radiation, toxins, free radicals, absence of growth factors or certain hor-
mones. These stimuli will generate mitochondrial-initiated events that will further result in caspase 9 
activation. On the other hand, the extrinsic pathway is initiated by transmembrane receptor-mediated 
interactions involving death receptors and corresponding ligands (e.g. TNFR1/TNF-?, FasR/FasL). The 
binding of the ligand to the death receptor induces a sequence of event leading to caspase 8 or caspase 
10 activation. Both intrinsic and extrinsic pathways lead to the activation of the executioners caspases: 
caspase 3, caspase 7 and caspase 6.[243,244] While there is a difference in substrate preference between 
the executioners caspases and initiator ones, there is an overlap in activity among each group render-
ing sometimes difficult to differentiate them with imaging probe.[245] The caspase 3 and 7 is a good 
example as they both share preference for similar substrates. It has been previously reported that 
DEVD-containing peptides (Asp-Glu-Val-Asp) are selective substrates for caspase 3 and to a lesser ex-
tent, caspase 7, with cleavage occurring after the second aspartic acid residue.[74,246] Imaging down-
stream effectors such as caspase 3/7 in cells represent a valuable way for measuring cell death activa-
tion. A bioluminogenic caspase 3/7 sensor is commercially available, in which D-aminoluciferin has 
been introduced at the C-terminus of the DEVD peptide and routinely used to detect apoptosis.[57-62,77] 
 Thrombin is another example of clinically relevant protease that plays a key role in many blood 
coagulation-related reactions that prevent a variety of mammalian organisms from extensive blood 
loss.[247,248] A thrombin-selective peptide sequence has been previously identified (Gly-Gly-Arg) and 
utilized in multiple in vitro tests to assess activity of the protease.[76,249] 
 Since both caspase 3 and thrombin are known to cleave at the C-terminal end of their corre-
sponding protease-specific sequence of amino acids, the synthesis of these peptides with the addition 
of D-cysteine at the C-terminal end was performed to yield L(Asp-Glu-Val-Asp)-D-Cys (DEVD-(D-Cys)) 
and L-(Gly-Gly-Arg)-D-Cys (GGR-(D-Cys)), respectively. These peptides were then incubated with in-
creasing concentrations of their corresponding proteases, followed by addition of HO-CBT or H2N-CBT 
and luciferase buffers sequentially. If the protease is active and could recognize its specific peptide 
sequence, free D-cysteine would be released in the course of the reaction. Therefore, addition of HO-
CBT or H2N-CBT would result in the formation of the corresponding D-luciferin or D-aminoluciferin. 
Application of the Split Luciferin Reaction for Non-Invasive Bioluminescent Imaging of Protease Activity 
48 
Further addition of luciferase would consequently result in significant light production, with more light 
output from the samples with higher concentrations of proteases (Scheme 3.1, Figure 3.1, Figure 3.2). 
The efficacy of the peptide specific cleavage can then be estimated by direct comparison of the light 
output from a D-cysteine caged peptide, with amount of light produced from equimolar amount of 
free D-cysteine.     
?
Scheme 3.1: Imaging protease activity using the split luciferin reaction. Overall representation of peptidic probe P4P3P2P1-(D-
Cys) cleavage by the desired protease and further reaction with HO-CBT or H2N-CBT to form the corresponding D-luciferin or 
D-aminoluciferin molecule. P1 to P4 represents amino acids. The choice of P4 to P1 residues will determine the substrate 
specificity for the desired protease. 
 Strong bioluminescent signals were observed following incubation of protease-specific pep-
tides with their corresponding proteases, and signal increased with increasing concentration of prote-
ase (Scheme 3.1, Figure 3.1, Figure 3.2). For example, concentration-dependent signal was observed 
when DEVD-(D-Cys) peptide was incubated with increasing amounts of caspase 3 and subsequently 
treated with H2N-CBT-containing luciferase buffer. Importantly, the overall signal produced from 
DEVD-(D-Cys) peptide incubated with caspase 3 reached 50% of the light output of the signal from the 
equimolar solution of the free D-cysteine control. This experiment shows that DEVD-(D-Cys) peptide 
remains a good substrate for caspase 3 even upon addition of a D-cysteine amino acid at the C-termi-
nus of the protease-specific sequence (Figure 3.1). 
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Figure 3.1: In vitro enzymatic assay of caspase 3 activity using DEVD-(D-Cys) peptide and H2N-CBT. (a) luminescence signal 
following incubation of DEVD-(D-Cys) peptide with increasing concentrations of caspase 3 (25, 50 and 100 nM) or D-cysteine 
control (200 μM) at 37 °C before addition of H2N-CBT (400 μM) followed by 1 h incubation at 37°C and subsequent imaging 
after addition of luciferase buffer. Error bars are ± SD of three measurements. (b) Total luminescent signal integrated over 2 
h (AUC). Error bars are ± SD of three measurements. Statistical analyses were performed with a two-tailed Student’s t test. 
All the groups are statistically significant with each other (P < 0.05) except between 25 and 0 nM (P=0.12). 
Similar results were obtained when D-cysteine was caged with the thrombin-selective peptide 
GGR (Figure 3.2). A four-fold increase in BL signal over background was observed when the GGR-(D-
Cys) peptide was incubated with thrombin protease followed by addition of H2N-CBT, and the signal 
was dependent on the protease concentration (Figure 3.2). The outcome of this in vitro enzymatic 
assays demonstrate the feasibility of using a combination of short D-cysteine-caged amino acid se-
quences with H2N-CBT to study the activity of proteases using bioluminescence. 
?
Figure 3.2: In vitro enzymatic assay of Thrombin activity using GGR-(D-Cys) peptide and H2N-CBT. (a) luminescence signal 
following incubation of GGR-(D-Cys) peptide (400 μM) with varying concentrations of thrombin (20, 10 and 5 units) over 3 h 
at 37 °C, followed by addition of H2N-CBT (400 μM in MeOH) and incubation for 1 h at rt. Immediately prior to quantification 
of bioluminescence emission, 5 μL of the reaction solution was added to a luciferase solution (60 μg/mL luciferase in 0.1M 
Tris-HCl, 2 mM ATP, 5 mM MgSO4). (b) Total bioluminescent signal integrated over 2 h (AUC). The blank control is luciferase 
solution alone. 
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???? In vitro???????????????????????????????????????
Previous experiments focused on the pre-incubation of the caged peptide probes with the ap-
propriate proteases. To determine if monitoring real-time activation of caspase 3 is possible, the pro-
tease, FLuc, peptide probes, HO-CBT and the necessary cofactors were incubated in vitro. In other 
words, all the components necessary for light emission were incubated simultaneously. Following 
cleavage of the peptide probe by caspase 3, the released D-cysteine moiety reacted with HO-CBT to 
form D-luciferin, which was subsequently oxidized by luciferase, resulting in caspase-dependent light 
emission and quantification of bioluminescence emission was performed immediately following addi-
tion of the peptide probe. To determine if increasing the concentration of caspase 3 caused an increase 
in bioluminescence signal, z-DEVD-(D-Cys) peptide, HO-CBT and varying concentrations of caspase 3 
were incubated with luciferase and cofactors in vitro. The higher the concentrations of caspase 3, the 
greater the light emission, which resulted in a dose-dependent light emission (Figure 3.3). Strikingly, 
the luminescence generated from 0.1 units per mL (U/mL) of caspase 3 was significantly above the 
background (P = 0.0031). As a control, the peptide probe was replaced by D-cysteine (cage-less peptide 
probe). Using same concentration of D-cysteine and peptide probe, the total luminescence resulting 
from D-cysteine and HO-CBT control is equivalent to light potentially emitted by 100% cleavage of the 
z-DEVD-(D-Cys) peptide by the protease. Therefore, 40 U/mL of caspase 3 was demonstrated to cleave 
approximately 70% of the peptide probe over 3h (Figure 3.3b). 
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Figure 3.3: In vitro enzymatic assay of caspase 3 activity using z-DEVD-(D-Cys) peptide and HO-CBT. (a) luminescence signal 
following incubation of luciferase (including co-factors), HO-CBT (100 μM) and z-DEVD-(D-Cys) peptide in presence of increas-
ing caspase 3 concentrations (0, 0.1, 0.5, 1.0, 5.0, 10 or 40 units/mL) or D-cysteine control (100 μM) for 3 h at 37 °C. Error 
bars are ± SD of three measurements. (b) Total luminescence integrated over 3 h (AUC). Error bars are ± SD of three meas-
urements. Statistical analyses were performed with a two-tailed Student’s t test. All the groups are statistically significant 
with each other (P < 0.05) except between 0.5 and 1.0 U/mL (P=0.06). 
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Next, split luciferin based probes for caspase 6, caspase 8 and caspase 9 were developed. These 
peptide probes were designed to be specific for each caspase by the addition of a D-cysteine moiety 
at the C-terminal of the caspase cleavage sequences that were reported in the literature. These sub-
strate sequences have also been used for commercially available fluorometric, colorimetric or biolu-
minescent probes.[77,250,251] The z-VEID-(D-Cys), z-LETD-(D-Cys) and z-LEHD-(D-Cys) probes were used 
for caspase 6, caspase 8 and caspase 9 respectively.[74,77,246] ????????? it has to be noted that another 
report has shown that caspase 8 also cleaves LEHD sequence more efficiently than IETD, another 
caspase 8 substrates.[250] The in vitro enzymatic evaluation of these probes with the respective caspa-
ses are depicted in Figure 3.4.  
Results obtained for the caspase 6 probe (z-VEID-(D-Cys)) were comparable to the data ob-
tained for the z-DEVD-(D-Cys)/caspase 3 experiments and resulted in dose-dependent BL emission. 
Importantly, light emission obtained when the probe was incubated with 40 U/mL of enzym resulted 
in approximately 51% of probe cleavage by caspase 6 in 3 h (Figure 3.4).  
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Figure 3.4: In vitro enzymatic assay of caspase 6, caspase 8 and caspase 9 activities imaging with respectively z-VEID-(D-Cys), 
z-LETD-(D-Cys) or z-LEHD-(D-Cys) peptide and HO-CBT. (a) Integrated luminescence signal over 3 h (AUC) resulting from incu-
bation of luciferase (including co-factors), HO-CBT (100 μM), z-VEID-(D-Cys) peptide in presence of increasing concentrations 
of caspase 6 (0, 0.1, 0.5, 1.0, 5.0, 10 and 40 units/mL) or D-cysteine control (100 μM) for 3 h at 37 °C. (b) Similar results for 
caspase 8 enzyme using z-LETD-(D-Cys) peptide. (c) Similar results for caspase 9 enzyme using z-LEHD-(D-Cys) peptide. Error 
bars are ± SD of three measurements. The associated luminescence in function of the time data are presented in Figure S3.1. 
Differences between all groups from 10 to 1 U/mL are statistically significant with each other (P < 0.01), and non-significant 
from 1 to 0 U/Ml (P > 0.5). 
 Light emission obtained with the highest concentration of caspase were much lower than for 
caspase 3 and 6, with approximately 6.7 % and 16.3 % of the probe cleaved for caspase 8 and caspase 
9, respectively. These differences in cleavage efficiency could be due to different affinities of the caspa-
ses with their respective peptide probe, or due to differences in activity of the caspase. Indeed, the 
units (U) for each enzyme refers to the value provided by the manufacture (Abcam) for each enzyme. 
1 U of caspase is defined as the enzyme activity that cleaves 1 nmol of colorimetric substrate per hour 
at 37 °C in a defined caspase buffer. Thus, the enzymatic activity for each caspase was investigated 
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using commercially available colorimetric probes in order to determine actual caspases activity, in or-
der to confirm or invalidate manufacture indications. Commercially available colorimetric probes con-
tain a peptide sequence that is specific for the corresponding caspases, with a para-nitroanilide group 
on the C-terminal. Once released upon caspase cleavage, the para-nitroaniline (pNA) has a high ab-
sorbance at 405 nm. By measuring the absorbance, the concentration of released pNA and thus the 
caspase activity can be determined. Activities of caspase 3, caspase 8 and caspase 9 were measured 
(Figure S3.2). Caspase 3 and caspase 9 have similar activities, with 100% of the probe cleaved after 
2.5h. On the other hand, caspase 8 shows very small activity according to the colorimetric assay. If it’s 
estimated that the baseline corresponds to the control group containing 10 U/mL of caspase 8 and no 
colorimetric probe, approximately 13% of pNA is released over 135 min (Figure S3.2). This low activity 
could explain the results obtained with the BL probe z-LETD-(D-Cys) (Figure 3.4b). On the other hand, 
caspase 9 seems to be very active. Thus the poor cleavage of the LEHD-(D-Cys) peptide compare to 
caspase 3, could not be explained by the difference in enzymatic activities. This suggests that the probe 
design may affect the reaction kinetics and that the cleavage of LEHD prior to a D-cysteine moiety may 
not be optimal for caspase 9, resulting in poor cleavage of the peptide. The carboxybenzyl group on 
the N-terminal could also influence the substrate affinity to the enzyme. 
To further investigate the specificity of the developed bioluminescent probes for caspases, a 
cross reactivity assay was performed with the four peptide probes and caspases (caspase 1, caspase 2, 
caspase 3, caspase 4, caspase 5, caspase 6 and caspase 9). Due to the poor activity of caspase 8 (Abcam 
plc, UK), it was decided not to include this protease in the assay (Figure 3.5). This in vitro enzymatic 
assay were performed with simultaneous incubation of caspase and luciferase enzymes, probes and 
HO-CBT as well as all the necessary cofactors, and subsequent luminescence emission was acquired 
over 3 hours. The total luminescence integrated over 3 h are depicted in figure 3.5. 
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Figure 3.5: Cross reactivity assay of the caspases specific split luciferin probes with different caspases. Integrated luminescent 
signal over 3 h (AUC) resulting from z-DEVD-(D-Cys), z-VEID-(D-Cys), z-LEHD-(D-Cys) and z-LETD-(D-Cys) probes (100 μL) incu-
bated with 10 U/mL of caspase 1 to caspase 6 as well as caspase 9, HO-CBT (100 μL) and luciferase enzyme at 37 °C. Error 
bars are ± SD of three measurements. 
The z-DEVD-(D-Cys) peptide shows specific strong cleavage by caspase 3. This peptide is also 
cleaved to a lower extant by caspase 6. The caspase 6 specific peptide, z-VEID-(D-Cys), shows also a 
specific cleavage by caspase 6, with very low light emission resulting incubation with other caspases. 
The z-LETD-(D-Cys) peptide is cleaved by caspase 9 more efficiently, but a significant amount of this 
peptide is also cleaved by caspase 6. It is more difficult to draw clear conclusion for that peptide, as 
this experiment do not include caspase 7 and caspase 8 enzymes. Nevertheless, the z-LETD-(D-Cys) 
peptide is significantly cleaved by caspase 9 and the signal is surprisingly higher than the one emitted 
from z-LEHD-(D-Cys) incubation with caspase 9, suggesting that the later would be a better substrate 
for caspase 9. This results are in contradiction with reported data on substrate specificity using fluoro-
genic tetrapeptide bearing an aminocoumarin on the C-terminal side.[246] But further investigation 
would be necessary in order to understand this trend and determine if the D-cysteine moiety at C-
terminal affects the sequence specificity.[252,253] Moreover, the enzyme unites used correspond to the 
manufacturer indication and were not tested in house, and thus variation on activities could vary. In 
order to have more accurate data, enzyme activities should be determined first using colorimetric 
probes, allowing to equal activities for every enzyme. This is necessary to have a reliable cross-reactiv-
ity assay. But the increased enzyme quantities as well as numerous colorimetric probes necessary is 
costly and time consuming, makes this assay out of range for a simple control experiment. Neverthe-
less, activities of caspase 3, 6 and 9 were show to be similar using colorimetric probes. Moreover, these 
data are useful for comparing cleavage efficiency of different peptides by the same protease. To con-
clude, these experiments have shown that split luciferin based probes could be used for substrate 
evaluation, and could potentially be useful for screening peptide libraries as substrates. It also has to 
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be noted that the caspase substrate specificity were reported to be overlapping and therefore no ab-
solutely specific substrates exist even if there is substrate preferences among caspases.[244,251] Caspase 
3 was nevertheless found to be one of the efficient target of a large number of short sequence sub-
strate.[250] Moreover, the tetrapeptide substrate is important for specificity, but the residue located 
after the cleavage site also influence rate of cleavage and small residue such as alanine, serine or gly-
cine are preferred.[254] Cysteine was not included in this report, but according to properties of preferred 
amino acids at the P1’ position, cysteine should not be problematic. However, isomeric factors were 
not included and could influence the enzyme/substrate interaction.  
?????? In vitro????????????????????????????????????????????????????????????????????????????
????????????????
An interesting feature of the split luciferin reaction, is that both of the luciferin precursors, D-
cysteine and CBT, could potentially be caged. By modifying these two molecules, with different molec-
ular patterns that could be removed selectively by distinct biological processes or enzymes, the split 
luciferin reaction could be an interesting tool for monitoring multiple processes using biolumines-
cence. To establish the potential use of these probes for dual-process imaging, caging both of the lu-
ciferin precursors for different enzymes was performed. This is an advantage that is offered by the use 
of the split luciferin reaction unlike the classical caged luciferin approach. As a proof of principle, an 
attempt of imaging ?-galactosidase (?-Gal) and caspase 3 at the same time was performed. ?-Gal is a 
hydrolase enzyme that catalyses the hydrolysis of ?-galactosides into monosaccharides. It’s an essen-
tial enzyme in human body also present in some bacteria strains and is widely used as reporter gene 
in molecular biology.[255] A caged-luciferin probe for ?-Gal imaging has been reported and consists of a 
galactoside-luciferin conjugate that has shown to be useful for monitoring ?-Gal activity in several ex-
perimental set-ups.[46,84,256,257] Using a similar approach, an HO-CBT molecules functionalized with a 
galactoside (Gal-CBT) on the phenolic atom was synthesized. Only if ?-Gal is present and active, a free 
luciferin will be formed after reaction with D-Cysteine. The D-Cysteine moiety will be available for re-
action only after cleavage of the DEVD-(D-Cys) peptide by caspase 3. Both ?-Gal and caspase 3 enzymes 
are therefore necessary for the in situ formation of a free D-luciferin molecule (Scheme 3.2). 
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Scheme 3.2: Dual caging on luciferin precursors for imaging multiple biomolecular activities using the split luciferin reaction. 
Galactoside-CBT (Gal-CBT) is selectively cleaved by ?-Galactosidase enzyme to generate a free HO-CBT molecule. D-cysteine 
reactivity towards CBT is masked by the DEVD peptidic sequence. Following cleavage of the z-DEVD-(D-Cys) peptide by 
caspase 3, the released free D-cysteine reacts with the CBT moiety to yield a D-Luciferin molecule, capable of light emission 
after reaction with Luciferase. 
A sequential assay was performed that consist first of incubating the z-DEVD-(D-Cys) peptide, 
Gal-CBT, caspase 3 enzyme and ?-Gal enzyme in a compatible buffer for 3 hours. The mixture was then 
added on a Luciferase solution containing all the necessary cofactors for light emission and biolumi-
nescence emission was then measured for 1 h (Figure S3.3). Total Luminescence emission over 1 h 
(AUC) (Figure 3.6) was calculated from integration of luminescence in function of the time (Figure 
S3.3). The light emission obtained when the z-DEVD-(D-Cys) peptide and Gal-CBT were incubated sim-
ultaneously with both caspase 3 and ?-Gal is a lot stronger than the negative controls, when one or 
both of the enzyme is missing (Figure 3.6, grey bars). 
?
Figure 3.6: Dual enzyme imaging using the split luciferin reaction. Total luminescence emission over 1h (AUC) resulting from 
Gal-CBT and z-DEVD-(D-Cys) probes (100 μM) simultaneous incubation with caspase 3 (10 U/mL) and ?-Gal (10 U/mL) en-
zymes, only ?-Gal (10 U/mL), only caspase 3 (10 U/mL) or without any enzymes (grey bars). As a positive control, caspase 3 
was incubated with HO-CBT and z-DEVD-(D-Cys) probe or ?-Gal with Gal-CBT and D-cysteine. Error bars are ± SD of three 
measurements. Statistical analyses were performed with a two-tailed Student’s t test. ***P < 0.001. ns P > 0.05. 
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The differences in light emission where both caged components of the split-luciferin are incu-
bated with both enzymes compared to the negative control are important, with an increase in total 
luminescence ranging from 240 to 700 times. Moreover, the difference with positive control is small 
and non-significant (P > 0.05). It can also be noticed that compared to the positive controls, where Gal-
CBT is replaced by free CBT or DEVD-(D-Cys) peptide by free D-Cysteine respectively, light emission is 
close to the dual imaging light emission. Collectively, these data demonstrate the feasibility of dual 
enzyme imaging using the split luciferin reaction in vitro. Moreover, the good signal to background 
ratio as well as the intense light emission resulting from simultaneous probe cleavage suggest that this 
methodology is efficient and selective. Both enzyme have to be present and active for a significant 
amount of D-luciferin formation. 
Of course, this approach does not allow assessment of individual enzyme activity. In a more 
complex experimental setting, the positive control groups will correspond to measurement of individ-
ual activities. Overall, these results suggest that dual caging of the split luciferin reaction can be used 
for multiple and simultaneous biomolecule activities imaging, with good signal to noise ratio and is 
promising for potential cell-based and in vivo experiments. Moreover, multiple caging could increase 
the specificity of imaging by introducing several cages selective for different enzymatic markers of the 
same biological pathway. 
For all enzyme/probe pairs tested, light emission was proportional to the enzymatic activity. 
In particular, split-luciferin probes for caspase 3 and caspase 6 imaging resulted on good signal to noise 
ratio and excellent cleavage efficiency of the caged D-cysteine probes. Moreover, the split luciferin 
reaction was efficiently used in in vitro enzymatic assay for dual enzyme imaging. Altogether, these 
data suggest that the Split Luciferin reaction for protease imaging and quantification is versatile and 
can potentially be applied to a multitude of different protease. 
???? ???????????????????????????????????????????????????????????????????????
?????
Having already established that the luciferin ligation reaction works efficiently in living trans-
genic reporter animals, the next step was to establish if this approach was appropriate to quantify the 
activity of caspase 3/7 in living mice (Figure 3.7, Figure 3.8). The focus was set on caspase 3/7 enzymes 
because a well-characterized mouse model of caspase 3/7 activation was previously reported using 
the commercially available DEVD-aminoluciferin substrate.[62,77] In that study, the activity of caspase 
3/7 was induced in the liver of FVB-luc+ mice by administration of lipopolysaccharide (LPS) and D-
galactosamine (D-GalN) to the animals, followed by injection of the DEVD-aminoluciferin substrate and 
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detection of the resulting light production with a CCD camera (Figure 3.7).[62] D-GalN-sensitized mice 
treated with LPS were reported to result in fulminant hepatitis, with strong apoptosis generated in 
liver tissue.[258] 
?
Figure 3.7: Caspase 3/7 activity imaging using luciferin ligation reaction in living transgenic reporter mice. Overall represen-
tation of caspase 3 activity imaging with DEVD-(D-Cys) peptide and H2N-CBT in a liver failure model in vivo. 
 This previously reported experiment was repeated using a similar mouse strain and DEVD-ami-
noluciferin substrate as a positive control. FVB-Luc+ mice were divided into four groups out of which 
two were injected with equal amounts of D-GalN and LPS followed by either injection of commercial 
DEVD-aminoluciferin, or a combination of our DEVD-(D-Cys) peptide and H2N-CBT. The other two con-
trol groups were injected with PBS and a combination of the same imaging reagents. The signals from 
each D-GalN/LPS treated group were compared to each other and their corresponding PBS controls.  
 The data shown in Figure 3.8 and Figure 3.9 indicate that a much greater signal was obtained 
from the two groups of animals treated with D-GalN/LPS in comparison to the control group, treated 
with PBS.  The ratio in average signal observed between the D-GalN/LPS-treated and control groups of 
mice injected with commercially available substrate was about 3-fold, which was similar to previously 
reported data[62] and statistically significant (P value : 0.00067, Figure 3.8a, Figure 3.9a). 
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Figure 3.8: Caspase 3/7 activity imaging using luciferin ligation reaction in living transgenic reporter mice. (a) Total lumines-
cence over 1 h from transgenic reporter mice treated with either PBS (control group) or combination of LPS (100 μg/kg in 50 
?L of PBS) and D-GalN (267 mg/kg in 50 ?L of PBS). Six hours post-treatment, the animals received i.p. injections of either 
DEVD-aminoluciferin (34 mg/kg in 100 ?L of PBS) or a combination of DEVD-(D-Cys) peptide (22.6 mg/kg in 100 ?L of PBS) 
and H2N-CBT (6.8 mg/kg in 20 ?L of DMSO). Statistical analyses were performed with a two-tailed Student’s t test. **P < 0.01 
(n=8 for DEVD-aminoluciferin groups and n=4 for combination of DEVD-(D-Cys) and H2N-CBT reagents). Error bars are ± SD 
for 8 and 4 measurements respectively. (b) Representative image of mice, 15 min post-injection of DEVD-aminoluciferin or a 
combination treatment with DEVD-(D-Cys) and H2N-CBT reagents. 
 At the same time, the ratio between the signals produced from D-GalN/LPS-treated and con-
trol groups of mice, injected with combination of DEVD-(D-Cys) peptide and H2N-CBT, was about 5.2 
fold, higher than the commercial DEVD-aminoluciferin substrate. Importantly, this difference was also 
statistically significant (P value: 0.00258, Figure 3.8a, Figure 3.9b). This exciting result could arise from 
proteolytic cleavage being more efficient when it has to cleave between two amino acids. However, 
when the protease has to cleave between the protease specific sequence and another non-amino acid 
type of molecule such as D-aminoluciferin, its efficiency might decrease, even when compared with 
the cleavage at a D-amino acid. 
?
Figure 3.9: Observed luminescence emission as a function of the time from caspase 3/7 selective bioluminescent probes after 
LPS and D-GalN or vehicle injection of FVB+Luc mice. (a) Luminescence emission in function of the time from i.p. injection of 
DEVD-aminoluciferin (34 mg/kg in 100 ?L of PBS, n=8) after LPS (100 μg/kg in 50 ?L of PBS) and D-GalN (267 mg/kg in 50 ?L 
of PBS) or vehicle (100 ?L PBS, n=8) treatment in FVB-Luc+ mice. Error bars are ± SD for eight measurements. (b) Luminescence 
emission in function of the time from IP injection of DEVD-D-Cys peptide (22.6 mg/kg in 100 ?L of PBS, n=4) and H2N-CBT (6.8 
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mg/kg in 20 ?L of DMSO, n=4) after LPS and D-GalN or vehicle treatment (n=4) in FVB-luc+ mice. Error bars are ± SD for four 
measurements. 
 Since the caged split-luciferin approach was successful in a model of hepatic apoptosis, 
whether this method could be widely applied for studies of caspase 3 and 7 activities in other animal 
models of apoptosis was investigated. For that, a xenograft animal models, in which human cancer 
cells were implanted in immune-deficient mice, was used.   
In order to establish a successful animal model, two different cancer cell lines were tested for 
apoptosis induction upon docetaxel treatment, a commonly used anti-cancer drugs for treatment of 
different type of human cancers, was performed.[259-262] Conditions where a majority of cells started to 
undergo apoptosis upon exposure to the drug were identified for SKOV3-luc-D3 ovarian cancer cells 
and docetaxel - a drug that has previously been reported to induce apoptosis in this particular cell 
line (Figure S3.4).[263] Therefore, this cell line, stably transfected with luciferase, was implanted subcu-
taneously in nude mice and the tumors were allowed to establish for 6 to 8 weeks.  
 The animals were then divided in 5 groups (Figure S3.5a): two groups injected with commercial 
DEVD-aminoluciferin substrate with and without docetaxel treatment, two groups that were injected 
with a combination of DEVD-(D-Cys) peptide and H2N-CBT with and without docetaxel treatment, as 
well as a control group injected with docetaxel and H2N-CBT alone. To calibrate for the difference in 
the tumor size, all the animals were injected with D-luciferin prior and after the treatment with docet-
axel or vehicle alone.   
 The results from the xenograft animal models, in which apoptosis was induced by treatment 
with docetaxel anticancer drug, were consistent with the ones obtained in the hepatic apoptosis model 
(P value: 0.0143, Figure S3.5b). However, no significant signal to background ratio was observed from 
the groups of the animals treated with docetaxel or corresponding vehicle followed by injection of 
commercial DEVD-aminoluciferin substrate (P value: 0.4138). At the same time, 2-fold increase in sig-
nal was observed in mice treated with docetaxel in comparison to the vehicle, followed by imaging 
with combination of DEVD-(D-Cys) peptide and H2N-CBT (Figure S3.5b). 
 Together, these results confirm that the combination of D-cysteine caged peptide sequences 
and H2N-CBT represents a valuable tool for quantification and imaging of caspase 3/7 activities directly 
in living mice. Since BLI is a very sensitive in vivo imaging modality, this tool could be used for screening 
of various proteases activity as well as identification of their new peptide specific substrates in vitro. 
Even though, only the viability of the split luciferin approach for imaging and quantification of caspase 
3/7 activity was demonstrated in vivo, many other proteases could be studied using this technique. 
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Based on the results presented here, the split luciferin reaction offers a valuable tool for the develop-
ment of BLI probes designed for proteases monitoring, both in in vitro and in vivo set-ups. 
???? ???????????
Studies of many biological processes in live cells with the help of biocompatible reactions has 
tremendously advanced our understanding of basic biology.[133] However, the great complexity of 
many human pathologies such as cancer, diabetes, and neurodegenerative diseases requires new tools 
that would allow studies of biological process on the level of the whole organism. In this chapter, split 
luciferin based probes for imaging enzymatic activity in vitro and in living animals were introduced. The 
enzymatic activities of multiple caspases as well as thrombin were efficiently imaged in a cell-free and 
real time set-up. These data demonstrated that the split luciferin approach is efficient and versatile, 
allowing a greatly improved accessibility of novel bioluminescent probes. It is noteworthy that the 
synthesis of short peptide sequences with C-terminal D-cysteine can be easily performed with the help 
of automated peptide synthesis.[239,240]  
 Since caging of D-cysteine can be combined with caging of amino or hydroxy groups on the 
CBT moiety, this reaction represents a powerful tool where two biological processes may be imaged 
simultaneously in living mice (Figure 3.10). Previously, several probes based on the full luciferin scaf-
fold were reported for sensitive imaging of different biomolecules in live animals, providing a basis for 
the development of dual imaging approaches.[57,59,71,84,85,92] Remarkably, as discussed in chapter 2, the 
signal produced in cells by the split luciferin reagents was several fold higher than the signal from 
equimolar amounts of already preformed D-luciferin and D-aminoluciferin (Figure 2.3, Figure 2.4), 
providing opportunities for more sensitive imaging of biological processes.  
?
Figure 3.10: Overall representation of the dual imaging concept for luciferin ligation. Both luciferin ligation precursors could 
be caged as sensors for two different biomolecules. Only when both become uncaged D-luciferin or D-aminoluciferin is 
formed as the result of split luciferin ligation reaction, allowing the production of light by luciferase. 
 Furthermore, the properties of the split luciferin reaction are well suited for the development 
of novel in vivo applications. One of them is the real-time imaging of protease activity directly in living 
animals. In this chapter, successful applications of this technology was demonstrated for real time non-
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invasive imaging of caspase 3/7 activity in a hepatic apoptosis model (Figure 3.6, Figure 3.7, Figure 3.8) 
as well as in tumor xenografts upon treatment with docetaxel (Figure S3.5). When compared to the 
commercially available DEVD-aminoluciferin substrate,[59,71,84,85,92,133,143,234]?the split luciferin ligation re-
agents had a significantly higher signal to background ratio, demonstrating high potential of this new 
method for sensitive imaging of apoptosis in vivo.  
 Even though, only the viability of the split luciferin approach for imaging and quantification of 
caspase 3/7 activity was demonstrated, many other proteases could be immediately studied using this 
technique. The examples of such proteases and their specific amino acid sequences include caspase 1 
(YVAD), caspase 2 (VDVAD) and caspase 12 (ATAD), dipeptidyl peptidase 4 (GP and VP), prostate spe-
cific antigen (HSSKLQ) and tryptase (PRNK).[58,74,77,79,234] Moreover, this method could also be applied 
to study wide variety of bacterial, viral and parasite proteases that are essential for the replication and 
the spread of infectious diseases.[80] Examples of these proteases include SARS protease (TSAVLQ), 
caspase-like (nLPnLD), and trypsin-like (LRR) activity of the proteasome.[77,81-83] All of these proteases 
play a very important role in multiple biological processes and are known to cleave at the end of cor-
responding specific amino acid sequences. These properties make them ideal candidates for imaging 
and quantification of their activities in animal models of disease using the split luciferin approach. All 
together, these results demonstrate high potential of this new in vivo ligation strategy for the field of 
chemical biology and medical research. 
Notes. Simultaneously to this work, another research group have also been investigating the 
use of the split luciferin reaction for other bioluminescence applications. Our work was published dur-
ing the same period.[230,231] 
???? ?????????????????????
General Material and Methods. Caged D-cysteine peptides DEVD-(D-Cys) and GGR-(D-Cys) 
peptides were custom made by Protein and Peptide Chemistry Facility (PPCF) - UNIL (University of 
Lausanne, Switzerland). Caged D-cysteine peptides z-DEVD-(D-Cys), z-VEID-(D-Cys), z-LETD-(D-Cys) and 
z-LEHD-(D-Cys) were custom made by Biomatik Corp. The chemicals used in the study were obtained 
from the following commercial sources and used without further purification. D-cysteine and H2N-CBT 
(Sigma-Aldrich), L-cysteine (Alfa Aesar), HO-CBT (ABCR GmbH), Adenosine 5'-triphosphate disodium 
salt (ATP, AppliChem GmbH) were used without further purifications. Luciferase (Sigma-Aldrich, prod. 
number L9506 or SRE0045), human thrombin (Sigma-Aldrich, prod. number T1063) and ?-Galacto-
sidase from Escherichia coli (Sigma-Aldrich prod. number G4155) were used without further purifica-
tion. Caspase 3 was kindly provided by Dr. Salvesen at Stanford-Burnham Medical Research Institute, 
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CA and used for in vitro imaging of caspase 3.[252] Active human caspase 1, active human caspase 2, 
active human caspase 3, active human caspase 4, active human caspase 5, active human caspase 6 and 
active human caspase 9 were purchased from Abcam plc and used for real-time in vitro assays. Detailed 
HRESI-MS measurements were conducted at the EPFL ISIC Mass Spectrometry Service using Micro 
Mass QTOF Ultima from Waters Corp. Millipore water was used for sample preparation of all the in 
vitro, cellular, and animal assays. Only Luciferase buffer was prepared as following: 60 ?g mL-1 lucifer-
ase in in 0.1M Tris-HCl  pH=7.4, 2 mM ATP, and 5 mM MgSO4. All in vitro and cellular studies were 
performed in clear bottom black 96 well plates (Becton Dickinson and Co.). Spectramax Gemini (Mo-
lecular Devices), IVIS 100 camera (Xenogen) or IVIS Spectrum camera (Xenogen) were used to measure 
the amount of BLI signal production. 
In vitro bioluminescent caspase 3 assay with DEVD-(D-Cys) peptide and H2N-CBT. Caspase 3 
was purified and characterized following the reported procedure (kindly provided by Dr. Salvesen at 
Stanford University, CA).[252] Different concentration solutions of caspase 3 (50, 100 and 200 nM) were 
prepared in caspase buffer (100 mM HEPES pH 7.4, 0.1% (w/v) CHAPS, 1 mM EDTA, 10 mM DTT, 1% 
(w/v) sucrose) and were aliquoted in a 96 well-plate (50 μL caspase 3 solution/well). The plate was 
incubated at 37 °C for 15 min for caspase pre-activation. Following pre-activation, 50 μL of a DEVD-(D-
Cys) solution (800 μM in caspase buffer) or 50 μL of a D-Cysteine solution (800 μM in caspase buffer) 
were added in each well and the plate was incubated at 37 °C for 3 h. After the incubation, 100 μL of 
a H2N-CBT solution (400 μM in MeOH) were added to the wells and the plate was incubated for another 
1 h at 37°C. Luciferase buffer (60 μg mL-1 luciferase in 0.1M Tris-HCl, 2mM ATP, 5 mM MgSO4) was 
freshly prepared and aliquoted in a second 96-well plate (115 μL/well). 5 μL of the resulting caspase 3 
containing solutions was quickly added to luciferase buffer immediately before reading biolumines-
cence emission using a Spectramax M5 (Molecular Devices). Bioluminescence signal from the plate 
was measured with 500 ms integration time for 2 h at 37 °C with 5 min intervals. The observed lumi-
nescence over time and the total luminescence collected over the period of 2 h is plotted on Figure 
3.1. 
In vitro bioluminescent Thrombin protease assay with GGR-(D-Cys) peptide and amino-CBT??
?????????????????????????????????????????????????????????????????????????????????????????????????
??????????????????????????????????????????????????????????????????????????????????????????????
???? ???????????? ??????????????????????????????????????????????????? ??????????? ?????????????????????
????????????????????????????????????????????????????????H2N-CBT ???????????????????? ?????????????
????????????????????????????????????????????????????????????????????????????????????????????? ???????????
??????????????? ???????????????????????????????????????????????????????????????????????????????
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??? ???????????????????? ?????????????????????? ????H2N-CBT ?????????????????????? ???? ???????????
????????????????????????????????????????????????????????????????????????????????? ?????????????????
????????????????????????????????????????????????????????????????????????????????????????
In vitro real time imaging of caspases activities. Active human caspase 3, active human 
caspase 6, active human caspase 8 and active human caspase 9 were purchased from Abcam plc and 
used without further purification. 1 U/μL stock solutions of caspases were prepared in PBS containing 
15% glycerol. From the caspase stock solution, the 0.25, 0.125, 0.025, 0.0125, 0.0025 and 0 U/μL dilu-
tion were prepared in PBS containing 15% glycerol. Stock solutions of HO-CBT, z-DEVD-(D-Cys) peptide, 
z-VEID-(D-Cys) peptide, z-LETD-(D-Cys) peptide, z-LEHD-(D-Cys) peptide (10 mM in DMSO) as well as D-
cystein stock solution (10 mM in PBS) were prepared. A 60 μg/mL luciferase enzyme solution was pre-
pared in caspase buffer (50 mM HEPES, pH 7.2, 50 mM NaCl, 0.1 % CHAPS, 10 mM EDTA, 5% Glycerol, 
10 mM DTT) and supplemented with 2 mM ATP and 5 mM MgSO4. In a black 96-well plate, 94 μL per 
well of the luciferase solution was added. 4 μL per well of the different caspase solutions were added 
in order to obtain the following final caspase concentrations: 4, 1, 0.5, 0.1, 0.05, 0.01 or 0 U of caspase 
per well (100 μL). This was followed by the addition of 1 μL of HO-CBT solution in the wells. Finally, 1 
μL of the peptide solution or D-cysteine solution was added in the wells containing the corresponding 
caspase. The plate was then immediately placed in the plate reader and BL acquisition was started. 
Bioluminescence measurements were performed with 1 min interval on a Tecan Infinite M1000 (Tecan 
Austria GmbH) plate reader for 3 h at 37°C. 
Colorimetric assay of caspases activities. Active human caspase 3, active human caspase 8 and 
active human caspase 9 were purchased from Abcam plc and used without further purification. 1 U/μL 
stock solutions of caspases were prepared in PBS containing 15% glycerol. Stock solutions of Ac-DEVD-
pNA, Ac-LETD-pNA peptide and Ac-LEHD-pNA colorimetric probes (10 mM in DMSO) were prepared. 
In a transparent 96-well plate, 98 μL of caspase buffer (50 mM HEPES, pH 7.2, 50 mM NaCl, 0.1 % 
CHAPS, 10 mM EDTA, 5% Glycerol, 10 mM DTT) was added in the wells. 1 μL of the colorimetric probe 
or pure DMSO was add, followed by the addition of 1 μL of corresponding caspase stock solution or 1 
μL of PBS containing 15% glycerol. Immediately after caspase addition, absorbance was measured at 
405 nm during 135 min at 15 min interval. 
In vitro real time cross-reactivity of caspase probes with different caspases. Active human 
caspase 1, active human caspase 2, active human caspase 3, active human caspase 4, active human 
caspase 5, active human caspase 6 and active human caspase 9 were purchased from Abcam plc and 
used without further purification. 1 U/μL stock solutions of caspases were prepared in PBS containing 
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15% glycerol. Stock solutions of HO-CBT, z-DEVD-(D-Cys) peptide, z-VEID-(D-Cys) peptide, z-LETD-(D-
Cys) peptide and z-LEHD-(D-Cys) peptide (10 mM in DMSO) were prepared. A 60 μg/mL luciferase en-
zyme solution was prepared in caspase buffer (50 mM HEPES, pH 7.2, 50 mM NaCl, 0.1 % CHAPS, 10 
mM EDTA, 5% Glycerol, 10 mM DTT) and supplemented with 2 mM ATP and 5 mM MgSO4. In a black 
96-well plate, 97 μL per well of the luciferase solution were added. 1 μL per well of the different 
caspase stock solutions were added. This was followed by the addition of 1 μL of HO-CBT solution in 
the wells. Finally, 1 μL of the peptide solutions were added in the wells. The plate was then immedi-
ately placed in the plate reader and acquisition was started. Bioluminescence measurements were 
performed on a Tecan Infinite M1000 (Tecan Austria GmbH) plate reader for 3 h at 37°C with 2 min 
interval. 
Synthesis of 6-(((2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-
2-yl)oxy)benzo[d]thiazole-2-carbonitrile (Cyanobenzothiazolyl ?-D-Galactopyranoside, Gal-CBT) (by 
Dr. Jens Frigell). Previous reports claimed that basic deacetylation works poorly due to the electro-
philic nitrile of the cyanobenzothiazole.[264] After experiencing similar troubles, an acidic deacetylation 
protocol was developed. 
2-Cyano-6-(2,3,4,6-tetra-O-acetyl-?-D-Galactopyranosyloxy)benzothiazole (100 mg, 0.197 
mmol) was synthesized according to the reported procedure and was then dissolved in CH2Cl2 (5 
mL).[264] Conc. H2SO4 (0.5 mL) was diluted in MeOH (5 mL) at 0 °C and slowly added to the CH2Cl2 solu-
tion. Over 4 h, steady formation of product was seen by LCMS analysis, but also an increase of for-
mation of cyanobenzothiazole (by-product) and the reactions was carefully quenched at 0 °C using 
NH4OH (25%) under rigorous stirring, trying to avoid any yellow/green coloration of the reactions, 
which indicated by-product formation. This could be avoided by keeping pH at 6 or lower. The white 
slurry was then diluted with 10 mL 1:1 CH2Cl2:MeOH and concentrated in vacuo (co-evaporating with 
toluene, 5 mL) resulting in a white solid. 2-Propanol (10 mL) was added and the suspension was soni-
cated to dissolve all product. The remaining white solid (salts) were filtered off. The clear 2-propanol 
solution is then concentrated in vacuo to give a white solid. The crude material was purified by column 
chromatography (CHCl3:MeOH 8:1) to give Cyanobenzothiazolyl ?-D-Galactopyranoside (66.3 mg, 99%) 
as a white solid, which was lyophilized. 1H NMR (400 MHz, D2O) ? 7.98 (d, i = 9.1 Hz, 1H), 7.71 (d, J = 
2.5 Hz, 1H), 7.39 (dd, J = 9.2, 2.5 Hz, 1H), 5.14 (d, J = 7.5 Hz, 1H), 4.04 (dd, J = 3.2, 1.0 Hz, 1H), 3.97 - 
3.79 (m, 5H). 13C NMR (101 MHz, D2O) ? 157.1 (s), 146.8 (s), 137.0(s), 135.6 (s), 125.0 (d), 119.4 (d), 
112.9 (s), 107.5 (d), 100.8 (d), 75.6 (d), 72.4 (d), 70.4 (d), 68.4 (d), 60.7 (t). HRMS calcd for C14H14N2O6S 
[MH+] 339.0651, found 339.0657. 
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In vitro simultaneous imaging of caspase 3 and ?-galactosidase using the split luciferin reac-
tion. Active human caspase 3 enzyme (Abcam plc) and ?-Galactosidase (Sigma-Aldrich) were used 
without further purification. 1 U/μL stock solution of caspase 3 was prepared in. 1 U/μL stock solution 
of PBS containing 15% glycerol. 1 U/μL stock solution of ?-galactosidase was prepared in 1 mM TRIS 
pH 7.5 containing 1 mM MgCl2 and 50% glycerol. Stock solutions of HO-CBT, z-DEVD-(DCys) peptide 
and Gal-CBT (10 mM in DMSO)  as well as D-cysteine stock solution (10 mM in PBS) were prepared.  
In a 96-well plate, 95 μL of reaction buffer (50 mM HEPES, pH 7.2, 150 mM NaCl, 0.1 % CHAPS, 
10 mM EDTA, 5% Glycerol, 10 mM DTT) were added. 1 μL of Gal-CBT stock solution or HO-CBT stock 
solution were added, as well as 1 μL of z-DEVD-(D-Cys) stock solution or D-cysteine stock solution. 1 uL 
of DMSO was added in the wells where D-cysteine was added and 1 μL of PBS was added in all the 
other wells. These solutions were supplemented with either 1 uL of ?-galactosidase stock solution or 
1 uL of caspase 3 stock solution or with both enzyme stock solutions. The plate was then incubated at 
37 °C protected from light.  
In another black 96-well plate, 80 μL of a 60 μg/mL luciferase enzyme solution in caspase buffer 
(50 mM HEPES, pH 7.2, 50 mM NaCl, 0.1 % CHAPS, 10 mM EDTA, 5% Glycerol, 10 mM DTT) and sup-
plemented with 2 mM ATP and 5 mM MgSO4 were aliquoted. Finally, using a multichannel micropi-
pette, 20 μL of the different enzymes solutions were transferred to the luciferase containing 96-well 
plate. The plate was then immediately placed in the plate reader and luminescence measurement was 
started. Bioluminescence measurements were performed approx. every minutes on a Tecan Infinite 
M1000 (Tecan Austria GmbH) plate reader for 3 h at 37°C. 
Animals. FVB-luc+ transgenic animals[217,218] (full abbreviation: FVB-Tg(CAG-luc,-
GFP)L2G85Chco/J) mice were kindly provided by the laboratory of Prof. Christopher Contag at Stanford 
University, rederived at  UC Davis, and bread at UC Berkeley. The breeding colony was housed in groups 
of 4-5 mice according to their age and gender with free access to food and water at 22 °C with regular 
light-dark cycle. All studies were approved and performed according to the guidelines of the Animal 
Care and Use Committee of the University of California, Berkeley. 
Experiments in a mouse model of subcutaneous cancer were carried out in strict accordance 
to the Swiss regulation on animal experimentation and the protocol (VD2363) was approved by the 
authority of the Canton Vaud, Switzerland (EXPANIM (Expérience sur animaux)–SCAV, Département 
de la sécurité et de l’environnement, Service de la consommation et des affaires vétérinaires). Swiss 
nude (swiss nu/nu) mice were obtained from Charles River Labs and were maintained at the EPFL UDP 
Application of the Split Luciferin Reaction for Non-Invasive Bioluminescent Imaging of Protease Activity 
66 
animal facility under pathogen free conditions and group housed in ventilated cages at 22°C with reg-
ular light-dark cycle. 
Real time non-invasive imaging of caspase 3/7 activities in FVB-luc+ mice. Female FVB-luc+ 
mice (4 mice per group), were anesthetized with isoflurane and injected IP with either lipopolysaccha-
rides (LPS) purchased from Sigma-Aldrich at concentrations of 100 μg kg-1 in 50 ?L of PBS followed by 
injections of D-(+)-Galactosamine hydrochloride (D-GalN) obtained from AppliChem GmbH at concen-
trations of 267 mg kg-1 in 50 ?L of PBS. The control group of mice was injected with 100 ?L of PBS 
(vehicle). Six hours after injection of an LPS/D-GalN combination or vehicle (PBS), mice were treated 
IP with either DEVD-(D-Cys) peptide (22.6 mg kg-1 in 100 ?L of PBS) plus 6-Amino-2-cyanobenzothiazole 
(H2N-CBT, 6.8 mg kg-1 in 20 ?L of DMSO) or DEVD-aminoluciferin substrate (34 mg kg-1 in 100 ?L of PBS) 
and imaged. A time period of 10 min between injections of DEVD-D-Cys and H2N-CBT was respected. 
The mice were imaged using IVIS Spectrum and bioluminescence images were obtained over 1 h at 
37°C with 1 min interval. The BLI signal was quantified using region-of-interest (ROI) analysis available 
on Living Image software 4.2 (Caliper Life Sciences). 
Induction of apoptosis in SCOV3-Luc-D3 ovarian cancer cells by docetaxel treatment. SKOV-
3-Luc-D3 cells (Caliper Life Sciences, Hopkinton, MA) were cultured in McCoy's 5A (modified) medium 
that contains 10% FBS, 1% GlutaMAX and 1% Penicillin/Streptomycin mixture. Cells were passed and 
plated in 10 cm petri dishes. Once the cells were 90% confluent, medium was replaced by McCoy's 5A 
(modified) medium that contains 10% FBS, 1% GlutaMAX, 1% Penicillin/Streptomycin mixture and 10 
μM of docetaxel (prepared from a stock solution of 100μM in EtOH) were added to each well. After a 
48 h of incubation, cells were stained either with propidium Iodide, FAM-DEVD-FMK (Vybrant® FAM 
caspase 8 Assay Kit - for Flow Cytometry, Life Technologies Corp.) or both and flow cytometry assay 
was performed using a BD SORP LSR II (Becton Dickinson and Company, Franklin Lakes, NJ). Results are 
presented in Figure S3.4. 
Real time non-invasive imaging of caspase 3/7 activities in tumor xenograft models. This ex-
periment was designed according to the work published by Hickson et al.[60] In the right flank of swiss 
nude mice, aged 5–6 months, 4 x 106 SKOV3-luc-D3 cells were inoculated subcutaneously in a 1:1 
mixture of Matrigel and growth medium. Tumor was allowed to establish to an appropriate volume 
according to Caliper Life Sciences protocol, supplied together with cell line (Xenogen Corporation, Al-
ameda, CA). Animals were then size matched into treatment groups and were injected IP with Docet-
axel (60mg/kg in 200μL of a 1:1:3 mixtures tween80/EtOH/saline solution) or vehicle (1:1:3 mixtures 
tween80/EtOH/saline solution)). 24 h after Docetaxel or vehicle treatment, mice were anesthetized 
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with isoflurane and injected IP with DEVD-(D-Cys) peptide (166.2 mg/kg in 100 ?L of PBS) plus H2N-CBT 
(50.24 mg/kg in 40 ?L of DMSO) or DEVD-aminoluciferin (250 mg/kg in 100 ?L of PBS) and imaged. A 
time period of 10 min between injection of DEVD-D-Cys and H2N-CBT was respected. Bioluminescence 
images were acquired over 1.5 h at 37 °C with 1 min interval. The BLI signal was quantified using region-
of-interest (ROI) analysis available on Living Image software 4.2 (Caliper Life Sciences). Observed BLI 
signal was collected from each animal every minute and the total luminescence produced over the 
course of 1.5 h was calculated (abbreviated as TL-1). 12 h after the first imaging session, mice were 
imaged again after IP injection of D-luciferin sodium salt (91.3 mg/kg in 100 ?L of PBS) in order to 
normalize the caspase 3/7 imaging signal in function of the cancer cell number, because all the animals 
had different tumor sizes. Observed BLI signal was collected from each animal and the total lumines-
cence produced over the course of 1.5 h was calculated (abbreviated as TL-2). The Logarithmic (Log) 
values of the integrated total luminescence resulting from injection of the caspase 3/7 probe and D-
luciferin (TL-1 and TL-2 respectively) were calculated in order to obtain a linear scale. For every mouse, 
the Log value of the caspase 3/7 selective probe TL-1 was subtracted by the D-luciferin TL-2 (Plotted 
Value (Figure S3.5) = Log (TL-1) - Log (TL-2)). Therefore, the bigger are the values, the smaller is the 
normalized light emission and the lower is the caspase 3/7 activity. Statistical analyses were performed 
with a two-tailed Student’s t test. *P < 0.05 (DEVD-(D-Cys) + H2N-CBT: n=9, DEVD-aminolucferin: n=4) 
and error bars are ± SD. 
???? ??????????????????????
 
Figure S3.1: In vitro enzymatic assay of caspase 6, caspase 8 and caspase 9 activities imaging with respectively z-VEID-(D-Cys), 
z-LETD-(D-Cys) or z-LEHD-(D-Cys) peptide and HO-CBT. (a) Luminescent signal in function of the time resulting from HO-CBT 
(100 μM) and z-VEID-(D-Cys) peptide or D-cysteine (100 μM) incubation in presence of increasing caspase 6 concentrations 
(0, 0.1, 0.5, 1.0, 5.0, 10 and 40 units/mL) and luciferase enzyme over 3 h at 37 °C. (b) Similar results for caspase 8 enzyme 
using z-LETD-(D-Cys) peptide. (c) Similar results for caspase 9 enzyme using z-LEHD-(D-Cys) peptide. Error bars are ± SD of 
three measurements. 
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Figure S3.2: Colorimetric assay of caspases activities. (a) Absorbance measured at 405 nm in function of the time during Ac-
DEVD-pNA incubation with or without 1 U of caspase 3 enzyme in caspase buffer. (b) Absorbance measured at 405 nm in 
function of the time during Ac-LETD-pNA incubation with or without 1 U of caspase 8 enzyme in caspase buffer. (c) Absorb-
ance measured at 405 nm in function of the time during Ac-LEHD-pNA incubation with or without 1 U of caspase 9 enzyme 
in caspase buffer. 
?
Figure S3.3: Dual enzyme imaging using the split luciferin reaction. Luminescence emission in function of the time resulting 
from Gal-CBT and z-DEVD-(D-Cys) probes simultaneous incubation with caspase 3 and ?-Gal enzymes, only ?-Gal, only caspase 
3 or without any enzymes (grey bars). As control, caspase 3 was incubated with HO-CBT and z-DEVD-(D-Cys) probe or ?-Gal 
with Gal-CBT and D-cysteine. Error bars are ± SD of three measurements. 
?
Figure S3.4: Flow cytometry data with a caspase 3/7 activation assay (FAM-DEVD-FMK - Propidium Iodide) on SKOV3 cells 
lines, 48 h post docetaxel incubations at 10 μM concentration. 
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Mice number
Docetaxel
(60mg/kg)
Caspase-3/7 
Probes
Group 1 9 + DEVD-D-Cys + NH2-CBT
Group 2 9 - DEVD-D-Cys + NH2-CBT
Group 3 4 + DEVD-aminoluciferin
Group 4 4 - DEVD-aminoluciferin
Group 5 4 + NH2-CBT
?
Figure S3.5: Docetaxel treatment on subcutaneous SKOV3-Luc-D3 xenografts model in nude mice for caspase 3/7 activation 
imaging. (a) Description of experimental groups of animals including number of mice per groups, docetaxel or vehicle treat-
ment and the type of caspase 3/7 selective bioluminescent probes used for imaging. (b) Swiss nude mice (NU(Ico)-Foxn1nu 
(outbred), Charles River Labs) bearing SKOV3-luc-D3 subcutaneous tumor were injected IP with Docetaxel (60 mg/kg in 200μL 
of a 1:1:3 mixture tween 80/EtOH/saline solution) or only vehicle. 24 h post injection mice were treated IP with either a 
combination of DEVD-(D-Cys) (166.2 mg/kg in 100 ?L of PBS) and H2N-CBT (50.24 mg/kg in 40 ?L of DMSO), DEVD-aminolu-
ciferin (250 mg/kg in 100 ?L of PBS), or H2N-CBT only (50.24 mg/kg in 40 ?L of DMSO). A 10 min time period was respected 
between inj. of DEVD-(D-Cys) and H2N-CBT. The animals were imaged for the period of 1.5 h and the total BLI signal was 
calculated (TL-1). 12 h after the imaging session, mice were imaged again after IP injection of D-luciferin sodium salt (91.3 
mg/kg in 100 ?L of PBS) in order to normalize the caspase 3/7 imaging signal in function of the cancer cell number. Biolumi-
nescence images were taken every minute during 1.5 h (TL-2). The data shown represent the difference between D-luciferin 
imaging (proportional to the tumor size) and DEVD-D-Cys and H2N-CBT imaging (proportional to tumor size and caspase 3/7 
activation level) on a linear scale. For every mouse, the Log value of the Caspase 3/7 selective probe TL-1 was subtracted by 
the Log value of D-luciferin TL-2 (Plotted Value = Log (TL-1) - Log (TL-2)). Therefore, the bigger are the values, the smaller is 
the normalized light emission and the lower is the caspase 3/7 activity. Statistical analyses were performed with a two-tailed 
Student’s t test. *P < 0.05 (DEVD-(D-Cys) + H2N-CBT: n=9, DEVD-aminolucferin: n=4) and error bars are ± SD. 
?
Movie S3.1: Imaging caspase activity with the split luciferin reaction. First the principle of bioluminescence imaging is de-
picted. the oxidation of D-aminoluciferin by firefly luciferase enzyme, a process that generates light. In a second sequence, 
the principle of “classical” caged luciferin is depicted with a DEVD-aminoluciferin probe, that get selectively cleaved by 
caspase 3 enzyme to release a free amino-D-luciferin molecule, capable of light emission. Then, the split luciferin reaction is 
animated, showing D-cysteine and H2N-CBT reacting selectively with each other in vivo to generate D-aminoluciferin. Finally, 
the last sequence depicts the caspase 3 dependent release of free D-cysteine from the caspase 3/7 peptide substrate DEVD-
(D-Cys) that allows selective reaction with H2N-CBT in vivo to form amino-D-luciferin with subsequent light emission from 
luciferase.[217,230] 
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Neutrophil Elastase (NE), also known as leukocyte elastase, is a chymotrypsin-like serine pro-
tease present in high concentration in neutrophil azurophil granules. These granules also contain mul-
tiple microbicidal products such as cationic peptides or other proteolytic enzymes such as Proteinase 
3 (PR3), Matrix Metalloproteinase 9 and Cathepsin G. Upon activation, neutrophils degranulate, re-
leasing the contents of azurophil granules.[265,266] NE displays proteolytic activity and is capable of cleav-
ing elastin and multiple matrix proteins such as fibronectin, laminin or type IV collagen and contributes 
to defence mechanisms against microbial pathogens. On the other hand, when NE is released in an 
uncontrolled manner, its proteolytic activity damages healthy tissues leading to organ injury. NE is 
implicated in a wide variety of diseases such as acute lung injury (ALI), acute respiratory distress syn-
drome (ARDS), cystic fibrosis (CF), non-small cell lung cancer in addition to other pathological lung 
conditions. NE activity has also been linked to many other diseases such as chronical wounds or rheu-
matoid arthritis.[266-270] 
Imaging NE could have favourable impact on different clinical applications such as diagnosis, 
monitoring efficiency of a therapy, determining the disease stage or location of neutrophil-mediated 
inflammation sites.[265,271,272] Due to its implication in numerous pathological conditions, non-invasive 
imaging probes for identification and quantification of NE activity have been developed using different 
imaging modalities and used for several applications, from in vitro enzymatic assay, to in vivo imaging 
on animals models of human pathologies.  
Traditionally, NE activity is quantified using colorimetric or fluorogenic synthetic peptide sub-
strates such as N-Methoxysuccinyl-Ala-Ala-Pro-Val-para-Nitroanilide (AAPV-pNA) probe or its fluores-
cent analogues.[273-275] These compounds have been extensively used but have only limited applicability 
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for cell-based or in vivo experiments. Chromogenic substrates based on conjugation of a peptide func-
tionalized on the C-terminal with a 4-nitroanilide moiety suffer from poor sensitivity. The correspond-
ing fluorogenic based probes gain in sensitivity but the substrate sequence cannot be modulated with 
an amino acid after the cleavage site (in direction of the C-terminal) and this approach is limited to 
certain fluorophores that are not well suited for in vivo applications. Different fluorogenic probes 
based on intramolecular quenched fluorescence have been developed for imaging and measuring NE 
activity. Förster resonance energy transfer (FRET) based probes were constructed with a fluorescent 
moiety (i.e. ortho-aminobenzoyl, 7-methoxycoumarin-4-yl) positioned on the N-terminal of the pep-
tide substrate and quenched by a fluorescent quencher (i.e. ethylenediamine, N-3-(2,4,-dinitropheny)-
L-2,3-diaminopropionyl) on the C-terminal. After cleavage of the specific peptide substrate by the en-
zyme of interest, the quencher is released and the fluorescent group is activated. This methodology 
was used for identification of specific substrates for NE or PR3 and further used for measuring their 
respective activities in purified enzyme or cell-based experiments.[276-280]                 
Similar strategies have also been used for the development of quenched fluorescent probes 
suitable for non-invasive in vivo imaging. Probes for fluorescent NE imaging consist of two near-infra-
red (NIR) fluorescent moieties covalently attached to both N- and C-terminus of a NE specific amino 
acid sequence (NE 680 FAST, PerkinElmer).[267] Using this construct, non-invasive in vivo imaging and 
quantification of NE activity were performed in a mouse model of ALI. Moreover, localization of active 
NE ex vivo in lung sections was confirmed by fluorescence microscopy.[267] Furthermore, a significant 
increase of active NE, in intradermal tumors of mice subjected to photo-dynamic therapy, have been 
reported in vivo using the NE680 FAST probe.[281] The same fluorogenic probe was also used for imaging 
NE activity in a colorectal cancer xenograft model in living mice[282] as well as ex vivo imaging and quan-
tification of NE activity in white adipose tissue and liver tissue of mice fed a high fat diet.[283] 
In addition to the optical fluorescence imaging of NE, probes intended for nuclear medicine 
imaging have been reported for in vivo applications. For example, an aptamer inhibitor of NE was radio-
labelled with 99mTc and used for diagnostic imaging of inflammation in a rat immune reaction model 
(reverse passive Arthus reaction).[284] Furthermore, a NE peptide inhibitor was labelled with 99mTc and 
used for imaging infection and neutrophil-mediated inflammation in monkeys.[285]  
To date, the probes reported for in vivo imaging of NE activity are either based on fluorescence 
or nuclear medicine imaging modalities. As fluorescence imaging is limited by tissue auto-fluorescence 
and poor tissue penetration, radioactive tracers suffer from other constrains, as they are dependent 
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on ionizing radiations that, with the associated costs, synthetic complexity, short half-life and radioac-
tive compounds handling, limit their utilization.[286,287] Bioluminescence imaging (BLI) represents a good 
option for pre-clinical imaging, offering high sensitivity, relatively low cost and ease of implementation, 
as long as the model under study is expressing luciferase.[6,114,209]  
Herein, the development of a novel probe for BLI of NE based on the split luciferin reaction is 
described. To date, no bioluminescent probes for NE imaging have been reported. A pentapeptide 
containing a D-cysteine residue on the C-terminal was designed, synthesized and further validated for 
NE imaging using enzymatic assay in vitro, primary cell culture of neutrophils and in vivo using a model 
of ALI.  Importantly, the in vivo experiments demonstrated that the probe could be used for real-time 
non-invasive imaging and quantification of NE activity in murine model of acute lung inflammation. 
???? ?????????????
Since caspase 3/7 activity was successfully imaged using the split luciferin reaction, a similar 
approach was applied for the development of a NE specific probe. A NE peptide substrate was used to 
mask the 1,2-aminothiol group of the D-cysteine moiety, blocking its ability to react with CBT. Different 
NE specific substrates have been reported and used for determining substrate affinity or activity de-
tection of the NE enzyme. This caging strategy requires the D-cysteine amino acid to be placed right 
after the cleavage site, reducing the choice of amino acid sequence for the design of the NE peptide 
substrate. Both colorimetric and fluorometric compounds have been reported and used for substrate 
specificity investigation of NE, revealing that the Ala-Ala-Pro-Val (AAPV) amino acid sequence is one of 
the most potent substrates when the P1’ is occupied by a synthetic group.[273,274] Moreover, neutrophil 
PR3 is the closest related protease to NE. These proteases share 54% homology, both are contained in 
azurophil granules, excreted by activated neutrophils and finally both share substrate preference for a 
valine residue in the P1 position.[288] Without modifying the P’ positions, the majority of NE substrate 
are also, to some extent, cleaved by PR3 protease.[278] Nevertheless, Kasperkiewicz et al. reported a 
synthetic NE substrate composed of unnatural amino acid residues, that is more specific for NE and is 
cleaved 900-fold more efficiently compared to PR3.[289] 
To develop a probe for the BLI of NE, investigation started with the AAPV amino acid sequence 
which is the most commonly used substrate of NE. N-terminal acetylated version of the peptide sub-
strate was synthesized to prevent aminopeptidase cleavage and increase its stability and half-life in 
serum.[290-292] The probe Ac-L(Ala-Ala-Pro-Val)-D-(Cys)-OH (Ac-AAPV-(D-Cys)) was synthesized using 
Fmoc solid phase peptide synthesis followed by acetate capping and HPLC purification. Upon cleavage 
of the probe by NE, a free D-cysteine moiety is released, which can subsequently react with 6-hydroxy-
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2-cyanobenzothiazole (CBT) moiety, forming D-luciferin molecules. The latter is oxidized by luciferase 
resulting in light emission. Therefore, D-luciferin formation is dependent on NE activity and the subse-
quent BL light emission is proportional to its activity (Figure 4.1).   
 
Figure 4.1: Imaging NE activity using a caged split luciferin probe. Overall representation of Ac-AAPV-(D-Cys) peptide probe 
cleavage by NE and further reaction of the released D-cysteine molecule with HO-CBT or H2N-CBT to form the corresponding 
luciferin molecule. 
???? In vitro????????????????????????????????????????????????????????????????
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The efficiency and specificity of the Ac-AAPV-(D-Cys) probe cleavage was first tested with na-
tive purified human neutrophil elastase (HNE) by real-time bioluminescence imaging. Different con-
centration of HNE were incubated with the Ac-AAPV-(D-Cys) probe, in the presence of HO-CBT and 
luciferase. To confirm the specificity of D-cysteine release by HNE, these experiments were performed 
in the presence and absence of sivelestat sodium salt, a specific competitive inhibitor of NE.[267,293] The 
Ac-AAPV-(D-Cys) peptide was efficiently cleaved by HNE. When the peptide was incubated with in-
creasing HNE concentrations, measurements resulted in a dose-dependent light emission (Figure 4.2). 
The higher the concentration of HNE, the greater the light emission from the probe and the signal 
generated by a concentration of 0.01 μg/mL of HNE is still significantly above light emission of the 
negative control without HNE (P = 0.0254). Moreover, a control experiment was performed where the 
peptide probe was replaced by D-cysteine (caged-less probe) and incubated with the highest concen-
tration of HNE (Figure 4.2b). Since the D-cysteine and peptide concentrations were equivalent, the 
total luminescence resulting from D-cysteine and HO-CBT control is equivalent to 100% cleavage of the 
Ac-AAPV-(D-Cys) peptide by the protease and it can be concluded that the luminescence generated 
from 0.5 μg/mL of HNE cleaves approximately 34 % of the peptide probe over 3h (Figure 4.2b). 
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Figure 4.2: In vitro enzymatic assay of HNE activity imaging with Ac-AAPV-(D-Cys) and HO-CBT split luciferin probe. (a) lumi-
nescent signal over 180 min following incubation of HO-CBT (100 μM), Ac-AAPV-(D-Cys) peptide (100 μM) with increasing 
concentrations of HNE (0, 0.01, 0.025, 0.05, 0.1, 0.25 and 0.5 μg/mL) and luciferase enzyme at 37 °C. Error bars are ± SD of 
three measurements. (b) Total luminescent signal integrated over 3 h (AUC) following incubation of luciferase, HO-CBT (100 
μM), Ac-AAPV-(D-Cys) peptide with increasing concentrations of HNE (0, 0.01, 0.025, 0.05, 0.1, 0.25 and 0.5 μg/mL) or D-
cysteine as control (100 μM) over 3 h at 37 °C. Error bars are ± SD of three measurements. Statistical analyses were performed 
with a two-tailed Student’s t test. Differences between all the groups are statistically significant with each other (P < 0.05) 
except between 0.05 and 0.1 μg/mL (P = 0.3). 
The negative control (peptide probe without HNE) generates negligible light emission, corre-
sponding to 0.39 % of the total luminescence emitted from 0.5 μg/mL HNE incubated with the probe. 
These data demonstrate that the uncaging of the NE probe is specific and stable under these experi-
mental conditions. However, in order to confirm the probe specificity further, sivelestat, an inhibitor 
of HNE, was added to the reaction as control. Subsequently, the probe was incubated with all the 
necessary material including 0.5 μg/mL of HNE and increasing concentration of sivelestat (Figure 4.3). 
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Figure 4.3: In vitro enzymatic assay of HNE activity imaging with Ac-AAPV-(D-Cys) peptide and HO-CBT in presence of sivelestat 
inhibitor. (a) luminescent signal over 3 h following incubation of HO-CBT (100 μM), Ac-AAPV-(D-Cys) peptide (100 μM), 0.5 
μg/mL HNE with increasing concentrations of sivelestat (0, 0.1, 0.3 and 3.0 μM) and luciferase enzyme at 37 °C. Error bars are 
± SD of three measurements. (b) Total luminescent signal integrated over 3 h (AUC). Error bars are ± SD of three measure-
ments. Statistical analyses were performed with a two-tailed Student’s t test. Differences between all the groups are statisti-
cally significant with each other (P < 0.05). 
Sivelestat dramatically reduces HNE activity, which results in a strong decrease in light emis-
sion. The total luminescence resulting from the probe incubation with HNE was reduced more than 3 
times when incubated with 0.1 μM sivelestat. That corresponds approximately to 27 % of total lumi-
nescence without inhibitor. Moreover, when the sivelestat concentration is increased to 3.0 μM, only 
1.1 % of the total luminescence emission without inhibitor was observed, highlighting once again the 
probe specificity to HNE. As an additional control, the effects of HNE on the luciferin/luciferase reaction 
or the split luciferin reaction were investigated by incubating different HNE concentrations with D-
cysteine and HO-CBT (Figure 4.4). High concentration of HNE (i.e. 0.5 μg/mL) does result in a small 
decrease in light emission. The total luminescence resulting from the reaction of D-cysteine and HO-
CBT was diminished by approximately 17 % if 0.5 μg/mL of HNE was present in solution (Figure 4.4b). 
A potential reason for this decrease in light emission, could be due to non-specific proteolytic degra-
dation of luciferase by high HNE concentrations. The light emission from all the other control with 
smaller HNE concentration resulted in no differences in total luminescence. Only the highest concen-
tration of HNE influenced the signal, meaning that when the Ac-AAPV-(D-Cys) probe is used, the ob-
served luminescence is actually smaller than it should be for a similar amount of luciferin formed. 
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Figure 4.4: In vitro enzymatic assay of HNE effect on luminescence emission using the split luciferin reaction. (a) luminescent 
signal over 3 h following addition of HO-CBT (100 μM) and D-cysteine (100 μM) with increasing concentrations of HNE (0, 
0.01, 0.025, 0.05, 0.1, 0.25 and 0.5 μg/mL), sivelestat (3.0 μM) and luciferase enzyme at 37 °C. Error bars are ± SD of three 
measurements. (b) Total luminescent signal integrated over 3 h (AUC). Error bars are ± SD of three measurements. Statistical 
analyses were performed with a two-tailed Student’s t test. Differences between all the groups are not statistically significant 
with each other (P > 0.05) except between 0.5 and 0.25 μg/mL or between 0.00 and 0.5 μg/mL + sivelestat (P > 0.05). 
Collectively, these data suggest that the Ac-AAPV-(D-Cys) probe, used in conjugation with HO-
CBT, provide an efficient method for both the imaging and quantification of HNE activity. The HNE 
concentration-dependent signal generated by the probe is selective, with a low detection limit, in the 
range of 10 ng/ml of enzyme, and suggest that the Ac-AAPV-(D-Cys) peptide could be a good candidate 
for imaging NE activity in biological environment. 
Importantly, it has been reported that PR3 and NE share a bit more than half amino acid ho-
mology, and that they can process more or less efficiently similar substrates.[267,294] Therefore, for cel-
lular or animals experiments, it has to be accounted that PR3 could be responsible for probe cleavage. 
However, it’s important to note that sivelestat is significantly less potent inhibitor of PR3 than HNE, 
making the use of this inhibitor a good control to exclude PR3 cleavage in the context of NE imaging 
experiments.[267] 
???? ?????????????????????????????????????????????????????????????????????
????? ????????? ????????? ???????????? ?????? ???? ?????? ?????????? ?????????
?????????
With promising results in vitro, investigation of NE activity imaging in living cells was under-
taken using the Ac-AAPV-(D-Cys) peptide and HO-CBT. The experimental design was to activate neu-
trophils after isolation from mice bone marrow and imaged subsequent NE activity. N-Formylmethio-
nyl-leucyl-phenylalanine (fMLP), a bacterial derived peptide, is a chemotactic compound that activates 
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neutrophils via different intracellular signalling pathways. Among other cellular response, activation 
results in neutrophil degranulation and superoxide generation.[295-297] Release of the granule content 
provokes excretion of a cocktail of molecules and proteins including serine proteases such as PR3, 
cathepsin G or NE.[271] 
  Neutrophils extracted from bone marrow of FVB-Luc+ mice were isolated using density gra-
dient separation by following an adapted reported procedure.[298] Unfortunately, after incubation of 
the extracted neutrophils with D-luciferin, no light emission was observed (data not shown). It was 
reported that leukocytes display varying levels of Fluc expression depending on the subsets.[217] There-
fore, Fluc will have to be supplemented exogenously in these experiments. First, extracted neutrophils 
were incubated with 10 μM fMLP or a vehicle control to trigger neutrophil activation and induce the 
release of granules content, including NE enzyme. The Ac-AAPV-(D-Cys) probe was added to the cell 
media and incubated for 45 min, followed by HO-CBT. Finally, a luciferase solution containing all nec-
essary cofactors was added to the cell immediately prior imaging. To confirm the specificity of D-cys-
teine release by HNE, these experiments were performed in the presence and absence of a specific NE 
inhibitor, sivelestat. Moreover, to confirm that neither fMLP nor sivelestat influence light emission, 
these experiments were performed with D-cysteine instead of the peptide probe (Figure 4.5). 
 
Figure 4.5: Imaging NE activity in activated mice neutrophils (a) Observed luminescence over 70 min after activation of neu-
trophils extracted from FVB-Luc+ mice bone marrow. After isolation, neutrophils were incubated with fMLP (10 μM) or DMSO 
and Ac-AAPV-(D-Cys) (100 μM) peptide or D-cysteine (10 μM) for 45 min. HO-CBT was then added to the cells, incubated for 
15 min and imaged. (b) Total luminescent signal integrated over 70 min (AUC). Error bars are ± SD for three measurements. 
Statistical analyses were performed with a two-tailed Student’s t test. **P < 0.01. 
First, light emission emitted when fMLP was used to activate neutrophils is similar than when 
cells were only treated with vehicle. This is in opposition to the expected results, as NE was supposed 
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to be released upon fMLP activation and consequently result in an increase in probe cleavage and thus 
in light emission. Yet, the sivelestat control resulted in a small decrease in light emission, suggesting 
that the signal observed is dependent on NE activity. This could be the result of neutrophil activation 
that occurred during the isolation procedure, resulting in no observable effect of fMLP. Moreover, 
after isolation, neutrophils were kept in RPMI 1640 media. This media contains a large amount of cys-
teine, that can result in the generation of background following the addition of HO-CBT addition. In 
order to determine if media could influence the background light emission, HO-CBT was incubated in 
RMPI 1640, DMEM or DPBS, followed by luciferase addition and subsequent BL measurement. The 
light emission measured from RPMI media after HO-CBT addition is 17 times higher than similar exper-
iment performed in saline solution (Figure S4.2). Therefore, repeating the neutrophil activation exper-
iments with PBS instead of RPMI 1640 could thus improve the conditions, assuming that PBS doesn’t 
influence cell viability and activation. Nevertheless, a high background signal does not explain high 
light emission from vehicle treated neutrophils imaged with peptide probe (Figure 4.5). Interestingly, 
an alternative hypothesis could be that the probe is cell permeable and can interact with all cellular 
NE irrespective of neutrophil activation and de-granulation. Further experiments to design a cell im-
permeable probe as an additional control would help to address this problem.   
???? ????? ?????????????????? ???????????????????????????????????????? ??? ???
?????????????
It was previously established that the split luciferin reaction has properties that are compatible 
with bioluminescence imaging in living animals. Using this methodology, caspase 3/7 activity was suc-
cessfully imaged in a liver apoptosis model in living mice. Since the Ac-AAPV-(D-Cys) peptide has been 
efficiently used for imaging and quantification of NE activity in vitro, this probe could be a good candi-
date for imaging NE in living animals. Thus, the goal of these in vivo studies is to validate the use of the 
NE split luciferin-based probe for imaging NE activity in living animals.  
For the first in vivo application of NE bioluminescence imaging using the split luciferin reaction, 
an acute lung inflammation model was adopted. Lung inflammation can be induced in mice by admin-
istration in the lungs of the bacterial pathogen associated molecular patterns (PAMPS) lipopolysaccha-
rides (LPS) and fMLP directly into the lungs.[267,299] LPS are large molecules composed of a lipid core 
conjugated to a carbohydrate chain and decorate the surface of Gram-negative bacteria. LPS is a highly 
potent antigen, which induces inflammatory responses in vivo. fMLP, a bacterial derived peptide, was 
shown to be a chemotactic compound as well as an activator of macrophages and neutrophils that 
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results in reactive oxygen species and neutrophil degranulation.[295] Whereas intravenous and intra-
peritoneal (i.p.) administration of LPS in mice have been reported for the development of acute lung 
injury models, it does not produce neutrophil infiltration in lung parenchyma and as a result is not 
suited to study the infiltration and activation of neutrophils into the lungs and the corresponding NE 
activity.[300-302] On the other hand, intranasal or intratracheal administration of LPS and fMLP induce a 
strong inflammatory response via multiple signalling pathways and provoke neutrophil infiltration of 
pulmonary tissue and as a consequence acute lung injury.[267,299,303] Neutrophils bronchoalveolar infil-
tration is produced by LPS, but the neutrophil activation and thus the neutrophil-associated enzymatic 
activities is dependent on fMLP treatment in mice.[299,304] 
As a first report of bioluminescence imaging of NE in vivo, an acute lung injury model was 
induced in mice transiently expressing luciferase enzyme in lung tissue. In order to induce neutrophil-
mediated inflammation, a reported procedure was followed with small modifications.[267,299] Mice were 
treated intratracheally with LPS and fMLP, inducing neutrophil recruitment and activation in the lung 
tissue. The Ac-AAPV-(D-Cys) peptide probe was then administered to the animal, followed by HO-CBT 
injection and imaging.  
BalbC mice were first transfected with a FLuc expression plasmid resulting in luciferase expres-
sion in the lung tissue. The luciferase construct, named RedLuc, consists of a codon-optimized lucifer-
ase from the luciola italic firefly that has a red-shifted emission peak at a wavelength of 617 nm.[305] 
Following transfection, luciferase expression level was measured by imaging mice after injection of D-
luciferin. The luciferase expression was determined to be stable from days 4 to 7 post transfection 
(Figure S4.3). Five days after DNA administration, mice were treated intratracheally with LPS, inducing 
an inflammatory response and neutrophil recruitment in the lung tissue. This was followed 24 h later 
by intratracheal fMLP treatment resulting in neutrophil activation and degranulation. After a delay of 
30 min, the Ac-AAPV-(D-Cys) peptide probe was injected i.p. in the animal. NE is released after activa-
tion of recruited neutrophils, and cleaves the probe, releasing free D-cysteine. In situ formation of D-
luciferin occurs following i.p. administration of HO-CBT 30 min after peptide injection (Figure 4.6). 
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Figure 4.6: NE activity imaging using split luciferin reaction in a mouse model of acute lung injury. Overall representation of 
mice treatment and NE activity imaging with Ac-AAPV-(D-Cys) peptide and HO-CBT in living animals transiently expressing 
luciferase enzyme in the lung tissue. 
Immediately after CBT administration, mice were placed in the imaging device and biolumi-
nescence was acquired over 1 h. Mice were divided into 3 groups that were all injected with Ac-AAPV-
(D-Cys) peptide and HO-CBT, and either received LPS and fMLP administration, LPS only or vehicle only. 
In order to estimate the intrinsic background generated by HO-CBT administration in this mouse 
model, one more group just received vehicle and HO-CBT without administration of the peptide probe 
(Figure 4.7).  
 
Figure 4.7: Imaging NE activity in a LPS/fMLP induced mouse acute lung injury model. (a) Total luminescence over 1 h from 
luciferase transfected BalbC mice treated with either vehicle, LPS intratracheally (12.5 μg/mouse in 40 μL PBS) or combination 
of LPS (12.5 μg/mouse in 40 μL PBS) and fMLP (32 μg/mouse in 40 μL PBS) intratracheally. fMLP was administered 24 hours 
after LPS treatment. 30 min post fMLP treatment, the animals received i.p. injections of either Ac-AAPV-(D-Cys) peptide (2.363 
mg/mouse in 200 ?L saline) or vehicle, followed by HO-CBT (0.83 mg/mouse in 400 ?L of 25% DMSO in PBS). Statistical anal-
yses were performed with a two-tailed Student’s t test. **P < 0.01, *P < 0.05 (n=3 for all the groups that receive peptide 
probe and HO-CBT. n=1 for the vehicle group that received only HO-CBT.). Error bars are ± SD for three measurements. (b) 
Representative image of mice, 30 min post-injection of HO-CBT. 
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Bioluminescence from the NE probe was greatest in the LPS/fMLP treated group (Figure 4.7, 
Figure 4.8). The ratio in average total light emission between the LPS/fMLP and vehicle treated groups 
is approximately 4-fold and the difference is statistically significant (P = 0.0095, Figure 4.7a). There is 
only a 2.4-fold increase in total luminescence between the LPS and the LPS/fMLP group that is also 
statistically significant (P = 0.0305). However, there is no statistical difference between vehicle and LPS 
treated groups (P = 0.3839). It can also be noticed that the light emission acquired over 60 min is in-
creasing in function of the time in LPS/fMLP treated mice, whereas a more constant or low increase is 
observed in other groups treated with the peptide probe and HO-CBT (Figure 4.8). 
 
Figure 4.8: Observed luminescence emission over 60 min from NE bioluminescent probes in a LPS/fMLP induced mouse acute 
lung injury model. Luminescence emission over 60 min following i.p. injection of Ac-AAPV-D-Cys peptide (2.363 mg/mouse in 
200 ?L saline) and HO-CBT (0.83 mg/mouse in 400 ?L of 25% DMSO in PBS) or only HO-CBT, after intratracheal LPS (12.5 
μg/mouse in 40 μL of PBS) and fMLP (32μg/mouse in 40 μL PBS) (n=3), only LPS (n=3) or vehicle treatment (n=3) in luciferase 
transfected BalbC mice. Error bars are ± SD for three measurements. 
These data provide strong evidence that NE activity can be efficiently imaged via the split lu-
ciferin reaction using Ac-AAPV-(D-Cys) peptide in an acute lung injury model in luciferase expressing 
mice. A significant increase in signal was observed only under LPS/fMLP treatment compared to the 
other experimental groups. This is in agreement with previous reports stating that both of these effec-
tors are necessary for neutrophil migration in the lungs and further activation.[267,299,303] The lower light 
emission observed when mice where only treated by LPS is in adequacy with the fact that fMLP is 
necessary for neutrophils activation that triggers NE release from neutrophil-granules.[267,304] Without 
fMLP, activation of neutrophils is less important, resulting in a lower NE concentration in lung tissues. 
These results obtained in vivo are also in agreement with previous report where NE activity was effi-
ciently imaged in similar neutrophil-mediated lung inflammation using a florigenic probe.[267] 
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Figure 4.9: Hematoxylin and eosin (HE) staining of formalin fixed paraffin embedded tissue sections from BalbC mice lungs 
after intratracheal treatment with LPS or saline as control. Histochemical images are representative of the lung tissue per 
experimental groups (n=3). (a) Negative control, 24 h after administration of 40 μl PBS intratracheally. No infiltration of neu-
trophils is visible (40x, HE). (b) 24 h after administration of LPS intratracheally (12.5 μg/mouse in 40 μL PBS). Neutrophils are 
visible within the capillaries in an increased amount (neutrophilia) (red arrows) and accumulate in small numbers within the 
alveoli (black arrow) (40x, HE). (c) 48 h after administration of LPS intratracheally (12.5 μg/mouse in 40 μL PBS), neutrophils 
accumulate in large groups in the alveoli (black arrows) leading to purulent pneumonia (40x, HE). 
 Analysis of lung sections confirmed that LPS treatment induced neutrophil-mediated inflam-
mation. Lungs from mice administered with LPS or PBS intratracheally were collected 24 and 48 h after 
treatment. Histological sections of the tissues were analysed after hematoxylin and eosin (HE) straining 
in collaboration with a pathologist. In lung tissues of control mice treated with PBS, no infiltrated neu-
trophils were visible (Figure 4.9a). However, 24 and 48 h after LPS administration, infiltrated neutro-
phils are clearly present. At the 24 h time point, neutrophils were principally located in the capillaries 
(neutrophilia), with a moderate number within the alveoli, whereas at 48 h a large number of neutro-
phils were mainly found in the lumen of the alveoli (Figure 4.9b-c).  
 
Figure 4.10: Immunohistochemical (IHC) staining of Ly6G antigen revealed by Bluemap on paraffin fixed histology sections 
from BalbC mice lungs after intratracheal treatment with LPS or saline as control. Immunohistochemical images are repre-
sentative of whole lung tissue. (a) Negative control, 24 h after administration of 40 μl PBS intratracheally. Very low and sprin-
kled Ly6G staining, mainly located in the capillaries (40x, IHC). (b) 48 h after administration of LPS intratracheally (12.5 
μg/mouse in 40 μL PBS). Strong Ly6G staining of neutrophils (in blue) in the lung alveoli (40x, IHC). 
Moreover, the analysis of Ly6G immunohistochemical staining of the tissue section revealed 
similar observations. Ly6G (Lymphocyte antigen 6 complex locus G6D) is an antigen expressed on gran-
ulocytes, also called polymorphonuclear cells. These white blood cells category encompass neutro-
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phils, the most abundant granulocytes, but also eosinophils, basophils and mast cells. Thus immuno-
histochemical staining of Ly6G demonstrates the presence of this cell population. In healthy lungs, 
neutrophils and other granulocytes are not present in the alveoli, whereas in inflammation conditions 
infiltrated granulocytes migrate into the alveoli in large numbers. This exact pattern was observed in 
mice lung sections where, 48h after LPS intratracheal administration, a large number of Ly6G positive 
cells are visible in the lung alveoli (Figure 4.10b). In contrast, control tissue that only received PBS, only 
a few Ly6G positive cells, located in capillaries are visible, which is an ordinary observation due to 
presence of a few granulocytes in the peripheral blood (Figure 4.10a). This is in agreement with in vivo 
NE imaging data obtained using the split luciferin approach as well as other reported data[267,306] and 
suggests that neutrophil-mediate inflammation was efficiently induced in the lungs by intratracheal 
administration of LPS. 
In order to confirm these promising results, further investigations of the NE probe Ac-AAPV-
(D-Cys) were performed in another mouse strain. The same LPS/fMLP acute lung injury model was 
induced in ubiquitously luciferase expressing FVB-Luc+ mice, using a slightly different experimental 
procedure. FVB-Luc+ mice were treated intranasally with LPS, followed 24 h later by intranasal fMLP 
administration. After a 2 h delay, the Ac-AAPV-(D-Cys) peptide probe was injected i.p. in the animals. 
In situ formation of D-luciferin occurs after HO-CBT i.p. administration, 30 min after peptide injection. 
Mice were then immediately placed in the imaging system and bioluminescence emission was acquired 
for 1h. Light emission from the chest region was quantified and luminescence over 60 min as well as 
the total luminescence (AUC) were calculated (Figure 4.11).  
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Figure 4.11: Imaging NE activity in a LPS/fMLP induced mouse FVB-Luc+ acute lung injury model. (a) Luminescence emission 
over 60 min from FVB-Luc+ mice treated with either vehicle or a combination of LPS (100 μg/mouse in 40 μL PBS) and fMLP 
(32 μg/mouse in 40 μL PBS) intranasally. fMLP was administered 24 hours after LPS treatment. 2 h post fMLP treatment, the 
animals received i.p. injections of either Ac-AAPV-(D-Cys) peptide (0.391 mg/mouse in 200 ?L saline) or vehicle, followed by 
HO-CBT (0.136 mg/mouse in 100 ?L of 20% DMSO in PBS). Error bars are ± SD for three measurements. (b) Total luminescence 
integrated over 1 h (AUC). Statistical analyses were performed with a two-tailed Student’s t test. *P < 0.05 (n=3). Error bars 
are ± SD for three measurements. 
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Compared to the previous experiments on transfected BalbC strain expressing luciferase en-
zyme only in the lung tissue, doses and timeline had to be adjusted. The peptide and HO-CBT doses 
were decreased. High doses were not necessary in FVB-Luc+ animal due to strong ubiquitous luciferase 
expression. Moreover, due to intranasal administration instead of intratracheal, LPS doses were in-
creased.  
The light emission observed in LPS/fMLP treated animals is significantly higher than the vehicle 
treated controls (P = 0.0195). However, total luminescence observed from the LPS/fMLP treated group 
is approximately two times higher than from vehicle treated group (Figure 4.10b). Compared to the 
experiments performed in transfected BalbC animals, the difference in total luminescence is smaller 
between both groups of FVB-Luc+ mice.  
Overall, these data demonstrate that the Ac-AAPV-(D-Cys) peptide used in combination with 
HO-CBT allows an efficient, selective and sensitive approach for NE imaging in vivo, in mouse models 
of acute lung injury. Accordingly, the split luciferin based probe for NE could be a valuable tool for 
imaging neutrophil-mediated inflammation as well as better understanding NE functions in several 
infection and inflammation models. This confirms that split luciferin based probes are valuable tools 
for non-invasive imaging of proteases in vivo, providing a potent methodology for generation of novel 
BLI probes. 
???? ???????????
In this chapter, imaging and quantification of NE using the split luciferin reaction were re-
ported. To our knowledge, this is the first report of BLI of NE activity. Ac-AAPV-(D-Cys) peptide, used 
in combination with HO-CBT, was validated for the imaging and quantification of NE activity in vitro 
and living animals. In vitro experiments with purified NE enzyme revealed that the developed split 
luciferin-based probe is efficient, selective and sensitive. On the other hand, the cell assay was not 
conclusive, with high light emission observed from neutrophils that were not activated by incubation 
with fMLP. However, a small decrease in light emission was observed upon NE inhibitor treatment, 
suggesting that neutrophils could have been activated during extraction procedure. Alternatively, the 
probe could be cell permeable and thus could interact with all cellular NE irrespective of neutrophil 
activation and degranulation. Designing a cell impermeable probe as an additional control would help 
to understand this problem. Further experiments are thus necessary for a full validation of the probe 
in a cell-based assay. Moreover, extraction of neutrophils from human blood and subsequent NE im-
aging experiments could be included in this study. 
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In vivo, NE activity was quantified and imaged in an acute lung inflammation model in two 
different mouse strains. A significant increase in light emission was observed from mice that received 
LPS/fMLP administration in the lungs compared to vehicle treated animals. Furthermore, bronchoalve-
olar lavage (BAL), a medical procedure routinely used for lung disease diagnosis, could be performed 
on mice challenged with LPS. This would provide evidence that NE can be imaged and quantified using 
the split luciferin reaction ex vivo in BAL fluids. As luciferase enzyme can be added exogenously, this 
would also provide a method for the quantification of NE activity in non-luciferase expressing animals. 
All together, these data provide evidence that NE can be efficiently imaged in a lung inflam-
mation model using the split luciferin reaction. This approach provides an efficient tool for BLI of NE 
activity in real time, non-invasively and in vivo. To date, the split luciferin reaction was used in vivo for 
quantification and visualization of caspase 3/7 activity as well as simultaneous imaging of caspase-8 
and hydrogen peroxide.[230,231,307] This study provides another report where the split luciferin reaction 
was used for BLI of protease in vivo, highlighting the versatility and good potential of the split luciferin 
reaction for imaging applications. 
???? ?????????????????????
General Material and Methods. Chemicals were obtained from commercial suppliers and used 
without further purification. For peptide synthesis, preloaded H-D-Cys(Trt)-2-chlorotrityl resin (particle 
size 100-200 mesh, loading 0.4 mmol/g, Advanced Chemtech), Fmoc-protected amino acids (Fmoc-L-
Valine-OH,  Fmoc-Proline-OH and Fmoc-Alanine-OH, purity > 99% Novabiochem), 1-Hydroxy-7-
azabenzotriazole (HOAt, purity > 99%, Fluorochem LTD), N,N’-diisopropylcarbodiimide (DIC, purity > 
99%, TCI GmbH), N,N’-dimethylformamide (DMF, ReagentPlus grade, Sigma-Aldrich or Technical grade, 
Thommen-Furler AG), dichloromethane (DCM, Technical grade, Thommen-Furler AG), methanol 
(MeOH, Technical grade, Thommen-Furler AG), acetonitrile (MeCN, HPLC gradient grade, Fischer Sci-
entific), diethyl ether (Et2O, for HPLC, > 99.9%, Sigma-Aldrich), piperidine (purity > 99.9%, Sigma-Al-
drich), trifluoroacetic acid (TFA, ReagentPlus, purity 99%, Sigma-Aldrich), triisopropylsilane (TIPS, pu-
rity 98%, Aldrich, Sigma-Aldrich), dithiothreitol (DTT, Molecular biology grade, LuBioScience),  Acetic 
anhydride (ReagentPlus, purity 99%, Sigma-Aldrich) and formic acid (FA, LC-MS Ultra grade, Fluka, 
Sigma-Aldrich) were used. 
Human Neutrophil Elastase (HNE) was purchased from Abcam plc, and used without further 
purification. Luciferase buffer was prepared as following: 60 ?g mL?1 Firefly luciferase (Sigma-Aldrich 
Chemie GmbH) in 0.1 M Tris-HCl pH = 7.4, 2 mM Adenosine 5'-triphosphate, disodium salt hydrate 
(ATP, AppliChem GmbH), and 5 mM Magnesium sulfate (MgSO4, Sigma-Aldrich). D-Cysteine (D-Cys, 
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purity >99%, Sigma-Aldrich) and 6-Hydroxy-benzothiazole-2-carbonitrile (HO-CBT, Endotherm GmbH), 
N-Methoxysuccinyl-Ala-Ala-Pro-Val-para-Nitroanilide (AAPV-pNA, NE substrate, Sigma-Aldrich), Lipo-
polysaccharides from Escherichia coli 0111:B4 (LPS, purified by gel-filtration chromatography, Sigma-
Aldrich), N-Formyl-Met-Leu-Phe (fMLP, BioXtra, ?99.0%, Sigma-Aldrich), Dimethyl sulfoxide (DMSO, 
for molecular biology, Sigma-Aldrich), DPBS (w/o CaCl2, w/o MgCl2, Life Technologies), 10X HBSS (Life 
Technologies), FBS (Life Technologies), RPMI 1640 (Life Technologies), N-{2-[({4-[(2,2-Dimethylpropa-
noyl)oxy]phenyl}sulfonyl)amino]benzoyl}glycine sodium salt (sivelestat sodium salt, >98 %, Tocris Bio-
science), Phosphate buffered saline (PBS, Life Technologies) and Percoll (pH 8.5-9.5, cell culture tested, 
Thermo Fisher Scientific Inc.) were used for assays without any further purification. DNA maxiprep kit 
was purchased from Clontech and JetPEI (in vivo-jetPEI) was purchased from Polyplus Transfection. 
Millipore water was used for sample preparation of all in vitro, cellular, and animal assays. All 
in vitro and cellular studies were performed in clear bottom black 96-well plates that were purchased 
from Becton Dickinson and Company (Franklin Lakes, NJ). Spectramax Gemini (Molecular Devices) or 
IVIS Spectrum camera (PerkinElmer) were used to measure the amount of BLI signal production. 
UPLC analytical analysis was performed on Water Acquity UPLC system coupled to a Waters 
Acquity TQ mass detector (Waters Corp., Milford, USA) with Acquity UPLC BEH Shield reverse phase 
C18 column (2.1x50 mm, 1.7 μm, Waters) using degassed HPLC gradient grade solvents from Fisher 
Chemicals (Loughborough, UK) and Millipore water both supplemented with 0.1% FA. Semi-prepara-
tive HPLC purification was performed using a semi-preparative Waters HPLC system coupled to a Wa-
ters Acquity TQ mass detector (Waters Corp., Milford, USA). An XTerra prep MS C18 OBD column 
(19x50 mm, 5.0 μm, Waters) was used in combination with Degazed MiliQ water supplemented with 
0.1% of FA (vol/vol) and MeCN supplemented with 0.1% of FA (vol/vol) as phases for the eluent. HRESI-
MS measurements were conducted at the EPFL ISIC Mass Spectrometry Service using Micro Mass QTOF 
Ultima from Waters Corp. 
Ac-L(Ala-Ala-Pro-Val)-D-(Cys)-OH (Ac-AAPV-(D-Cys)) peptide synthesis. Peptide was synthe-
sized using Fmoc solid-phase peptide synthesis with a D-cysteine preloaded chloro-trityl resin (H-D-
Cys(Trt)-2-Cl-Trt-Resin, 100-200 mesh, 0.4 mmol/g, Advanced Chem Tech) on a 0.4 mmol scale. Se-
quentially, Fmoc-L-valine, Fmoc-L-proline, and 2 times Fmoc-L-alanine were used. For each coupling, 
the Fmoc protected amino acid residue (3 eq., 1.2 mmol), 1-hydroxy-7-azabenzotriaole (HOAt, 3 eq., 
1.2 mmol) and N,N?-diisopropylcarbodiimide (DIC, 3 eq., 1.2 mmol) and DMF (20 mL) were loaded in a 
reaction vessel over the resin and stirred at rt for 6 h. The suspension was then filtered and the resin 
was washed sequentially with DMF, methanol and dichloromethane (DCM). Fmoc deprotection was 
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performed by resuspending the resin in a 20% (v/v) piperidine solution in DMF (20 mL) for 10 min 
under stirring at rt. After filtration the solid was washed sequentially with DMF, methanol and DCM. 
These steps were then repeated until the last amino acid coupling and Fmoc deprotection. Acetate 
capping was performed by suspending the resin in DMF (20 mL) supplemented with pyridine (3 eq., 
94.92 mg, 97.06 uL) and acetic anhydride (3 eq., 122.50 mg, 121.69 uL) for 30 min at rt under stirring, 
followed by washing sequentially with DMF, methanol and DCM. Amino acid side-chain deprotection 
and peptide cleavage from the resine was performed by resuspending 3 times the resin in 10 mL of a 
DCM/TFA/H2O/triisopropylsilane/dithiothreitol (5 ml DCM, 4.5 mL TFA, 0.25 mL H2O, 0.25 mL triiso-
propylsilane and 0.3 mg tithiothreitol) solution for 10 min at rt. Resin was removed by filtration. Com-
bined liquid phases were concentrated under reduced pressure, and the peptide was precipitated with 
ice-cold diethyl ether (20 mL). The precipitate was recovered and washed twice with ice-cold diethyl 
ether (20 mL) and dried under reduced pressure. further purified by semi-preparative HPLC to yield 
the desired Ac-Ala-Ala-Pro-Val-(D-Cys)-OH product. Purity was confirmed by HRMS and analytical 
HPLC. HRMS (ESI-TOF) m/z: [M+Na]+ calcd for C21H35N5O7SNa, 524.2155; found, 524.2164. Isolated 
yield after purification is 51%. 
Bioluminescent Neutrophil Elastase Assay with Ac-AAPV-(D-Cys) Peptide and HO-CBT. 
1ug/uL HNE stock solution was prepared by dissolving the lyophilized Active Human NE (abcam, 
ab91099) in in 50 mM Sodium Acetate pH 5.5 buffer supplemented with 150 mM NaCl. From this stock 
solution, different HNE solutions were prepared at 0.0, 0.05, 0.025, 0.01, 0.005, 0.0025 and 0.001 
ug/uL in 100 mM Tris-HCl, pH 7.5, 500 mM NaCl. 
In a black flat transparent bottom 96-well plate, 96 μL of a Luciferase solution containing 60 
μg/mL of firefly luciferase enzyme in assay buffer (100 mM Tris-HCl, pH 7.5, 500 mM NaCl, 2 mM ATP, 
5 mM MgSO4) was added in the wells. 1 uL of the HNE solutions were added in the black 96-well, each 
concentration in triplicates. When necessary, 1 uL of sivelestat solutions (3 uM, 30 uM or 300 uM in 
DMSO) was added to the corresponding wells. Wells that did not received sivelestat solution, were 
supplemented with 1 uL of DMSO. In every wells, either 1 μL of a Ac-AAPV-c solution (10 mM in PBS) 
or 1 μL of a D-Cys solution (10 mM in PBS) were added. This was followed by addition of 1uL of a HO-
CBT solution (10 mM in DMSO) simultaneously in all the wells. Bioluminescence signal from the plate 
was immediately measured every 1.5 min with 1000 ms integration time for 3 h at rt. 
Colorimetric assessment of Neutrophil Elastase activity. 1ug/uL HNE stock solution was pre-
pared by dissolving the lyophilized Active Human NE (abcam, ab91099) in in 50 mM Sodium Acetate 
pH 5.5 buffer supplemented with 150 mM NaCl. In a black flat transparent bottom 96-well plate, 98 μL 
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of NE-buffer (100 mM Tris-HCl, pH 7.5, 500 mM NaCl) were added in the wells. In every wells, either 1 
μL of a AAPV-pNA solution (10 mM in DMSO) or 1 μL of DMSO were added. Absorbance at 405 nm was 
measured for 15 min. Then,1 uL of the HNE solution were added in the black 96-well. Wells where no 
HNE was added, received 1 uL of vehicle. Absorbance at 405 nm was again measured every 15 min for 
4h. 
Animals. FVB-luc+ transgenic mice[217,218] (full abbreviation: FVB-Tg(CAG-luc,-
GFP)L2G85Chco/J) were obtained from The Jackson Laboratory and bread at the EPFL SPF animal fa-
cility. The breeding colony was housed in groups of 4-5 mice according to their age and gender with 
free access to food and water at 22 °C with regular light-dark cycle. All studies were carried out in strict 
accordance to the Swiss regulation on animal experimentation and the experimental procedure (li-
cense VD2969) was approved by the authority of the Canton Vaud, Switzerland (EXPANIM (Expérience 
sur animaux)–SCAV, Département de la sécurité et de l’environnement, Service de la consommation 
et des affaires vétérinaires). 
Female inbred BalbC (BALB/cAnCrl) mice (7–8 week-old) were housed in groups of 4-5 mice 
according to their age with free access to food and water at 22 °C with regular light-dark cycle. Exper-
iments were performed in compliance with national and international laws and policies (Guide for the 
Care and Use of Laboratory Animals, Institute of Laboratory Animal Resources Commission on Life Sci-
ences, National Research Council (1996) Guide for the care and use of laboratory animals. National 
Academy Press, Washington, DC). Animal studies were approved by the Institutional Animal Care and 
Use Committee at Chiesi Farmaceutici, Parma, Italy.  
Real time non-invasive imaging and quantification of Neutrophil Elastase activity in mice 
neutrophils using the split luciferin ligation reaction. Two 20-22 weeks old FVB-luc+ female were sac-
rificed using CO2 inhalation. Femurs and tibias were collected and put in ice cold PBS. Femurs were 
separated from tibias at the knee joint. Ends of bones were cut clean with a sharp surgical scissor. Bone 
marrow (BM) was flushed from bone with 10 mL of ice cold DPBS supplemented with 0.1% FBS using 
a 29 gauge insulin syringe. BM solution was gently mixed by performing up and downs with a micropi-
pette. Solution was then filtered on a 40 μm nylon cell strainer. The recovered solution was centrifuged 
(12 min, 260 g, 4 °C) and the pellet was resuspended in 4 mL DPBS containing 0.1% FBS. A 90 % percoll 
stock solution in 10 x HBSS was prepared. 52 %, 64 % and 72 % percoll stock solution (90% in 10 x HBSS) 
were prepared in DPBS supplemented with 0.1% FBS. In two 15 mL conical tube, 2 mL of each percoll 
dilution were layered from the more concentrated (72 %, bottom) to the less concentrated one (52 %, 
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top). 2 mL of the BM solution were carefully layered over the 52 % percoll stock solution, and centri-
fuged for 30 min at 110 g and 4 °C. Neutrophil layer that has formed at the interface between 72 % 
and 64 % percoll stock solution were harvested and diluted up to 10 mL with DPBS solution containing 
0.1 % FBS and centrifuged 5 min at 260 g and 4 °C. Cells were resuspended again in 10 mL DPBS solution 
containing 0.1 % FBS and centrifuged 5 min at 260 g and 4 °C. This last step was repeated once. Finally, 
cells were resuspended in 2 mL RPMI 1640 supplemented with 1 % penicillin and streptomycin, 
counted and diluted to a 1·106 cell per mL.  
In a black flat transparent bottom 96-well plate, 100000 cells (100 μL) were added in each 
wells, and cells were placed at 37 °C for 15 min. In every wells, either 1 μL of an fMLP solution (1 mM 
in DMSO) or vehicle was added as well as 1 μL of sivelestat solution (3 μM in DMSO) or pure DMSO. 
Then 1 μL of Ac-AAPV-(D-Cys) probe solution (10 mM in H2O) or 1 μL of D-Cys solution (1 mM in H2O) 
were added. The plate was incubated at 37 °C for 45 min and 1 uL of HO-CBT solution (10 mM in DMSO) 
was added in the wells. After another 15 min incubation at 37 °C, 50 μL of a 120 μg/mL luciferase 
enzyme solution in luciferase buffer (4 mM ATP, 10 mM MgSO4 in 100 mM TRIS-HCl pH 8) were added 
in all the well. The plate was then immediately imaged using an IVIS100 imaging system using auto-
matic settings at 37 °C for 1 h with an acquisition per minute. Photons emitted from the wells were 
quantified using Living Image® software (Caliper Life Sciences). 
Split luciferin background estimation using different buffers. In a black flat transparent bot-
tom was used. In every wells, either 99 μL of RPMI 1640 supplemented with 1 % penicillin and strep-
tomycin, 99 μL of DMEM or 99 μL of DPBS were added. One μL of HO-CBT solution (10 mM in DMSO) 
was added in all the wells and the plate was incubated for 15 min at 37 °C. Then, 50 μL of a 120 μg/mL 
luciferase enzyme solution in luciferase buffer (4 mM ATP, 10 mM MgSO4 in 100 mM TRIS-HCl pH 8) 
were added in all the well. The plate was then immediately imaged using an IVIS100 imaging system 
using automatic settings at 37 °C for 1 h with an acquisition per minute. Photons emitted from the 
wells were quantified using Living Image® software (Caliper Life Sciences). 
In vivo mice transfection (by Dr. Fabio Stellari and Francesca Ruscitti). The pLenti-UbC-Red-
FLuc-T2A-Puro (RedLuc-puro, Figure S4.4) plasmid was obtained from Perkin Elmert and amplified us-
ing Clontech DNA maxiprep kit. In vivo JetPEI (Polyplus Transfection) was applied as a carrier for deliv-
ering DNA to lung tissues according to manufacturer protocol. Briefly, the plasmid DNA and JetPEI mix 
were formulated with a final N/P ratio of 7. Forty ?g of RedLuc-puro and 7 ?L of JetPEI were both 
diluted into 200 ?L 5% glucose. The two solutions were then mixed and incubated for 15 min at room 
Bioluminescence Imaging of Neutrophil Elastase Activity Using the Split Luciferin Reaction 
91 
temperature. The entire mixture was then injected intravenously into tail vein of BalbC mice. The ex-
pression of UbC-Luc was monitored through imaging with an IVIS imaging system 1 day, 4 days, 5 days 
and 7 days after DNA delivery. Briefly, mice were injected intraperitoneal (i.p.) with luciferin (150 
mg/kg) and bioluminescence was measured 15 min following luciferin injection. Mice were anesthe-
tized with 1.5 % isoflurane and images were acquired with an IVIS imaging system. Photons emitted 
from the chest region were quantified using Living Image® software (Caliper Life Sciences) (Figure 
S4.3). 
Real time non-invasive imaging of HNE activity in transiently transgenic mice. 4 days after 
DNA delivery, the transfected BalbC mice (3 mice per group), were anesthetized with isoflurane and 
challenged intratracheally with either 12.5 μg/mouse of LPS solubilized in 40 μL PBS or PBS only. After 
a 24 h delay, mice were administered intratracheally with 32 μg/mouse of fMLP in 40 μL PBS or PBS 
only. This was followed 30 min later by i.p. injections of the Ac-AAPV-(D-Cys) peptide (2.363 mg/mouse 
in 200 ?L saline). After another 30 min delay, mice were treated i.p. with HO-CBT (0.83 mg/mouse in 
400 ?L of 25% DMSO solution in PBS) and immediately imaged. Mice were anesthetized with 4.0 % 
isoflurane and maintained under light anesthesia with 1.5 % isoflurane. Bioluminescence images were 
acquired with an IVIS lumina II imaging system every 5 min for 1 h at 37°C with exposure time set to 5 
min. Photons emitted from the chest region were quantified using Living Image® software (Caliper Life 
Sciences). 
Preparation of lung tissue for Histology (by Dr. Fabio Stellari and Francesca Ruscitti). 24 or 
48 h after intratracheal LPS administration (12.5 μg/mouse in 40 uL PBS) in female BalbC mice (7–8 
week-old), animals were sacrificed and lungs were carefully excised. Lungs were then inflated with a 
cannula through the trachea by gentle infusion with 0.6 ml of 10 % neutral-buffered formalin solution 
and were placed in a vial containing 10 % neutral-buffered formalin solution and fixed for at least 48 
hours. The whole lungs were dehydrated in graded ethanol series, clarified in xylene and paraffin em-
bedded. 
Hemotoxylin and Eosine staining on mice lung tissue. Preparation of tissue sections and stain-
ing procedures were performed at the EPFL histology core facility (HCF). Briefly, dewaxed and rehy-
drated paraffin sections were placed in Harris Hematoxylin solution for 5 min, washed and differenti-
ated in 1 % acid-alcohol for a few seconds. The slides were then placed in a Eosine-Phloxine solution 
for 1 min, briefly washed with water, dehydrated, cleared and mounted. 
Immunohistochemical staining of Ly6G antigen on mice lung tissue. Preparation of tissue sec-
tions and Immunohistochemical staining procedures were performed at the EPFL histology core facility 
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(HCF). Immunohistochemical detection of neutrophils (rat anti Ly6G, clone 1A8, diluted 1:200) was 
performed using the fully automated Ventana Discovery XT (Roche Diagnostics, Rotkreuz, Switzerland), 
according to manufacturers instructions. Briefly, dewaxed and rehydrated paraffin sections were pre-
treated with heat using standard condition (36 minutes) CC1. The primary antibodies were incubated 
1 hour at 37 °C. After incubation with a donkey ?-rat biotin (Jackson ImmunoResearch Laboratories), 
chromogenic revelation was performed with BlueMap kit (Roche Diagnostics, Rotkreuz, Switzerland) 
with 32 minutes of substrate incubation. 
Real time non-invasive imaging of HNE activity in FVB-Luc+ mice. FVB-Luc+ mice (3 mice per 
group), were anesthetized with isoflurane and challenged intranasally with either 100 μg/mouse of 
LPS solubilized in 40 μL PBS or vehicle. After a 24 h delay, mice were administered intranasally with 32 
μg/mouse of fMLP in 40 μL PBS or PBS only. This was followed 2 h later by i.p. injections of the Ac-
AAPV-(D-Cys) peptide (0.391 mg/mouse in 200 ?L saline). After another 30 min delay, mice were 
treated i.p. with HO-CBT (0.136 mg/mouse in 100 ?L of 20% DMSO solution in PBS) and immediately 
placed in the imaging system. Mice were anesthetized with 4.0 % isoflurane and maintained under 
light anaesthesia with 1.5 % isoflurane. Bioluminescence images were acquired with an IVIS Spectrum 
imaging system every min for 1 h at 37°C with automatic settings. Photons emitted from the chest 
region were quantified using Living Image® software (Caliper Life Sciences). 
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Figure S4.1: Colorimetric assay of HNE activity. Absorbance measured at 405 nm in function of the time during AAPV-pNA 
incubation with or without 1.0 ug of HNE enzyme in NE-buffer. 
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Figure S4.2: Background assessment resulting from the reaction between HO-CBT and cysteine present in different buffers. 
(a) Observed luminescence as a function of time after HO-CBT (100 μM) incubated for 15 min in RPMI 1640 + 1 % penicillin 
and streptomycin (P/S), DMEM or DPBS. (b) Total luminescent signal integrated over 60 min (AUC). Error bars are ± SD for 
three measurements. Statistical analyses were performed with a two-tailed Student’s t test. Differences between all the 
groups are statistically significant (P < 0.002). 
 
Figure S4.3: Determination of luciferase expression in BalbC transfected mice 1 day, 4 days, 5 days and 7 days after DNA 
delivery. mice were injected i.p. with D-luciferin (150 mg/kg in 100 μL PBS) and bioluminescence was measured 15 min fol-
lowing luciferin injection. Error bars are ± SD. Statistical analyses were performed with a two-tailed Student’s t test. Differ-
ences in light emission between day 4, day 5 and day 7 are not statistically significant (P > 0.14). 
Bioluminescence Imaging of Neutrophil Elastase Activity Using the Split Luciferin Reaction 
94 
 
Figure S4.4: Plasmid map of pLenti-UbC-RedFLuc-T2A-Puro (RedLuc-puro) that expresses Luciferase under UbC promoter. 
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Investigation of biological processes in living cells using biocompatible reactions has vastly ad-
vanced our understanding of basic biology. Nevertheless, the increased complexity of many human 
pathologies such as cancer, infections or neurodegenerative diseases requires novel tools to study the 
biological process on the level of whole organism. However, only a handful of biocompatible reactions 
have yet been reported to efficiently occur in the complex biological environment of living animals. 
The recent focus on 2-cyanobenzothiazole (CBT)-based ligation reaction in the literature has 
sparked our interest. This reaction has been used for various applications, including fluorescent label-
ling of proteins and nanostructures formation. Importantly, it was shown to occur selectively in 
cells.[197] As the reaction between D-cysteine and hydroxy- or amino-CBT, named split luciferin reac-
tion, yield the D-luciferin molecule as product, this reaction had substantial potential for BLI applica-
tions.  
In this work, the split luciferin reaction was shown to efficiently occur in living cells and in vivo, 
generating bioluminescence emission. Remarkably, in cells the signal produced by the split luciferin 
reagents was several fold higher than the signal from equimolar amounts of already formed D-luciferin 
and D-aminoluciferin, providing opportunities for more sensitive imaging of biological processes, in 
vitro. The bioluminescence signal produced by the split luciferin reagents in vivo was approximately 
one order of magnitude lower than the light emission generated respectively by D-luciferin or amino-
analogue, but still largely above the background. The influence of endogenous L-cysteine on signal was 
found to be negligible in both living cells and animals within the conditions used in these experiments. 
In addition, the intensity of the light output with split luciferin reaction can be significantly enhanced 
by using higher D-cysteine concentration for the in vivo studies.  
Moreover, the split luciferin approach helps remedy an important problem in the BLI field, 
which is signal instability of D-luciferin and D-aminoluciferin probes in vivo. Important signal variations 
over short periods of time have been observed utilizing these probes, which in turn induce significant 
errors for quantification of tumor size or amount of transcriptional activation.[36,219,220] The use of split 
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luciferin approach in animals with D-cysteine and HO-CBT results in major signal stabilization without 
the use of any specially synthesized expensive reagents or complex procedures. 
 The split luciferin ligation reaction possesses several unique features which make it highly val-
uable for a vast variety of imaging applications. The two reagents can be modified (caged) for their use 
as bioluminogenic probes. D-cysteine modification is very well suited to the development of probes 
for real-time imaging of protease activity. A successful application of this technology was therefore 
demonstrated in this study for real time non-invasive imaging of caspase 3/7 activity using a DEVD-(D-
Cys) peptide in conjugation with H2N-CBT. The probe was validated in a hepatic apoptosis animal model 
as well as in tumor xenografts model during chemotherapy. When compared to the commercially avail-
able DEVD-aminoluciferin substrate,?the split luciferin ligation reagents had significantly higher signal 
to background ratio, demonstrating the high potential of this new method for sensitive imaging of 
apoptosis. The applicability of this novel tool was further confirmed via studying other proteases (i.e. 
caspase 6, caspase 8, caspase 9 and thrombin) in vitro.  
 In a further development, another bioluminogenic probe based on the split luciferin approach 
was developed for imaging and quantification of Neutrophil Elastase (NE) activity. The use of Ac-AAPV-
(D-Cys) peptide in combination with HO-CBT yielded an efficient, selective and sensitive in vitro quan-
tification method for NE activity. Moreover, imaging of NE activity upon activation of murine neutro-
phils ex vivo was promising, even though further experiments are needed for a complete validation of 
the probe in cellular assays. The same approach was efficiently applied to NE imaging in vivo, in mouse 
models of acute lung injury. These results conclude that the split luciferin based probe developed in 
this study is an efficient tool for non-invasive NE imaging in vivo and could be a valuable tool for a 
better understanding of NE function in neutrophil mediated inflammations. 
In the present study, we focused on application of the split luciferin approach to monitor 
caspase 3/7 and NE activities. Furthermore, the same technique could be extended to identify new 
protease specific peptides as well as to study activities of other proteases.[80,85,86,109,238] The examples 
of such proteases and their specific amino acid sequences include caspase 1 (YVAD), caspase 2 (VDVAD) 
and caspase 12 (ATAD), dipeptidyl peptidase 4 (GP and VP), tryptase (PRNK) and prostate specific an-
tigen (HSSKLQ).[58,74,77,79,234] Moreover, split luciferin method could also be applied to study a wide va-
riety of bacterial, viral and parasite proteases that are essential for the replication and the spread of 
infectious diseases.[80] Examples of these proteases and their specific amino acid sequences include 
SARS protease (TSAVLQ), caspase-like (nLPnLD), and trypsin-like (LRR) activity of proteasome.[77,81-83] 
All of these proteases mentioned above play important roles in various biological processes and are 
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known to cleave at the C-terminal of the corresponding specific peptide sequence. Hence, their activ-
ities could then be monitored using split luciferin based probes. It is noteworthy to mention that the 
synthesis of peptide sequences with a C-terminal D-cysteine can be easily performed using automated 
peptide synthesis,[239,240] allowing the generation of a large library of peptide probes to screen sub-
strates for the target of interest.  
Since caging of D-cysteine can be combined with caging of amino or hydroxy groups on the 
CBT moiety, this reaction represents a powerful tool for dual imaging of biological processes. Two bi-
ological events could be monitored simultaneously in living mice by using only the two caged luciferin 
precursors. Previously, multiple probes based on “caging” the luciferin scaffold were reported for sen-
sitive imaging of various biomolecules in live animals, providing a basis for the development of dual 
imaging approaches.[50,57,59,71,84,85,92] 
The CBT-based ligation reaction could also be used for bioconjugation in tandem with other 
biocompatible reactions. Indeed, the CBT-based ligation reagents do not react with azides, and thus 
could be used in combination with the Staudinger reaction, strain promoted azide-alkyne click reaction 
or tetrazine reactions with trans-cyclooctenes.[161,187] This approach could be particularly useful to 
study simultaneous events in biological systems. Moreover, the kinetics of in vivo split luciferin ligation 
reaction is three orders of magnitude higher than that of Staudinger ligation, opening a wide range of 
opportunities for the study of fast biological processes.  
 In summary, this study demonstrates the high potential and versatility of split luciferin reaction 
for the field of chemical biology and biomedical research. This biocompatible ligation reaction offers a 
robust methodology for the development of novel bioluminogenic probes with improved accessibility. 
We sincerely hope that this methodology will prove to be an efficient tool to improve the knowledge 
on biological systems and disease-associated molecular mechanisms to in turn improve our diagnostic 
ability of these various diseases and improve the appropriate response to them. 
 
  
 99 
? ???????????
(1) Lee, J. J. Siberian Fed. U. 2008, 3, 194-205. 
(2) Widder, E. A. Science 2010, 328, 704-708. 
(3) Badr, C. E.; Tannous, B. A. Trends Biotechnol. 2011, 29, 624-633. 
(4) Wilson, T.; Hastings, J. W. Annu. Rev. Cell Dev. Biol. 1998, 14, 197-230. 
(5) Keyaerts, M.; Caveliers, V.; Lahoutte, T. Trends Mol. Med. 2012, 18, 164-172. 
(6) Prescher, J. A.; Contag, C. H. Curr. Opin. Chem. Biol. 2010, 14, 80-89. 
(7) Haddock, S. H. D.; Moline, M. A.; Case, J. F. Ann. Rev. Mar. Sci. 2010, 2, 443-493. 
(8) Hall, M. P.; Unch, J.; Binkowski, B. F.; Valley, M. P.; Butler, B. L.; Wood, M. G.; Otto, P.; Zimmerman, K.; Vidugiris, 
G.; Machleidt, T.; Robers, M. B.; Benink, H. A.; Eggers, C. T.; Slater, M. R.; Meisenheimer, P. L.; Klaubert, D. H.; Fan, 
F.; Encell, L. P.; Wood, K. V. ACS Chem. Biol. 2012, 7, 1848-1857. 
(9) Scott, D.; Dikici, E.; Ensor, M.; Daunert, S. Annu. Rev. Anal. Chem. 2011, 4, 297-319. 
(10) Meighen, E. A. Annu. Rev. Genet. 1994, 28, 117-139. 
(11) Close, D. M.; Patterson, S. S.; Ripp, S.; Baek, S. J.; Sanseverino, J.; Sayler, G. S. PLoS One 2010, 5, e12441. 
(12) Luker, K. E.; Luker, G. D. Antiviral Res. 2008, 78, 179-187. 
(13) Zhao, H.; Doyle, T. C.; Coquoz, O.; Kalish, F.; Rice, B. W.; Contag, C. H. J. Biomed. Opt. 2005, 10, 041210. 
(14) Miloud, T.; Henrich, C.; Hammerling, G. J. J. Biomed. Opt. 2007, 12, 054018. 
(15) Bhaumik, S.; Gambhir, S. S. Proc. Natl. Acad. Sci. USA 2002, 99, 377-382. 
(16) Loening, A. M.; Wu, A. M.; Gambhir, S. S. Nat. Methods 2007, 4, 641-643. 
(17) Tannous, B. A.; Kim, D. E.; Fernandez, J. L.; Weissleder, R.; Breakefield, X. O. Mol. Ther. 2005, 11, 435-443. 
(18) Santos, E. B.; Yeh, R.; Lee, J.; Nikhamin, Y.; Punzalan, B.; Punzalan, B.; La Perle, K.; Larson, S. M.; Sadelain, M.; 
Brentjens, R. J. Nat. Med. 2009, 15, 338-344. 
(19) Contag, C. H.; Contag, P. R.; Mullins, J. I.; Spilman, S. D.; Stevenson, D. K.; Benaron, D. A. Mol. Microbiol. 1995, 18, 
593-603. 
(20) Rice, B. W.; Cable, M. D.; Nelson, M. B. J. Biomed. Opt. 2001, 6, 432-440. 
(21) Doyle, T. C.; Wang, Q.; Contag, C. H. Revealing biomolecular mechanisms through in vivo bioluminescence 
imaging. In Molecular Imaging with Reporter Genes; Gambhir, S. S., Yaghoubi, S. S., Eds.; Cambridge University 
Press: 2010, p 41-69. 
References 
100 
(22) de Wet, J. R.; Wood, K. V.; DeLuca, M.; Helinski, D. R.; Subramani, S. Mol. Cell. Biol. 1987, 7, 725-737. 
(23) Fraga, H.; Fernandes, D.; Fontes, R.; Esteves da Silva, J. C. G. FEBS J. 2005, 272, 5206-5216. 
(24) Bai, H. X.; Zhu, P.; Wu, W. X.; Li, J.; Ma, Z.; Zhang, W.; Cheng, Y. N.; Du, L. P.; Li, M. Y. MedChemComm 2015, 6, 
418-424. 
(25) White, E. H.; Worther, H.; Seliger, H. H.; Mcelroy, W. D. J. Am. Chem. Soc. 1966, 88, 2015-2019. 
(26) Rhodes, W. C.; Mcelroy, W. D. J. Biol. Chem. 1958, 233, 1528-1537. 
(27) Fraga, H.; Fernandes, D.; Novotny, J.; Fontes, R.; Esteves da Silva, J. C. G. ChemBioChem 2006, 7, 929-935. 
(28) Airth, R. L.; Rhodes, W. C.; Mcelroy, W. D. Biochim. Biophys. Acta 1958, 27, 519-532. 
(29) Fontes, R.; Dukhovich, A.; Sillero, A.; Sillero, M. A. G. Biochem. Biophys. Res. Commun. 1997, 237, 445-450. 
(30) Lembert, N. Biochem. J 1996, 317, 273-277. 
(31) Nakamura, M.; Maki, S.; Amano, Y.; Ohkita, Y.; Niwa, K.; Hirano, T.; Ohmiya, Y.; Niwa, H. Biochem. Biophys. Res. 
Commun. 2005, 331, 471-475. 
(32) Marques, S. M.; Esteves da Silva, J. C. G. IUBMB Life 2009, 61, 6-17. 
(33) Fraga, H.; Esteves da Silva, J. C. G.; Fontes, R. Tetrahedron Lett. 2004, 45, 2117-2120. 
(34) Fontes, R.; Ortiz, B.; de Diego, A.; Sillero, A.; Sillero, M. A. G. FEBS Lett. 1998, 438, 190-194. 
(35) Pinto da Silva, L.; Esteves da Silva, J. C. G. Photochem. Photobiol. Sci. 2011, 10, 1039-1045. 
(36) Shinde, R.; Perkins, J.; Contag, C. H. Biochemistry 2006, 45, 11103-11112. 
(37) Woodroofe, C. C.; Shultz, J. W.; Wood, M. G.; Osterman, J.; Cali, J. J.; Daily, W. J.; Meisenheimer, P. L.; Klaubert, D. 
H. Biochemistry 2008, 47, 10383-10393. 
(38) Reddy, G. R.; Thompson, W. C.; Miller, S. C. J. Am. Chem. Soc. 2010, 132, 13586-13587. 
(39) Evans, M. S.; Chaurette, J. P.; Adams, S. T.; Reddy, G. R.; Paley, M. A.; Aronin, N.; Prescher, J. A.; Miller, S. C. Nat. 
Methods 2014, 11, 393-395. 
(40) Harwood, K. R.; Mofford, D. M.; Reddy, G. R.; Miller, S. C. Chem. Biol. 2011, 18, 1649-1657. 
(41) Mofford, D. M.; Reddy, G. R.; Miller, S. C. J. Am. Chem. Soc. 2014, 136, 13277-13282. 
(42) Conley, N. R.; Dragulescu-Andrasi, A.; Rao, J. H.; Moerner, W. E. Angew. Chem. Int. Ed. 2012, 51, 3350-3353. 
(43) Woodroofe, C. C.; Meisenheimer, P. L.; Klaubert, D. H.; Kovic, Y.; Rosenberg, J. C.; Behney, C. E.; Southworth, T. L.; 
Branchini, B. R. Biochemistry 2012, 51, 9807-9813. 
(44) McCutcheon, D. C.; Paley, M. A.; Steinhardt, R. C.; Prescher, J. A. J. Am. Chem. Soc. 2012, 134, 7604-7607. 
(45) Branchini, B. R.; Hayward, M. M.; Bamford, S.; Brennan, P. M.; Lajiness, E. J. Photochem. Photobiol. 1989, 49, 689-
695. 
(46) Geiger, R.; Schneider, E.; Wallenfels, K.; Miska, W. Biol. Chem. Hoppe-Seyler 1992, 373, 1187-1191. 
(47) Adams, S. T.; Miller, S. C. Curr. Opin. Chem. Biol. 2014, 21, 112-120. 
(48) Berger, F.; Paulmurugan, R.; Bhaumik, S.; Gambhir, S. S. Eur. J. Nucl. Med. Mol. Imag. 2008, 35, 2275-2285. 
References 
101 
(49) Miska, W.; Geiger, R. Biol. Chem. Hoppe-Seyler 1988, 369, 407-411. 
(50) Li, J.; Chen, L. Z.; Du, L. P.; Li, M. Y. Chem. Soc. Rev. 2013, 42, 662-676. 
(51) Razgulin, A.; Ma, N.; Rao, J. H. Chem. Soc. Rev. 2011, 40, 4186-4216. 
(52) Lakhani, S. A.; Masud, A.; Kuida, K.; Porter, G. A.; Booth, C. J.; Mehal, W. Z.; Inayat, I.; Flavell, R. A. Science 2006, 
311, 847-851. 
(53) Estaquier, J.; Vallette, F.; Vayssiere, J. L.; Mignotte, B. Adv. Exp. Med. Biol. 2012, 942, 157-183. 
(54) Miyashita, T.; OkamuraOho, Y.; Mito, Y.; Nagafuchi, S.; Yamada, M. J. Biol. Chem. 1997, 272, 29238-29242. 
(55) Shin, S.; Sung, B. J.; Cho, Y. S.; Kim, H. J.; Ha, N. C.; Hwang, J. I.; Chung, C. W.; Jung, Y. K.; Oh, B. H. Biochemistry 
2001, 40, 1117-1123. 
(56) Rohn, T. T.; Head, E. Rev. Neurosci. 2008, 19, 383-393. 
(57) Liu, J. J.; Wang, W. G.; Dicker, D. T.; El-Deiry, W. S. Cancer Biol. Ther. 2005, 4, 885-892. 
(58) O'Brien, M. A.; Daily, W. J.; Hesselberth, P. E.; Moravec, R. A.; Scurria, M. A.; Klaubert, D. H.; Bulleit, R. F.; Wood, 
K. V. J. Biomol. Screen. 2005, 10, 137-148. 
(59) Shah, K.; Tung, C. H.; Breakefield, X. O.; Weissleder, R. Mol. Ther. 2005, 11, 926-931. 
(60) Hickson, J.; Ackler, S.; Klaubert, D.; Bouska, J.; Ellis, P.; Foster, K.; Oleksijew, A.; Rodriguez, L.; Schlessinger, S.; 
Wang, B.; Frost, D. Cell Death Differ. 2010, 17, 1003-1010. 
(61) Scabini, M.; Stellari, F.; Cappella, P.; Rizzitano, S.; Texido, G.; Pesenti, E. Apoptosis 2011, 16, 198-207. 
(62) Biserni, A.; Martorana, F.; Roncoroni, C.; Klaubert, D.; Maggi, A.; Ciana, P. Identification of apoptotic cells in 
reporter mice using modified luciferin. 2010. Promega Corporation Web site, 
http://ch.promega.com/resources/pubhub/identification-ofapoptotic-cells-in-reporter-mice-using-modified-
luciferin/. Acessed April 2016 
(63) Geiger, G. A.; Parker, S. E.; Beothy, A. P.; Tucker, J. A.; Mullins, M. C.; Kao, G. D. Cancer Res. 2006, 66, 8172-8181. 
(64) Bassi, D. E.; Fu, J.; Lopez de Cicco, R.; Klein-Szanto, A. J. Mol. Carcinog. 2005, 44, 151-161. 
(65) Bassi, D. E.; Mahloogi, H.; Klein-Szanto, A. J. P. Mol. Carcinog. 2000, 28, 63-69. 
(66) Molloy, S. S.; Anderson, E. D.; Jean, F.; Thomas, G. Trends Cell Biol. 1999, 9, 28-35. 
(67) Bassi, D. E.; Lopez De Cicco, R.; Mahloogi, H.; Zucker, S.; Thomas, G.; Klein-Szanto, A. J. Proc. Natl. Acad. Sci. USA 
2001, 98, 10326-10331. 
(68) Coppola, J. M.; Bhojani, M. S.; Ross, B. D.; Rehemtulla, A. Neoplasia 2008, 10, 363-370. 
(69) Hosaka, M.; Nagahama, M.; Kim, W. S.; Watanabe, T.; Hatsuzawa, K.; Ikemizu, J.; Murakami, K.; Nakayama, K. J. 
Biol. Chem. 1991, 266, 12127-12130. 
(70) Henrich, S.; Cameron, A.; Bourenkov, G. P.; Kiefersauer, R.; Huber, R.; Lindberg, I.; Bode, W.; Than, M. E. Nat. 
Struct. Biol. 2003, 10, 520-526. 
(71) Dragulescu-Andrasi, A.; Liang, G.; Rao, J. Bioconjugate Chem. 2009, 20, 1660-1666. 
(72) Sapio, M. R.; Fricker, L. D. Proteomics Clin. Appl. 2014, 8, 327-337. 
(73) Chang, Y. C.; Chao, P. W.; Tung, C. H. Bioorg. Med. Chem. Lett. 2011, 21, 3931-3934. 
References 
102 
(74) Talanian, R. V.; Quinlan, C.; Trautz, S.; Hackett, M. C.; Mankovich, J. A.; Banach, D.; Ghayur, T.; Brady, K. D.; Wong, 
W. W. J. Biol. Chem. 1997, 272, 9677-9682. 
(75) Roy, S.; Sharom, J. R.; Houde, C.; Loisel, T. P.; Vaillancourt, J. P.; Shao, W.; Saleh, M.; Nicholson, D. W. Proc. Natl. 
Acad. Sci. USA 2008, 105, 4133-4138. 
(76) van Berkel, S. S.; van der Lee, B.; van Delft, F. L.; Wagenvoord, R.; Hemker, C.; Rutjes, F. P. J. T. ChemMedChem 
2012, 7, 606-617. 
(77) Cosby, N.; Scurria, M.; Daily, W.; Ugo, T. Cell Notes 2007, 18, 9-11. 
(78) Gorrell, M. D. Clin. Sci. 2005, 108, 277-292. 
(79) Hedstrom, L. Chem. Rev. 2002, 102, 4501-4523. 
(80) Wilson, J. W.; Schurr, M. J.; LeBlanc, C. L.; Ramamurthy, R.; Buchanan, K. L.; Nickerson, C. A. Postgrad. Med. J. 
2002, 78, 216-224. 
(81) Huang, C. K.; Wei, P.; Fan, K. Q.; Liu, Y.; Lai, L. H. Biochemistry 2004, 43, 4568-4574. 
(82) Cheng, S. C.; Chang, G. G.; Chou, C. Y. Biophys. J. 2010, 98, 1327-1336. 
(83) Kisselev, A. F.; Callard, A.; Goldberg, A. L. J. Biol. Chem. 2006, 281, 8582-8590. 
(84) Wehrman, T. S.; von Degenfeld, G.; Krutzik, P. O.; Nolan, G. P.; Blau, H. M. Nat. Methods 2006, 3, 295-301. 
(85) Yao, H.; So, M. K.; Rao, J. Angew. Chem. Int. Ed. 2007, 46, 7031-7034. 
(86) Zhou, W. H.; Shultz, J. W.; Murphy, N.; Hawkins, E. M.; Bernad, L.; Good, T.; Moothart, L.; Frackman, S.; Klaubert, 
D. H.; Bulleit, R. F.; Wood, K. V. Chem. Commun. 2006, 4620-4622. 
(87) Zhou, W.; Andrews, C.; Liu, J.; Shultz, J. W.; Valley, M. P.; Cali, J. J.; Hawkins, E. M.; Klaubert, D. H.; Bulleit, R. F.; 
Wood, K. V. ChemBioChem 2008, 9, 714-718. 
(88) Rush, J. S.; Beatty, K. E.; Bertozzi, C. R. ChemBioChem 2010, 11, 2096-2099. 
(89) Vorobyeva, A. G.; Stanton, M.; Godinat, A.; Lund, K. B.; Karateev, G. G.; Francis, K. P.; Allen, E.; Gelovani, J. G.; 
McCormack, E.; Tangney, M.; Dubikovskaya, E. A. PLoS One 2015, 10, e0131037. 
(90) Cohen, A. S.; Dubikovskaya, E. A.; Rush, J. S.; Bertozzi, C. R. J. Am. Chem. Soc. 2010, 132, 8563-8565. 
(91) Sellmyer, M. A.; Bronsart, L.; Imoto, H.; Contag, C. H.; Wandless, T. J.; Prescher, J. A. Proc. Natl. Acad. Sci. USA 
2013, 110, 8567-8572. 
(92) Van de Bittner, G. C.; Dubikovskaya, E. A.; Bertozzi, C. R.; Chang, C. J. Proc. Natl. Acad. Sci. USA 2010, 107, 21316-
21321. 
(93) Tian, X. D.; Li, Z. Y.; Lau, C. W.; Lu, J. Z. Anal. Chem. 2015, 87, 11325-11331. 
(94) Ke, B. W.; Wu, W. X.; Liu, W.; Liang, H.; Gong, D. Y.; Hu, X. T.; Li, M. Y. Anal. Chem. 2016, 88, 592-595. 
(95) Shao, Q.; Jiang, T.; Ren, G.; Cheng, Z.; Xing, B. Chem. Commun. 2009, 4028-4030. 
(96) Yang, Y.; Shao, Q.; Deng, R.; Wang, C.; Teng, X.; Cheng, K.; Cheng, Z.; Huang, L.; Liu, Z.; Liu, X.; Xing, B. Angew. 
Chem. Int. Ed. 2012, 51, 3125-3129. 
(97) Jones, L. R.; Goun, E. A.; Shinde, R.; Rothbard, J. B.; Contag, C. H.; Wender, P. A. J. Am. Chem. Soc. 2006, 128, 
6526-6527. 
References 
103 
(98) Wender, P. A.; Goun, E. A.; Jones, L. R.; Pillow, T. H.; Rothbard, J. B.; Shinde, R.; Contag, C. H. Proc. Natl. Acad. Sci. 
USA 2007, 104, 10340-10345. 
(99) Henkin, A. H.; Cohen, A. S.; Dubikovskaya, E. A.; Park, H. M.; Nikitin, G. F.; Auzias, M. G.; Kazantzis, M.; Bertozzi, C. 
R.; Stahl, A. ACS Chem. Biol. 2012, 7, 1884-1891. 
(100) Terai, T.; Nagano, T. Pflugers Arch. 2013, 465, 347-359. 
(101) Madani, F.; Lindberg, S.; Langel, U.; Futaki, S.; Graslund, A. J Biophys 2011, 2011, 414729. 
(102) Mishra, A.; Lai, G. H.; Schmidt, N. W.; Sun, V. Z.; Rodriguez, A. R.; Tong, R.; Tang, L.; Cheng, J. J.; Deming, T. J.; 
Kamei, D. T.; Wong, G. C. L. Proc. Natl. Acad. Sci. USA 2011, 108, 16883-16888. 
(103) Bechara, C.; Sagan, S. FEBS Lett. 2013, 587, 1693-1702. 
(104) Hirose, H.; Takeuchi, T.; Osakada, H.; Pujals, S.; Katayama, S.; Nakase, I.; Kobayashi, S.; Haraguchi, T.; Futaki, S. 
Mol. Ther. 2012, 20, 984-993. 
(105) Mofford, D. M.; Adams, S. T.; Reddy, G. S. K. K.; Reddy, G. R.; Miller, S. C. J. Am. Chem. Soc. 2015, 137, 8684-8687. 
(106) Meisenheimer, P. L.; Uyeda, H. T.; Ma, D. P.; Sobol, M.; McDougall, M. G.; Corona, C.; Simpson, D.; Klaubert, D. H.; 
Cali, J. J. Drug Metab. Dispos. 2011, 39, 2403-2410. 
(107) Roncoroni, C.; Rizzi, N.; Brunialti, E.; Cali, J. J.; Klaubert, D. H.; Maggi, A.; Ciana, P. Pharmacol. Res. 2012, 65, 531-
536. 
(108) Valley, M. P.; Zhou, W.; Hawkins, E. M.; Shultz, J.; Cali, J. J.; Worzella, T.; Bernad, L.; Good, T.; Good, D.; Riss, T. L.; 
Klaubert, D. H.; Wood, K. V. Anal. Biochem. 2006, 359, 238-246. 
(109) Zhou, W. H.; Valley, M. P.; Shultz, J.; Hawkins, E. M.; Bernad, L.; Good, T.; Good, D.; Riss, T. L.; Klaubert, D. H.; 
Wood, K. V. J. Am. Chem. Soc. 2006, 128, 3122-3123. 
(110) Contag, C. H. functional imaging using bioluminescent markers. In Molecular Imaging: Principles and Practice; 
weissleder, R., Ed.; People's Medical Publishing House: 2010, p 118-138. 
(111) Edinger, M.; Sweeney, T. J.; Tucker, A. A.; Olomu, A. B.; Negrin, R. S.; Contag, C. H. Neoplasia 1999, 1, 303-310. 
(112) Hawes, J. J.; Reilly, K. M. Toxicol. Pathol. 2010, 38, 123-130. 
(113) Contag, C. H.; Spilman, S. D.; Contag, P. R.; Oshiro, M.; Eames, B.; Dennery, P.; Stevenson, D. K.; Benaron, D. A. 
Photochem. Photobiol. 1997, 66, 523-531. 
(114) McCaffrey, A.; Kay, M. A.; Contag, C. H. Mol. Imaging 2003, 2, 75-86. 
(115) d'Enfert, C.; Vecchiarelli, A.; Brown, A. J. Virulence 2010, 1, 174-176. 
(116) Luker, K. E.; Smith, M. C.; Luker, G. D.; Gammon, S. T.; Piwnica-Worms, H.; Piwnica-Worms, D. Proc. Natl. Acad. 
Sci. USA 2004, 101, 12288-12293. 
(117) Kuchimaru, T.; Iwano, S.; Kiyama, M.; Mitsumata, S.; Kadonosono, T.; Niwa, H.; Maki, S.; Kizaka-Kondoh, S. Nat. 
Commun. 2016, 7, 11856. 
(118) Branchini, B. R.; Ablamsky, D. M.; Murtiashaw, M. H.; Uzasci, L.; Fraga, H.; Southworth, T. L. Anal. Biochem. 2007, 
361, 253-262. 
(119) Branchini, B. R.; Ablamsky, D. M.; Davis, A. L.; Southworth, T. L.; Butler, B.; Fan, F.; Jathoul, A. P.; Pule, M. A. Anal. 
Biochem. 2010, 396, 290-297. 
(120) Branchini, B. R.; Southworth, T. L.; Khattak, N. F.; Michelini, E.; Roda, A. Anal. Biochem. 2005, 345, 140-148. 
References 
104 
(121) Liang, Y. J.; Walczak, P.; Bulte, J. W. M. J. Biomed. Opt. 2012, 17, 016004. 
(122) Tsien, R. Y. Annu. Rev. Biochem. 1998, 67, 509-544. 
(123) Crivat, G.; Taraska, J. W. Trends Biotechnol. 2012, 30, 8-16. 
(124) Gautier, A.; Juillerat, A.; Heinis, C.; Correa, I. R.; Kindermann, M.; Beaufils, F.; Johnsson, K. Chem. Biol. 2008, 15, 
128-136. 
(125) Juillerat, A.; Gronemeyer, T.; Keppler, A.; Gendreizig, S.; Pick, H.; Vogel, H.; Johnsson, K. Chem. Biol. 2003, 10, 313-
317. 
(126) Los, G. V.; Encell, L. P.; McDougall, M. G.; Hartzell, D. D.; Karassina, N.; Zimprich, C.; Wood, M. G.; Learish, R.; 
Ohane, R. F.; Urh, M.; Simpson, D.; Mendez, J.; Zimmerman, K.; Otto, P.; Vidugiris, G.; Zhu, J.; Darzins, A.; Klaubert, 
D. H.; Bulleit, R. F.; Wood, K. V. ACS Chem. Biol. 2008, 3, 373-382. 
(127) Griffin, B. A.; Adams, S. R.; Tsien, R. Y. Science 1998, 281, 269-272. 
(128) Griffin, B. A.; Adams, S. R.; Jones, J.; Tsien, R. Y. Methods Enzymol. 2000, Volume 327, 565-578. 
(129) Uttamapinant, C.; White, K. A.; Baruah, H.; Thompson, S.; Fernandez-Suarez, M.; Puthenveetil, S.; Ting, A. Y. Proc. 
Natl. Acad. Sci. USA 2010, 107, 10914-10919. 
(130) Rashidian, M.; Dozier, J. K.; Distefano, M. D. Bioconjugate Chem. 2013, 24, 1277-1294. 
(131) Hang, H. C.; Yu, C.; Kato, D. L.; Bertozzi, C. R. Proc. Natl. Acad. Sci. USA 2003, 100, 14846-14851. 
(132) Horisawa, K. Front. Physiol. 2014, 5, 457. 
(133) Sletten, E. M.; Bertozzi, C. R. Angew. Chem. Int. Ed. 2009, 48, 6974-6998. 
(134) Rogers, A. B. Gastric Helicobacter spp. in Animal Models: Pathogenesis and Modulation by Extragastric 
Coinfections. In Helicobacter Species: Methods and Protocols; Houghton, J., Ed.; Humana Press: Totowa, NJ, 2012, 
p 175-188. 
(135) LaFerla, F. M.; Green, K. N. Cold Spring Harb. Perspect. Med. 2012, 2, a006320. 
(136) Peters, M.; Trembovler, V.; Alexandrovich, A.; Parnas, M.; Birnbaumer, L.; Minke, B.; Shohami, E. J. Neurotrauma 
2012, 29, 2831-2834. 
(137) Langdon, S. P. Curr. Drug Targets 2012, 13, 1535-1547. 
(138) Fedele, M.; Gualillo, O.; Vecchione, A. J. Biomed. Biotechnol. 2012, 2010, 404130. 
(139) Li, Z. Q.; Zhao, G. P.; Qian, S. Q.; Yang, Z. J.; Chen, X. Y.; Chen, J.; Cai, C.; Liang, X. B.; Guo, J. J. Ethnopharmacol. 
2012, 144, 305-312. 
(140) Agard, N. J.; Baskin, J. M.; Prescher, J. A.; Lo, A.; Bertozzi, C. R. ACS Chem. Biol. 2006, 1, 644-648. 
(141) Sletten, E. M.; Nakamura, H.; Jewett, J. C.; Bertozzi, C. R. J. Am. Chem. Soc. 2010, 132, 11799-11805. 
(142) Jewett, J. C.; Sletten, E. M.; Bertozzi, C. R. J. Am. Chem. Soc. 2010, 132, 3688-3690. 
(143) Chang, P. V.; Prescher, J. A.; Sletten, E. M.; Baskin, J. M.; Miller, I. A.; Agard, N. J.; Lo, A.; Bertozzi, C. R. Proc. Natl. 
Acad. Sci. USA 2010, 107, 1821-1826. 
(144) Ning, X. H.; Guo, J.; Wolfert, M. A.; Boons, G. J. Angew. Chem. Int. Ed. 2008, 47, 2253-2255. 
(145) Stockmann, H.; Neves, A. A.; Stairs, S.; Ireland-Zecchini, H.; Brindle, K. M.; Leeper, F. J. Chemical Science 2011, 2, 
932-936. 
References 
105 
(146) Lin, F. L.; Hoyt, H. M.; van Halbeek, H.; Bergman, R. G.; Bertozzi, C. R. J. Am. Chem. Soc. 2005, 127, 2686-2695. 
(147) Saxon, E.; Bertozzi, C. R. Science 2000, 287, 2007-2010. 
(148) Saxon, E.; Armstrong, J. I.; Bertozzi, C. R. Org. Lett. 2000, 2, 2141-2143. 
(149) Prescher, J. A.; Dube, D. H.; Bertozzi, C. R. Nature 2004, 430, 873-877. 
(150) Dube, D. H.; Prescher, J. A.; Quang, C. N.; Bertozzi, C. R. Proc. Natl. Acad. Sci. USA 2006, 103, 4819-4824. 
(151) Nilsson, B. L.; Kiessling, L. L.; Raines, R. T. Org. Lett. 2000, 2, 1939-1941. 
(152) Hangauer, M. J.; Bertozzi, C. R. Angew. Chem. Int. Ed. 2008, 47, 2394-2397. 
(153) Chang, P. V.; Prescher, J. A.; Hangauer, M. J.; Bertozzi, C. R. J. Am. Chem. Soc. 2007, 129, 8400-8401. 
(154) van Berkel, S. S.; van Eldijk, M. B.; van Hest, J. C. M. Angew. Chem. Int. Ed. 2011, 50, 8806-8827. 
(155) Yang, J.; Seckute, J.; Cole, C. M.; Devaraj, N. K. Angew. Chem. Int. Ed. 2012, 51, 7476-7479. 
(156) Devaraj, N. K.; Thurber, G. M.; Keliher, E. J.; Marinelli, B.; Weissleder, R. Proc. Natl. Acad. Sci. USA 2012, 109, 
4762-4767. 
(157) Devaraj, N. K.; Weissleder, R.; Hilderbrand, S. A. Bioconjugate Chem. 2008, 19, 2297-2299. 
(158) Lang, K.; Davis, L.; Wallace, S.; Mahesh, M.; Cox, D. J.; Blackman, M. L.; Fox, J. M.; Chin, J. W. J. Am. Chem. Soc. 
2012, 134, 10317-10320. 
(159) Blackman, M. L.; Royzen, M.; Fox, J. M. J. Am. Chem. Soc. 2008, 130, 13518-13519. 
(160) Li, Z. B.; Cai, H. C.; Hassink, M.; Blackman, M. L.; Brown, R. C. D.; Conti, P. S.; Fox, J. M. Chem. Commun. 2010, 46, 
8043-8045. 
(161) Liang, Y.; Mackey, J. L.; Lopez, S. A.; Liu, F.; Houk, K. N. J. Am. Chem. Soc. 2012, 134, 17904-17907. 
(162) Neves, A. A.; Stockmann, H.; Harmston, R. R.; Pryor, H. J.; Alam, I. S.; Ireland-Zecchini, H.; Lewis, D. Y.; Lyons, S. K.; 
Leeper, F. J.; Brindle, K. M. FASEB J. 2011, 25, 2528-2537. 
(163) Neves, A. A.; Stockmann, H.; Wainman, Y. A.; Kuo, J. C. H.; Fawcett, S.; Leeper, F. J.; Brindle, K. M. Bioconjugate 
Chem. 2013, 24, 934-941. 
(164) Vugts, D. J.; Vervoort, A.; Stigter-van Walsum, M.; Visser, G. W. M.; Robillard, M. S.; Versteegen, R. M.; Vulders, R. 
C. M.; Herscheid, J. D. M.; van Dongen, G. A. M. S. Bioconjugate Chem. 2011, 22, 2072-2081. 
(165) Baskin, J. M.; Prescher, J. A.; Laughlin, S. T.; Agard, N. J.; Chang, P. V.; Miller, I. A.; Lo, A.; Codelli, J. A.; Bertozzi, C. 
R. Proc. Natl. Acad. Sci. USA 2007, 104, 16793-16797. 
(166) Laughlin, S. T.; Baskin, J. M.; Amacher, S. L.; Bertozzi, C. R. Science 2008, 320, 664-667. 
(167) Laughlin, S. T.; Bertozzi, C. R. ACS Chem. Biol. 2009, 4, 1068-1072. 
(168) Dehnert, K. W.; Baskin, J. M.; Laughlin, S. T.; Beahm, B. J.; Naidu, N. N.; Amacher, S. L.; Bertozzi, C. R. 
ChemBioChem 2012, 13, 353-357. 
(169) van den Bosch, S. M.; Rossin, R.; Verkerk, P. R.; ten Hoeve, W.; Janssen, H. M.; Lub, J.; Robillard, M. S. Nucl. Med. 
Biol. 2013, 40, 415-423. 
(170) Gallo, J.; Kamaly, N.; Lavdas, I.; Stevens, E.; Nguyen, Q. D.; Wylezinska-Arridge, M.; Aboagye, E. O.; Long, N. J. 
Angew. Chem. Int. Ed. 2014, 53, 9550-9554. 
References 
106 
(171) Zeglis, B. M.; Sevak, K. K.; Reiner, T.; Mohindra, P.; Carlin, S. D.; Zanzonico, P.; Weissleder, R.; Lewis, J. S. J. Nucl. 
Med. 2013, 54, 1389-1396. 
(172) Nichols, B.; Qin, Z. T.; Yang, J.; Vera, D. R.; Devaraj, N. K. Chem. Commun. 2014, 50, 5215-5217. 
(173) Rossin, R.; Verkerk, P. R.; van den Bosch, S. M.; Vulders, R. C. M.; Verel, I.; Lub, J.; Robillard, M. S. Angew. Chem. 
Int. Ed. 2010, 49, 3375-3378. 
(174) Rossin, R.; van den Bosch, S. M.; ten Hoeve, W.; Carvelli, M.; Versteegen, R. M.; Lub, J.; Robillard, M. S. 
Bioconjugate Chem. 2013, 24, 1210-1217. 
(175) Rossin, R.; van Duijnhoven, S. M. J.; Lappchen, T.; van den Bosch, S. M.; Robillard, M. S. Mol. Pharm. 2014, 11, 
3090-3096. 
(176) Schilling, C. I.; Jung, N.; Biskup, M.; Schepers, U.; Brase, S. Chem. Soc. Rev. 2011, 40, 4840-4871. 
(177) Debets, M. F.; van der Doelen, C. W. J.; Rutjes, F. P. J. T.; van Delft, F. L. ChemBioChem 2010, 11, 1168-1184. 
(178) Lemieux, G. A.; de Graffenried, C. L.; Bertozzi, C. R. J. Am. Chem. Soc. 2003, 125, 4708-4709. 
(179) Kiick, K. L.; Saxon, E.; Tirrell, D. A.; Bertozzi, C. R. Proc. Natl. Acad. Sci. USA 2002, 99, 19-24. 
(180) Laughlin, S. T.; Bertozzi, C. R. Nat. Protoc. 2007, 2, 2930-2944. 
(181) Codelli, J. A.; Baskin, J. M.; Agard, N. J.; Berozzi, C. R. J. Am. Chem. Soc. 2008, 130, 11486-11493. 
(182) Poloukhtine, A. A.; Mbua, N. E.; Wolfert, M. A.; Boons, G. J.; Popik, V. V. J. Am. Chem. Soc. 2009, 131, 15769-
15776. 
(183) Debets, M. F.; van Berkel, S. S.; Schoffelen, S.; Rutjes, F. P. J. T.; van Hest, J. C. M.; van Delft, F. L. Chem. Commun. 
2010, 46, 97-99. 
(184) Karver, M. R.; Weissleder, R.; Hilderbrand, S. A. Bioconjugate Chem. 2011, 22, 2263-2270. 
(185) Taylor, M. T.; Blackman, M. L.; Dmitrenko, O.; Fox, J. M. J. Am. Chem. Soc. 2011, 133, 9646-9649. 
(186) Devaraj, N. K.; Upadhyay, R.; Hatin, J. B.; Hilderbrand, S. A.; Weissleder, R. Angew. Chem. Int. Ed. 2009, 48, 7013-
7016. 
(187) Knall, A. C.; Slugovc, C. Chem. Soc. Rev. 2013, 42, 5131-5142. 
(188) Haun, J. B.; Devaraj, N. K.; Hilderbrand, S. A.; Lee, H.; Weissleder, R. Nat. Nanotechnol. 2010, 5, 660-665. 
(189) Haun, J. B.; Devaraj, N. K.; Marinelli, B. S.; Lee, H.; Weissleder, R. Acs Nano 2011, 5, 3204-3213. 
(190) Yang, K. S.; Budin, G.; Reiner, T.; Vinegoni, C.; Weissleder, R. Angew. Chem. Int. Ed. 2012, 51, 6598-6603. 
(191) Budin, G.; Yang, K. S.; Reiner, T.; Weissleder, R. Angew. Chem. Int. Ed. 2011, 50, 9378-9381. 
(192) White, E. H.; McCapra, F.; Field, G. F. J. Am. Chem. Soc. 1963, 85, 337-343. 
(193) Ren, H. J.; Xiao, F.; Zhan, K.; Kim, Y. P.; Xie, H. X.; Xia, Z. Y.; Rao, J. Angew. Chem. Int. Ed. 2009, 48, 9658-9662. 
(194) Liang, G.; Ren, H.; Rao, J. Nat. Chem. 2010, 2, 54-60. 
(195) Ye, D.; Liang, G.; Ma, M. L.; Rao, J. Angew. Chem. Int. Ed. 2011, 50, 2275-2279. 
(196) Deng, Y.; Liu, S.; Mei, K.; Tang, A. M.; Cao, C. Y.; Liang, G. L. Org. Biomol. Chem. 2011, 9, 6917-6919. 
References 
107 
(197) Yuan, Y.; Liang, G. L. Org. Biomol. Chem. 2014, 12, 865-871. 
(198) Yuan, Y.; Zhang, J.; Wang, M. J.; Mei, B.; Guan, Y. F.; Liang, G. L. Anal. Chem. 2013, 85, 1280-1284. 
(199) Nguyen, D. P.; Elliott, T.; Holt, M.; Muir, T. W.; Chin, J. W. J. Am. Chem. Soc. 2011, 133, 11418-11421. 
(200) Cui, L.; Rao, J. 2-Cyanobenzothiazole (CBT) Condensation for Site-Specific Labeling of Proteins at the Terminal 
Cysteine Residues. In Site-Specific Protein Labeling: Methods and Protocols; Gautier, A., Hinner, J. M., Eds.; 
Springer New York: New York, NY, 2015, p 81-92. 
(201) Cheng, Y. F.; Peng, H. J.; Chen, W. X.; Ni, N. T.; Ke, B. W.; Dai, C. F.; Wang, B. H. Chem. Eur. J. 2013, 19, 4036-4042. 
(202) Wang, P.; Zhang, C. J.; Chen, G. C.; Na, Z. K.; Yao, S. Q.; Sun, H. Y. Chem. Commun. 2013, 49, 8644-8646. 
(203) Wang, H. C.; Yu, C. C.; Liang, C. F.; Huang, L. D.; Hwu, J. R.; Lin, C. C. ChemBioChem 2014, 15, 829-835. 
(204) Cao, C. Y.; Chen, Y.; Wu, F. Z.; Deng, Y.; Liang, G. L. Chem. Commun. 2011, 47, 10320-10322. 
(205) Miao, Q. Q.; Bai, X. Y.; Shen, Y. Y.; Mei, B.; Gao, J. H.; Li, L.; Liang, G. L. Chem. Commun. 2012, 48, 9738-9740. 
(206) Liang, G. L.; Ronald, J.; Chen, Y. X.; Ye, D. J.; Pandit, P.; Ma, M. L.; Rutt, B.; Rao, J. H. Angew. Chem. Int. Ed. 2011, 
50, 6283-6286. 
(207) Jeon, J.; Shen, B.; Xiong, L. Q.; Miao, Z.; Lee, K. H.; Rao, J.; Chin, F. T. Bioconjugate Chem. 2012, 23, 1902-1908. 
(208) Inkster, J. A.; Colin, D. J.; Seimbille, Y. Org. Biomol. Chem. 2015, 13, 3667-3676. 
(209) Massoud, T. F.; Gambhir, S. S. Genes Dev. 2003, 17, 545-580. 
(210) Oballa, R. M.; Truchon, J. F.; Bayly, C. I.; Chauret, N.; Day, S.; Crane, S.; Berthelette, C. Bioorg. Med. Chem. Lett. 
2007, 17, 998-1002. 
(211) McBean, G. J.; Flynn, J. Biochem. Soc. Trans. 2001, 29, 717-722. 
(212) Knickelbein, R. G.; Seres, T.; Lam, G.; Johnston, R. B.; Warshaw, J. B. Am. J. Physiol. Lung Cell. Mol. Physiol. 1997, 
273, L1147-L1155. 
(213) Chen, Z.; Fei, Y. J.; Anderson, C. M. H.; Wake, K. A.; Miyauchi, S.; Huang, W.; Thwaites, D. T.; Ganapathy, V. J. 
Physiol. 2003, 546, 349-361. 
(214) Shikano, N.; Nakajima, S.; Kotani, T.; Ogura, M.; Sagara, J. I.; Iwamura, Y.; Yoshimoto, M.; Kubota, N.; Ishikawa, N.; 
Kawai, K. Nucl. Med. Biol. 2007, 34, 659-665. 
(215) Goun, E. A.; Pillow, T. H.; Jones, L. R.; Rothbard, J. B.; Wender, P. A. ChemBioChem 2006, 7, 1497-1515. 
(216) White, E. H.; Steinmetz, M. G.; Miano, J. D.; Wildes, P. D.; Morland, R. J. Am. Chem. Soc. 1980, 102, 3199-3208. 
(217) ACS Chemical Biology Website. http://pubs.acs.org/doi/suppl/10.1021/cb3007314 (April 17, 2016) 
(218) Cao, Y. A.; Wagers, A. J.; Beilhack, A.; Dusich, J.; Bachmann, M. H.; Negrin, R. S.; Weissman, I. L.; Contag, C. H. Proc. 
Natl. Acad. Sci. USA 2004, 101, 221-226. 
(219) Gross, S.; Piwnica-Worms, D. Nat. Methods 2005, 2, 607-614. 
(220) Chandran, S. S.; Williams, S. A.; Denmeade, S. R. Luminescence 2009, 24, 35-38. 
(221) Vieira, J.; Pinto da Silva, L.; Esteves da Silva, J. C. G. J. Photochem. Photobiol., B 2012, 117, 33-39. 
(222) Kelkar, M.; De, A. Curr. Opin. Pharmacol. 2012, 12, 592-600. 
References 
108 
(223) Welsh, D. K.; Noguchi, T. Cold Spring Harb. Protoc. 2012, 2012, 852-866. 
(224) Kim, S. B. Protein Eng. Des. Sel. 2012, 25, 261-269. 
(225) Zinn, K. R.; Chaudhuri, T. R.; Szafran, A. A.; O'Quinn, D.; Weaver, C.; Dugger, K.; Lamar, D.; Kesterson, R. A.; Wang, 
X. D.; Frank, S. J. ILAR J. 2008, 49, 103-115. 
(226) Chaudhari, A. J.; Darvas, F.; Bading, J. R.; Moats, R. A.; Conti, P. S.; Smith, D. J.; Cherry, S. R.; Leahy, R. M. Phys. 
Med. Biol. 2005, 50, 5421-5441. 
(227) King, M.; Wagner, A. Bioconjugate Chem. 2014, 25, 825-839. 
(228) Patterson, D. M.; Nazarova, L. A.; Prescher, J. A. ACS Chem. Biol. 2014, 9, 592-605. 
(229) Rossin, R.; Robillard, M. S. Curr. Opin. Chem. Biol. 2014, 21, 161-169. 
(230) Godinat, A.; Park, H. M.; Miller, S. C.; Cheng, K.; Hanahan, D.; Sanman, L. E.; Bogyo, M.; Yu, A.; Nikitin, G. F.; Stahl, 
A.; Dubikovskaya, E. A. ACS Chem. Biol. 2013, 8, 987-999. 
(231) Van de Bittner, G. C.; Bertozzi, C. R.; Chang, C. J. J. Am. Chem. Soc. 2013, 135, 1783-1795. 
(232) McLaughlin, J. N.; Patterson, M. M.; Malik, A. B. Proc. Natl. Acad. Sci. USA 2007, 104, 5662-5667. 
(233) Ito, K.; Nishimura, W.; Maeda, M.; Gomi, K.; Inouye, S.; Arakawa, H. Anal. Chim. Acta 2007, 588, 245-251. 
(234) Denmeade, S. R.; Lou, W.; Lovgren, J.; Malm, J.; Lilja, H.; Isaacs, J. T. Cancer Res. 1997, 57, 4924-4930. 
(235) Monsees, T.; Miska, W.; Geiger, R. Anal. Biochem. 1994, 221, 329-334. 
(236) Ray, P.; De, A.; Patel, M.; Gambhir, S. S. Clin. Cancer. Res. 2008, 14, 5801-5809. 
(237) Laxman, B.; Hall, D. E.; Bhojani, M. S.; Hamstra, D. A.; Chenevert, T. L.; Ross, B. D.; Rehemtulla, A. Proc. Natl. Acad. 
Sci. USA 2002, 99, 16551-16555. 
(238) Cali, J. J.; Ma, D. P.; Sobol, M.; Simpson, D. J.; Frackman, S.; Good, T. I.; Daily, W. J.; Liu, D. Expert Opin. Drug 
Metab. Toxicol. 2006, 2, 629-645. 
(239) Merrifield, R. B. Science 1965, 150, 178-185. 
(240) Merrifield, R. B.; Stewart, J. M. Nature 1965, 207, 522-523. 
(241) Paley, M. A.; Prescher, J. A. MedChemComm 2014, 5, 255-267. 
(242) Jurisicova, A.; Antenos, M.; Varmuza, S.; Tilly, J. L.; Casper, R. F. Mol. Human Reprod. 2003, 9, 133-141. 
(243) Elmore, S. Toxicol. Pathol. 2007, 35, 495-516. 
(244) Pop, C.; Salvesen, G. S. J. Biol. Chem. 2009, 284, 21777-21781. 
(245) Nicholls, S. B.; Hyman, B. T. Methods Enzymol. 2014, 544, 251-269. 
(246) Thornberry, N. A.; Ranon, T. A.; Pieterson, E. P.; Rasper, D. M.; Timkey, T.; GarciaCalvo, M.; Houtzager, V. M.; 
Nordstrom, P. A.; Roy, S.; Vaillancourt, J. P.; Chapman, K. T.; Nicholson, D. W. J. Biol. Chem. 1997, 272, 17907-
17911. 
(247) Donahue, B. S.; Gailani, D.; Higgins, M. S.; Drinkwater, D. C.; George, A. L. Circulation 2003, 107, 1003-1008. 
(248) Angelillo-Scherrer, A.; de Frutos, P. G.; Aparicio, C.; Melis, E.; Savi, P.; Lupu, F.; Arnout, J.; Dewerchin, M.; 
Hoylaerts, M. F.; Herbert, M.; Collen, D.; Dahlback, B.; Carmeliet, P. Nat. Med. 2001, 7, 215-221. 
References 
109 
(249) Seife, C. Science 1997, 277, 1602-1603. 
(250) McStay, G. P.; Salvesen, G. S.; Green, D. R. Cell Death Differ. 2008, 15, 322-331. 
(251) Timmer, J. C.; Salvesen, G. S. Cell Death Differ. 2007, 14, 66-72. 
(252) Stennicke, H. R.; Salvesen, G. S. Methods 1999, 17, 313-319. 
(253) Stennicke, H. R.; Salvesen, G. S. Apoptosis 2000, 322, 91-100. 
(254) Stennicke, H. R.; Renatus, M.; Meldal, M.; Salvesen, G. S. Biochem. J 2000, 350, 563-568. 
(255) Husain, Q. Crit. Rev. Biotechnol. 2010, 30, 41-62. 
(256) Masuda-Nishimura, I.; Fukuda, S.; Sano, A.; Kasai, K.; Tatsumi, H. Lett. Appl. Microbiol. 2000, 30, 130-135. 
(257) Yang, X. Y.; Janatova, J.; Andrade, J. D. Anal. Biochem. 2005, 336, 102-107. 
(258) Mignon, A.; Rouquet, N.; Fabre, M.; Martin, S.; Pages, J. C.; Dhainaut, J. F.; Kahn, A.; Briand, P.; Joulin, V. Am. J. 
Respir. Crit. Care Med. 1999, 159, 1308-1315. 
(259) Lyseng-Williamson, K. A.; Fenton, C. Drugs 2005, 65, 2513-2531. 
(260) Dieras, V. Oncology 1997, 11, 31-33. 
(261) Fulton, B.; Spencer, C. M. Drugs 1996, 51, 1075-1092. 
(262) Michael, A.; Syrigos, K.; Pandha, H. Prostate Cancer Prostatic Dis. 2009, 12, 13-16. 
(263) Halder, J.; Landen, C. N.; Lutgendorf, S. K.; Li, Y.; Jennings, N. B.; Fan, D.; Nelkin, G. M.; Schmandt, R.; Schaller, M. 
D.; Sood, A. K. Clin. Cancer. Res. 2005, 11, 8829-8836. 
(264) Amess, R.; Baggett, N.; Darby, P. R.; Goode, A. R.; Vickers, E. E. Carbohydr. Res. 1990, 205, 225-233. 
(265) Shapiro, S. D. Am. J. Respir. Cell Mol. Biol. 2002, 26, 266-268. 
(266) Lee, W. L.; Downey, G. P. Am. J. Respir. Crit. Care Med. 2001, 164, 896-904. 
(267) Kossodo, S.; Zhang, J.; Groves, K.; Cuneo, G. J.; Handy, E.; Morin, J.; Delaney, J.; Yared, W.; Rajopadhye, M.; 
Peterson, J. D. Int. J. Mol. Imaging. 2011, 2011, 581406. 
(268) Kawabata, K.; Hagio, T.; Matsuoka, S. Eur. J. Pharmacol. 2002, 451, 1-10. 
(269) Korkmaz, B.; Horwitz, M. S.; Jenne, D. E.; Gauthier, F. Pharmacol. Rev. 2010, 62, 726-759. 
(270) Moroy, G.; Alix, A. J. P.; Sapi, J.; Hornebeck, W.; Bourguet, E. Anticancer Agents Med. Chem. 2012, 12, 565-579. 
(271) Pham, C. T. N. Nat. Rev. Immunol. 2006, 6, 541-550. 
(272) Lee, W. L.; Downey, G. P. The role of Neutrophils in acute lung injury. In Etiology and Treatment of Acute Lung 
Injury: From Bench to Bedside; Matalon, S., Sznajder, J. I., Eds. 2001; Vol. 336, p 113-123. 
(273) Castillo, M. J.; Nakajima, K.; Zimmerman, M.; Powers, J. C. Anal. Biochem. 1979, 99, 53-64. 
(274) Nakajima, K.; Powers, J. C.; Ashe, B. M.; Zimmerman, M. J. Biol. Chem. 1979, 254, 4027-4032. 
(275) Janoff, A. Biochem. J 1969, 114, 157-159. 
References 
110 
(276) Korkmaz, B.; Attucci, S.; Hazouard, E.; Ferrandiere, M.; Jourdan, M. L.; Brillard-Bourdet, M.; Juliano, L.; Gauthier, F. 
J. Biol. Chem. 2002, 277, 39074-39081. 
(277) Korkmaz, B.; Hajjar, E.; Kalupov, T.; Reuter, N.; Brillard-Bourdet, M.; Moreau, T.; Juliano, L.; Gauthier, F. J. Biol. 
Chem. 2007, 282, 1989-1997. 
(278) Koehl, C.; Knight, C. G.; Bieth, J. G. J. Biol. Chem. 2003, 278, 12609-12612. 
(279) Korkmaz, B.; Attucci, S.; Jourdan, M. L.; Juliano, L.; Gauthier, F. J. Immunol. 2005, 175, 3329-3338. 
(280) Korkmaz, B.; Attucci, S.; Juliano, M. A.; Kalupov, T.; Jourdan, M. L.; Juliano, L.; Gauthier, F. Nat. Protoc. 2008, 3, 
991-1000. 
(281) Mitra, S.; Modi, K. D.; Foster, T. H. J. Biomed. Opt. 2013, 18, 101314. 
(282) Ho, A. S.; Chen, C. H.; Cheng, C. C.; Wang, C. C.; Lin, H. C.; Luo, T. Y.; Lien, G. S.; Chang, J. S. Oncotarget 2014, 5, 
473-480. 
(283) Talukdar, S.; Oh, D. Y.; Bandyopadhyay, G.; Li, D. M.; Xu, J. F.; McNelis, J.; Lu, M.; Li, P. P.; Yan, Q. Y.; Zhu, Y. M.; 
Ofrecio, J.; Lin, M.; Brenner, M. B.; Olefsky, J. M. Nat. Med. 2012, 18, 1407-1412. 
(284) Charlton, J.; Sennello, J.; Smith, D. Chem. Biol. 1997, 4, 809-816. 
(285) Rusckowski, M.; Qu, T.; Pullman, J.; Marcel, R.; Ley, A. C.; Ladner, R. C.; Hnatowich, D. J. J. Nucl. Med. 2000, 41, 
363-374. 
(286) Leblond, F.; Davis, S. C.; Valdes, P. A.; Pogue, B. W. J. Photochem. Photobiol., B 2010, 98, 77-94. 
(287) Rahmim, A.; Zaidi, H. Nucl. Med. Commun. 2008, 29, 193-207. 
(288) Rao, N. V.; Hoidal, J. R. Chapter 589 - Myeloblastin. In Handbook of Proteolytic Enzymes; Salvesen, N. D. R., Ed.; 
Academic Press: 2013, p 2666-2675. 
(289) Kasperkiewicz, P.; Poreba, M.; Snipas, S. J.; Parker, H.; Winterbourn, C. C.; Salvesen, G. S.; Drag, M. Proc. Natl. 
Acad. Sci. USA 2014, 111, 2518-2523. 
(290) Jenssen, H.; Aspmo, S. Serum Stability of Peptides. In Peptide-Based Drug Design; Otvos, L., Ed.; Humana Press: 
2008; Vol. 494, p 177-186. 
(291) Powell, M. F.; Stewart, T.; Otvos, L.; Urge, L.; Gaeta, F. C. A.; Sette, A.; Arrhenius, T.; Thomson, D.; Soda, K.; Colon, 
S. M. Pharm. Res. 1993, 10, 1268-1273. 
(292) Sato, A. K.; Viswanathan, M.; Kent, R. B.; Wood, C. R. Curr. Opin. Biotechnol. 2006, 17, 638-642. 
(293) Kawabata, K.; Suzuki, M.; Sugitani, M.; Imaki, K.; Toda, M.; Miyamoto, T. Biochem. Biophys. Res. Commun. 1991, 
177, 814-820. 
(294) Wiesner, O.; Litwiller, R. D.; Hummel, A. M.; Viss, M. A.; McDonald, C. J.; Jenne, D. E.; Fass, D. N.; Specks, U. FEBS 
Lett. 2005, 579, 5305-5312. 
(295) Sato, T.; Hongu, T.; Sakamoto, M.; Funakoshi, Y.; Kanaho, Y. Mol. Cell. Biol. 2013, 33, 136-145. 
(296) Nick, J. A.; Avdi, N. J.; Young, S. K.; Knall, C.; Gerwins, P.; Johnson, G. L.; Worthen, G. S. J. Clin. Invest. 1997, 99, 
975-986. 
(297) Sandborg, R. R.; Smolen, J. E. Lab. Invest. 1988, 59, 300-320. 
(298) Boxio, R.; Bossenmeyer-Pourie, C.; Steinckwich, N.; Dournon, C.; Nusse, O. J. Leukocyte Biol. 2004, 75, 604-611. 
(299) Corteling, R.; Wyss, D.; Trifilieff, A. BMC Pharmacol. 2002, 2, 1-8. 
References 
111 
(300) Lefort, J.; Singer, M.; Leduc, D.; Renesto, P.; Nahori, M. A.; Huerre, M.; Creminon, C.; Chignard, M.; Vargaftig, B. B. 
J. Immunol. 1998, 161, 474-480. 
(301) Miotla, J. M.; Teixeira, M. M.; Hellewell, P. G. Am. J. Respir. Cell Mol. Biol. 1998, 18, 411-420. 
(302) Asti, C.; Ruggieri, V.; Porzio, S.; Chiusaroli, R.; Melillo, G.; Caselli, G. F. Pulm. Pharmacol. Ther. 2000, 13, 61-69. 
(303) Chen, L. Y.; Pan, W. W.; Chen, M.; Li, J. D.; Liu, W.; Chen, G. Q.; Huang, S.; Papadimos, T. J.; Pan, Z. K. J. Immunol. 
2009, 182, 2518-2524. 
(304) Panaro, M. A.; Mitolo, V. Immunopharmacol. Immunotoxicol. 1999, 21, 397-419. 
(305) Branchini, B. R.; Southworth, T. L.; DeAngelis, J. P.; Roda, A.; Michelini, E. Comp. Biochem. Physiol. B, Biochem. 
Mol. Biol. 2006, 145, 159-167. 
(306) Kawabata, K.; Hagio, T.; Matsumoto, S.; Nakao, S.; Orita, S.; Aze, Y.; Ohno, H. Am. J. Respir. Crit. Care Med. 2000, 
161, 2013-2018. 
(307) Godinat, A.; Budin, G.; Morales, A. R.; Park, H. M.; Sanman, L. E.; Bogyo, M.; Yu, A.; Stahl, A.; Dubikovskaya, E. A. 
Curr. Protoc. Chem. Biol. 2014, 6, 169-189. 
 

 113 
? ????????
???? ?????????????????
 
CONTACT INFORMATION 
Name and Address Aurélien Godinat      
  Chemin de la Forêt 6  
  1024 Ecublens 
  Switzerland 
Phone number  +41 (0)79 786 61 73 
E-mail address  aurelien.godinat@epfl.ch, aurelien.godinat@gmail.com 
PERSONAL INFORMATION 
Nationality  Swiss / French 
Date & place of birth October 30th, 1984, Nyon (VD), Switzerland 
EDUCATION 
11.2011-11.2016 Ph.D. studies in chemical biology  
Laboratory of bioorganic chemistry and molecular imaging (LCBIM) 
Swiss Federal Institute of Technology, Lausanne (EPFL)  
under the supervision of Prof. Elena A. Dubikovsakaya 
11.2009-02.2011 Master of Science (M.Sc.) in biological and molecular Chemistry 
Swiss Federal Institute of Technology, Lausanne (EPFL) 
10.2004-08.2009 Bachelor of Science (B.Sc.) in Chemistry 
Swiss Federal Institute of Technology, Lausanne (EPFL) 
08.2001-06.2004 High school - Swiss cantonal scientific maturity (biology and chemistry) 
Annexes 
114 
PROFESSIONAL QUALIFICATIONS 
Languages  French: native  
   English: full professional proficiency 
   German: limited professional proficiency 
   Italian: basic notions 
Certificate Animal Experimentation certificate (Module 1, Introductory Course in Labora-
tory Animal Science, theoretical and practical) 
AWARDS 
•? European Society of Molecular Imaging Young Investigator Award 2013 - (May 2013, Turin, Italy) 
•? Runners-up best poster presentation at the Swiss Chemical Society Fall Meeting 2013 - (September 
2013, Lausanne, Switzerland) 
PUBLICATIONS 
•? Vorobyeva, A. G.; Stanton, M.; Godinat, A.; Lund, K. B.; Karateev, G. G.; Francis, K. P.; Allen, E.; 
Gelovani, J. G.; McCormack, E.; Tangney, M.; Dubikovskaya, E. A. PlosOne, 2015, 10, e0131037. 
•? Geissbuehler, S.; Sharipov, A.; Godinat, A.; Bocchio, N. L.; Sandoz, P. A.; Huss, A.; Jensen, N. A.; 
Jakobs, S.; Enderlein, J.; Van der Goot, F. G.; Dubikovskaya, E. A.; Lasser, T.; Leutenegger, M. Nature 
Communications, 2014, 5, 5830. 
•? Godinat, A.; Budin, G.; Morales, A. R.; Park, H. M.; Sanman, L. E.; Bogyo, M.; Yu, A.; Stahl, A.; Du-
bikovskaya, E. A. Curr. Prot. Chem. Biol. 2014, 6, 169–189. 
•? Godinat, A.; Park, H. M.; Miller, S. C.; Cheng, K.; Hanahan, D.; Sanman, L. E.; Bogyo, M.; Yu, A.; 
Nikitin, G. N.; Stahl, A.; Dubikovskaya, E. A. ACS Chem. Biol. 2013, 8, 987–999. 
•? Vechorkin, O.; Godinat, A.; Scopelliti, R.; Hu, X. Angew. Chem. Int. Ed. 2011, 50, 11777–11781. 
•? Borcard, F.; Godinat, A.; Staedler, D.; Comas Blanco, H.; Dumont, A.-L.; Chapuis-Bernasconi, C.; 
Scaletta, C.; Applegate, L. A.; Krauss Juillerat, F.; Gonzenbach, U.; Gerber-Lemaire, S.; Juillerat-Jean-
neret, L. Bioconjugate Chem. 2011, 22, 1422–1432. 
•? Thommes, K.; Fernandez-Zumel, M. A.; Buron, C.; Godinat, A.; Scopelliti, R.; Severin, K. Eur. J. Org. 
Chem. 2011, No. 2, 249–255. 
Annexes 
115 
PATENTS APPLICATIONS 
•? Dubikovskaya, E. A.; Godinat, A. Precursor molecule for the synthesis of d-luciferin. PCT Int. Appl. 
2013. Patent number WO2014057139 A3. 
•? Sinisi, R.; Dubikovskaya, E.; Budin, G.; Karateev, G.; Frigell, J.; Konovalova, A.; Godinat, A. Biolumi-
nescence imaging of small biomolecules, PCT Int. Appl. 2014. Patent number WO2014111906 A1. 
BOOK CHAPTER 
•? Godinat, A.; Karatas, H.; Budin, G.; Dubikovskaya, E. A. (Submitted for publication) Chemical liga-
tion for molecular imaging. In Chemical Ligation: Tools for Biomolecule Synthesis and Modification.; 
D’Andrea, L.; Romanelli, A., Eds.; John Wiley & Sons. 
•? Karatas, H.; Godinat, A.; Budin, G.; Dubikovskaya, E. A. (Manuscript in preparation) Modified lucif-
erins for sensing molecular changes in vivo. In Visualizing Chemical Communications Among Mi-
gratory Cells In Vivo.; Contag, C. H.; Kusy, S.; Prescher, J. A., Eds.; Springer. 
PROFESSIONAL MEMBERSHIPS 
•? Member of the European Society of Molecular Imaging 
•? Member of the Swiss Chemical Society 
 
 
 
 
 
 
 
 
 

  
